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Abstract 
The emergence and rapid spread of multi-drug resistant (MDR) 
Enterobacteriaceae is one of the most challenging problems we currently faced. 
However, locally, no details on the strains causing outbreaks are available. Furthermore, 
globally, we still do not understand what makes certain clones capable of spreading 
widely while others are only confined to sporadic cases. Aim: Our aim was to 
characterize the virulence factors, antibiotic and disinfectant susceptibilities of local 
clonal and sporadic Escherichia coli and Klebsiella pneumoniae strains and to analyze 
the data to reveal which particular feature might be responsible for the outbreak potential 
of clonal isolates. Methods: Escherichia coli and Klebsiella pneumoniae strains 
collected from countries of the Arabian Peninsula were subjected to genotyping by PCR 
targeting a broad spectrum of virulence and antibiotic resistance genes. This was 
followed by antibiotic susceptibility tests, serum resistance and biofilm formation assays 
and molecular typing by macro-restriction analysis and multilocus sequence typing. 
Results: Our study shows that among blood stream E. coli isolates, the rate of strains 
expressing R4 core type is currently much higher than seen before, most likely due to a 
few multi-resistant clones that have emerged recently. Further studies should reveal 
whether, beyond their more extensive antimicrobial resistance, the presence of the 
previously rare core types, or possibly the lower base-line immunity in the population 
against them, contributes to their recent epidemiological success. We also show that a 
majority of local K. pneumoniae clones do not possess considerably more virulence-
related features than sporadic isolates. Rather, they are clearly distinguishable from the 
latter group by their broader spectrum of resistance to non-ß-lactam antibiotics, well 
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substantiated by the increased carriage of the respective resistance genes. Resistance to 
disinfectants was observed to be more common among K. pneumoniae strains non-
susceptible to carbapenems than among the antibiotic sensitive isolates. We speculate 
that this may also increase the outbreak potential of the strains. Finally, we show that a 
considerable part of local carbapenem resistant K. pneumoniae strains are still 
susceptible to fosfomycin, although the rate of resistance to fosfomycin, particularly 
among blood stream isolates, is already alarming. Conclusions: Together, data reveals 
that it is particularly the increased resistance rather than any specific virulence-related 
feature that makes strains spread as clones. A well-organized surveillance system based 
on molecular typing is needed in the country to follow the characteristics of the spread 
of multidrug resistance organisms in the region. 
 
Keywords: Virulence factors, clonality, antibiotic and disinfectant resistance, 
fosfomycin, Enterobacteriaceae. 
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 )cibarA ni( tcartsbA dna eltiT
انخصائص انجينيت نمعذل انضراوة و انتنسيم انجيني و انقذرة عهى مقاومت انمضاداث انحيىيت و انمطهراث 
 نهبكتيريا انمعىيت انمعزونت من شبت انجزيرة انعربيت  
 انمهخص
 
)  RDMنؼذد يٍ الأدٔٚت (ٚشكم اَخشبس انبكخٛشٚب انًمبٔيت نهًعبداث انحٕٛٚت ٔ خبصت انبكخٛشٚب انًؼٕٚت انًمبٔيت 
يٍ اكزش انخحذٚبث صؼٕبت فٙ انٕلج انحبنٙ، فؼهٗ انصؼٛذ انًحهٙ لاحخٕفش أ٘ حفبصٛم ػٍ انسلالاث انًسببت فٙ 
حفشٙ الأبئت. أيب ػهٗ انصؼٛذ انؼبنًٙ  فبَُب لا َسخطٛغ اٌ َفسش سبب لذسة بؼط انسلالاث ػهٗ الاَخشبسػهٗ َطبق 
 أسغ يٍ غٛشْب.
 
 eainomuenp alleisbelK dna iloc aihcirehcsE يٍ خصبئص بكخٛشٚب فٙ ْزا انبحذ سٛخى انخحمكانٓذف: 
انخٙ لذ حؼضص الاَخشبس انُبصح نسلالاث يؼُٛت دٌٔ الاخشٖ أ٘ أٌ حظٓش حٕسغ َسٛهٙ، ٔ سٛخى دساست رنك بخحذٚذ 
ببلإظبفت انٗ دساست لذسة ْزة انبكخٛشٚب ػهٗ يمبٔيت انًعبداث انحٕٛٚت     srotcaf  ecneluriv  خصبئص صُٛبث
.  ٔ بزنك سخسبْى ْزِ انذساست ػهٗ فٓى انؼٕايم انًؤدٚت لاَخشبسسلالاث يؼُٛت انًسخخذيت حبنٛب ببلاظبفت  نهًطٓشاث
 دٌٔ غٛشْب.
 
يٍ  eainomuenp alleisbelK dna iloc aihcirehcsEنمذ حى صًغ يضًٕػبث يٍ بكخٛشٚب  انٕسبئم ٔ انطشق:
خلال ْزِ انذساست اسخخذيج يضًٕػت ٔاسؼت يٍ انخمُٛبث انكلاسٛكٛت ٔ انضضٚئٛت يزم ٔ دٔل شبّ انضضٚشة انؼشبٛت. 
نخحذٚذ   RCPنخحذٚذ انخُسٛم انضُٛٙ نهبكخٛشٚب ، ٔ انخًُٛط انضُٛٙ بٕاسطت   TSLMانبصًبث انضضٚئٛت  بٕاسطت 
ٔ صُٛبث انبكخٛشٚب    srotcaf ecnelurivغ ٔ رنك نٛشًم ححذٚذ خصبئص صُٛبثانًسخٕٖ انضُٛٙ ػهٗ َطبق أس
 . mlifoibانًمبٔيت انًعبداث انحٕٛٚت ، ٔ لذ  حى اٚعب ححذٚذ يؼذل يمبٔيت انًصم ٔ يؼذل حشكٛم 
 x
 
 erocانًؼضٔنت يٍ يضشٖ انذو ححًم انُٕع انُبدس  iloc aihcirehcsEانُخبئش: اسخطؼُب اٌ َزبج اٌ َسبت بكخٛشٚب 
ًمبٔيت  فٙ أَٜت نسلالاث انٔرنك لذ ٚشصغ انٗ ظٕٓسػذد يٍ أ اٌ يؼذل ظٕٓسْب أػهٗ بكزٛش يٍ لبم  4R epyt
الأخٛشة، ٔ نزنك ٚخٕصب اصشاء يضٚذا يٍ انذساسبث ٔ الابحبد نهكشف ػٍ سبب صٚبدة انًمبٔيت نذٚٓب ٔسبب ػٕدة 
يب ارا كبَج ْزِ انضٚبدة يشحبطت ببَخفبض يؼذل انًُبػت نلإَاع انُبدسة ٔ  epyt erocظٕٓس الإَاع انُبدسة يٍ  
 نذٖ انسكبٌ.  epyt erocيٍ 
 
لا حًهك خصبئص حضٚذ يٍ  eainomuenp alleisbelKٔ لذ اربخج انذساست اٚعب اٌ يؼظى انسلالاث انًحهٛت نم 
ٔ رنك  matcal-ßاث انحٕٛٚت غٛش ظشأحٓب غٛش اٌ نٓب لذسة ٔاسؼت ػهٗ يمبٔيت الإَاع الاخشٖ يٍ انًعبد
لاحخٕائٓب ػهٗ انضُٛبث انلاصيت نزنك، ٔ لذ اربخج انذساست اٚعب اٌ يؼذل انًمبٔيت نهًطٓشاث كبٌ اكزش شٕٛػب ػُذ 
يمبسَت يغ الإَاع الاخشٖ ٔنٓزا افخشظُب اٌ ْزا لذ  smenepabracانًمبٔيت نم  eainomuenp alleisbelK
 alleisbelKّ انًمبٔيت دٌٔ غٛشْب، ببلاظبفت انٗ رنك فمذ اربخج انذساست اٌ بؼط يٍ ٚسبْى فٙ اَخشبس ْزِ انسلان
ػهٗ انشغى يٍ اٌ يؼذل انًمبٔيت  nicymofsofيبصانج ػشظت نم  smenepabracانًمبٔيت نم   eainomuenp
 نٓزة انسلانّ انًؼضٔنت يٍ يضشٖ انذو ٚؼخبش ػبنٛب ٔ ٚؼذ يؤششا نهخطش.  
 
ئص يؼُٛت يٍ انبٛبَبث انًخٕفشة نذُٚب اٌ انضٚبدة فٙ يؼذل انًمبٔيت نهبكخٛشٚب نٛس يشحبطب بخصبحشٛش الاسخُخبس: 
لذ ػضص بذٔسِ الاَخشبس انُبصح نسلالاث يؼُٛت دٌٔ الاخشٖ،  ٔ َأيم أٌ ْزِ ٔ ْزا  srotcaf ecnelurivصُٛبث 
ذٔنت لبئى ػهٗ انخحهٛم انضضٚئٙ نًخببؼت َظبو يشالبت صٛذ فٙ انانذساست  سخسبػذ فٙ سٍ انخذابٛشانٕلبئٛت كخأسٛس 
 )  فٙ ْزِ انًُطمت. RDMنؼذد يٍ الأدٔٚت (انًمبٔيت خصبئص اَخشبس انبكخٛشٚب 
 
،  انسلالاث انبكخٛشٚت ، يمبٔيت انًعبداث انحٕٛٚت ٔ انًطٓشاثيؼذل انعشأة،  مفاهيم انبحث انرئيست:
  انبكخٛشٚب انًؼٕٚت.انفٕسفبيبٚسٍ،  
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Chapter 1: Introduction 
 
The problem of antibiotic resistance is one of the most significant challenges we 
face today. Only 70 years after the discovery of the first antimicrobial agent, the 
possibility of losing these, once considered "miracle" drugs, is a reality (Gootz, 2010). 
The problem affects practically any drug and species, but due to their complex cell wall 
structure, it is most threatening among Gram-negative bacteria (Walsh and Toleman, 
2012). Regretfully, there are few, if any, promising new drugs in the research/production 
pipelines. Hence, the recent warning of the WHO, i.e., that this trend is to "...reverse 
medical progress...", is not unrealistic (WHO, 2000). 
 
ß-lactam drugs occupy a special niche among antibiotics. Beyond the relative 
ease of dosing them and their usually good, or acceptable tissue distribution, they act on 
a target, i.e. the cell wall, which we, their hosts, do not have. Hence, compared to other 
antibiotics, they are relatively safe. Consequently, emerging resistance to this group is 
probably the most painful development (Gootz, 2010; Martinez et al., 2009; WHO, 
2000)   
 
After resistance started emerging to simple ß-lactams (penicillins, 
aminopenicillins, 1
st
 and 2
nd
 generation cephalosporins) and concomitantly to other 
agents (e.g. tetracyclines, sulfonamids, quinolones, etc.) (Gootz, 2010; Martinez et al., 
2009; WHO, 2000), at least for a while, 3
rd
 and 4
th
 generation cephalosporins offered a 
solution, and in selected cases, they still can be used to treat life-threatening infections. 
But with the rapid emergence of extended spectrum ß-lactamase (ESBL) enzymes 
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combined with the often clonal spread of strains carrying them, we face a new problem 
(Stokes and Gillings, 2011). Furthermore, it was before long that the problem spilled out 
from hospitals to the community and nowadays ESBL producing Escherichia coli or 
Klebsiella pneumoniae isolates acquired in the community are very common (Martinez 
et al., 2009). All these developments gradually lead to the increased use of carbapenems, 
i.e., the "ultimate" ß-lactam antibiotics. As predicted, resistance to these drugs also 
became more and more common leaving only "far from ideal" drugs, e.g. tigecycline or 
colistin in the armory (Falagas et al., 2005; Xu et al., 2013). 
 
One way of spreading resistance relates to the spread of resistant bacteria, i.e., 
colonizing, infecting one susceptible host after the other. Beyond that, however, as 
antibiotic resistance genes are frequently located on plasmids, i.e., on mobile genetic 
elements, they can also spread from cell to cell, often not even respecting species 
boundaries. Finally, as a third level of its spread, resistance genes are not infrequently 
linked to genetic structures capable of relocating within the genome, i.e., transposons, 
integrons etc., (Stokes and Gillings, 2011).  
 
The fact that spreading of resistant strains strongly depends on the fitness and/or 
virulence of the microbial cell raises important questions: what are the fitness-, and 
virulence-related factors of highly resistant bacteria?  In my thesis, I have tried to answer 
this question by focusing on a unique group of such pathogens, i.e., carbapenem resistant 
Klebsiella pneumoniae a group of strains probably representing the most serious current 
threat to our hospitals. I have also studied the respective factors and genes of 
Escherichia coli strains isolated exclusively from blood, focusing particularly on the 
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possible effects of deep cell wall structures on the emergence of some of the globally 
spreading clones.  
 
The presence of antibiotics clearly represents a strong pressure towards selecting 
drug resistant variants. However, antibiotics are not the only agent bacteria are exposed 
to in hospitals, in the community and increasingly, in the environment, as well (Gilbert 
and McBain, 2003). Biocides and disinfectants are usually applied in extremely high 
concentrations, but by distance and with time they lose their activity, and bacteria with 
decreased susceptibility to some of these agents may have an advantage over others to 
survive (Maillard, 2002; Russell, 2002).  This decreased susceptibility is usually the 
result of increased expression of the so-called multidrug resistance efflux pumps 
expelling various toxic substances from the cell. However, as they often also expel 
antibiotics, they may also cause resistance to those compounds (Levy, 2002b). In 
another part of my thesis, I have studied whether resistance to antibiotics relates to 
decreased susceptibility to disinfecting agents. 
 
With the decreasing efficacy of our standard antibiotics, alternative drugs are 
needed. Theoretically, they could be new ones (and we are very short of those), but also 
older ones, that have not been used extensively so far to treat serious infections. One of 
these agents is fosfomycin. Therefore, in the last part of my thesis, I have studied the 
fosfomycin susceptibility of local carbapenem resistant isolates. 
 
With this work, my intention was to provide a humble contribution to a better 
understanding of the complex mechanism of the spread of antibiotic resistance. I would 
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like to hope that the results will help, even if to a small extent only, to improve our 
actions to control the problem. 
1.1 Antibiotics 
 
Antibiotics, a group of antimicrobial agents, are produced by microorganisms, albeit 
some are currently synthetized chemically for mass-production or the original structure 
is chemically modified to increase efficacy and/or improve pharmacological features. 
Antibiotics have well-defined modes of action with more or less restricted spectrum of 
bacterial species they are effective against (Forbes et al., 2002; Greenwood et al., 2007). 
The effect of antibiotics can be bacteriostatic or bactericidal, the result depends on the 
drug and species, and in some cases on the concentration. They are grouped by their 
mode of action and, within the same action-groups, by their chemical structure. The 
main modes of action with examples are shown in Table 1. (Tortora et al., 2013; Willey 
et al., 2008). 
 
Table 1: Main mode of action of antibiotics 
 
The majority of my thesis work has focused on bacteria resistant to ß-lactam 
antibiotics and fosfomycin, so I will focus on these two groups. 
 
Mode of action Examples 
Inhibition of cell wall synthesis ß-lactams, Glycopeptides, Fosfomycin 
Inhibition of protein synthesis Aminoglycosides, Macrolides, Tetracyclines, 
Chloramphenicol 
Interference with nucleic acid 
synthesis 
Quinolones, Fluoroquinolones, Rifampin 
Cell membrane disruption Polymyxins 
Antimetabolites Sulfonamides, Trimethoprim 
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1.1.1 ß-Lactam Antibiotics 
 
 Members of this group includes penicillins, cephalosporins, monobactams and 
carbapenems. To all, a unique structure, the ß-lactam ring is characteristics. The 
structures of the main ß-lactam groups are shown on Figure 1. All act in the same way, 
i.e., by inhibiting cell wall synthesis. Due to the variations in their molecular structure, 
they have different chemical properties and spectrums of activity. (Harvey et al., 2007; 
Willey et al., 2008) 
 
Figure 1: Chemical structure of the main β-lactams  
(Nordmann et al., 2012a). 
 
These drugs interfere with the transpeptidase enzymes (called Penicillin Binding 
Proteins, PBPs) involved in the synthesis of the peptidoglycan molecule, i.e., the key 
structural component of the cell wall (Kong et al., 2010; Scheffers and Pinho, 2005). 
Bacterial species may contain between four to six different types of PBP involved in cell 
wall cross-linking. The synthesis of the cell wall, i.e., the structure necessary to resist 
high intracellular osmotic pressure, stops upon the drugs‘ interference with PBPs and the 
cell lyses. Consequently, ß-lactam drugs are bactericidal to almost all species that are 
susceptible to them (Forbes et al., 2002; Harvey et al., 2007). 
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1.1.1.1 Penicillins 
 
Penicillins can be classified into four main groups according to their spectrum of 
activity and structure. In the first group are natural penicillins (Penicillin G and 
Penicillin V). They are effective against non-ß-lactamase producing Gram-positive 
aerobic organisms, including Streptococcus, against anaerobs like Clostridium spp., and 
against some Gram-negative bacteria like Neisseria meningitidis. With the exception of 
a few species, extensive resistance has developed in most organisms against these agents 
(Murray et al., 2012; Willey et al., 2008). The second group is made of penicillinase 
resistant penicillins (oxacillin, cloxacillin, dicloxacillin, methicillin and nafcillin). They 
are effective against Staphylococcus spp. that produce ß-lactamase (penicillinase). 
Aminopenicillins (ampicillin, amoxicillin, bacampicillin) belong to the third group. 
Their spectrum is extended towards Gram-negative organisms like Haemophilus 
influenzae, E. coli and Proteus mirabilis. Extended spectrum penicillins (carbenicillin, 
ticarcillin, mezlocillin and  piperacillin), also known as anti-pseudomonas penicillins, 
form the fourth group. They have increased activity against Gram-negative organisms 
including Pseudomonas spp., Enterobacter spp., and Proteus spp. (Doi and Chambers, 
2015; Murray et al., 2012; Willey et al., 2008) 
 
1.1.1.2 Cephalosporins 
  
Cephalosporins are classified into five generations on the basis of their spectrum 
of activity and resistance to various ß-lactamases.  First generation agents (e.g., 
cephalexin, cefalotin and cefazolin) are active primarily against Gram-positive 
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organisms, including methicillin sensitive S. aureus and have limited activity against 
Gram-negative bacilli. Second generation agents (e.g., cefaclor, cefuroxime and 
cefoxitin) have increased activity against Gram-negative bacilli and variable activity 
against Gram-positive cocci. Third generation agents (e.g., ceftazidime, cefotaxime and 
ceftriaxone) exhibit significantly increased activity against Gram-negative bacilli. The 
fourth generation drugs (e.g., cefepime) have further increased their spectrum of activity 
against both Gram-positive and Gram-negative bacteria (Murray et al., 2012; Willey et 
al., 2008). Members of the relatively recent fifth generation (e.g., ceftaroline) have 
increased affinity even to altered PBPs, particularly to PBP2a, i.e., the mutated version 
of the protein present in methicillin resistant Staphylococcus aureus (MRSA); hence,  it 
is the only ß-lactam effective against this group of pathogens (Craig and Andes, 2015; 
Harvey et al., 2007; Murray et al., 2012). The 3
rd
 and 4
th
 generation cephalosporins 
continued to be the ß-lactam drugs to be used in life-threatening infections despite the 
emergence of extensive resistance over the last few years. (Cole et al., 2015; Dancer, 
2001; Lee et al., 2015). 
1.1.1.3 Monobactams 
 
Monobactams (e.g. aztreonam) are bactericidal antibiotics with a spectrum that is 
restricted to aerobic Gram-negative bacteria (Forbes et al., 2002; Willey et al., 2008). 
1.1.1.4 Carbapenems 
 
Carbapenems have a structure that renders them highly resistant to ß-lactamases. 
They are active against most Gram-positive and Gram-negative aerobic and anaerobic 
bacteria. The four most commonly used carbapenems are imipenem, meropenem 
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ertapenem and doripenem. Imipenem is used along with the inhibitor cilastatin to 
prevent its metabolism by the renal dehydropeptidases (DHP-1). Unlike meropenem, 
imipenem is more active against Gram-positive than Gram-negative bacteria. 
Meropenem demonstrats a long half-life with higher blood levels and therefore does not 
require the co-administration of cilastatin (Murray et al., 2012; Willey et al., 2008). 
Ertapenem is not active against non-fermenting organisms like Acinetobacter and 
Pseudomonas; therefore it is not used in nosocomial infections without a known 
etiology. Doripenem is a newly approved carbapenem with a broad spectrum coverage 
and anti-pseudomonal activity and is used for the treatment of serious nosocomial 
infections including ventilator associated pneumonia. Today carbapenems are the 
ultimate ß-lactam drugs, particularly in the treatment of severe Gram-negative infections 
(Falagas et al., 2014; Hawkey and Livermore, 2012; McLaughlin et al., 2013; Papp-
Wallace et al., 2011; Zhanel et al., 2007). 
 
1.1.2 Fosfomycin 
 
Fosfomycin was initially isolated in 1969 from cultures of Streptomyces fradiae, 
although it can now be produced by chemical synthesis. There are three forms of 
fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium for oral 
use, and fosfomycin disodium for intravenous use (Karageorgopoulos et al., 2011). 
 
Fosfomycin has a unique mechanism of action and is often synergistic with other 
classes of antibiotics, including ß-lactams, aminoglycosides and fluoroquinolones. It is 
bactericidal and inhibits the bacterial cell wall biogenesis by inactivating the enzyme 
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UDP-N-acetylglucosamine-3-enolpyruvyltransferase, also known as MurA. During 
peptidoglycan biosynthesis, this enzyme catalyzes the ligation of phosphoenolpyruvate 
(PEP) to the 3'-hydroxyl group of UDP-N-acetylglucosamine. This pyruvate moiety 
provides the linker that bridges the glycan and peptide portion of peptidoglycan. 
Fosfomycin is a PEP analog that inhibits MurA by alkylating an active site cysteine 
residue (Cys 115 in the Escherichia coli enzyme) (Karageorgopoulos et al., 2011; 
Michalopoulos et al., 2011).  
 
Fosfomycin has broad antibacterial activity, covering both Gram-positive and 
Gram-negative pathogens, and has an excellent activity against extended spectrum β-
lactamase (ESBL) producing pathogens, notably against E. coli and K. pneumoniae. 
Lately, it is increasingly mentioned as a ―rescue drug‖ for infections due to carbapenem 
resistant organisms. Although development of bacterial resistance during therapy has 
been documented, little is known about the rate of resistance among MDR Gram-
negative bacteria  (Falagas et al., 2008; Neuner et al., 2012; Senol et al., 2010). 
 
1.2 Resistance to Antibiotics 
 
 Resistance to antimicrobial treatment, in a broad sense, can be attributed to 
several cellular and non-cellular factors. Examples of situations in the latter group are 
when, the antibiotics cannot reach an otherwise susceptible cell in sufficiently high 
concentration because of its location (e.g. bone tissues, prostate or the central nervous 
system) or unique growth pattern (e.g. biofilms). Although these situation can lead to 
unsuccessful antibiotic treatment, i.e., resistance to therapy, they are not considered to be 
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cases of antibiotic resistance, per se¸ since resistance derives from the native (intrinsic), 
or acquired features of the microbial cell.(Blair et al., 2015; Chen et al., 2009; Davies 
and Davies, 2010; Opal and Pop-Vicas, 2015). 
 
Intrinsic resistance is a type of antibiotics resistance that result from the normal, 
standard, wild type genetic, structural or physiologic features of a microorganism. It is 
associated with a majority strains that represent a particular taxonomical entity, group, 
genus or species. Consequently, when such a particular strain is isolated, these aspect of 
its antibiotic resistance profile are predictable, for as observed with e.g., ertapenem 
resistance of non-fermenting Gram-negative rods (Forbes et al., 2002; Opal and Pop-
Vicas, 2015). 
 
Acquired resistance, on the other hand, results from alterations in the wild type 
genetic make-up of a microorganism. This type of resistance is associated with particular 
strains of a given taxonomical entity only (e.g., meropenem resistance of non-fermenting 
Gram-negative rods). Consequently, the presence of this acquired resistance is not 
predictable based on taxonomy. This type of resistance can be acquired by: 
 a mutation  
 horizontal gene transfer, i.e., uptake and successful expression of new 
genetic material into the genome of the cell 
(Alekshun and Levy, 2007; Forbes et al., 2002; Magiorakos et al., 2012) 
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1.2.1 Mechanisms of Antibiotic Resistance 
 
Bacteria share some common strategies leading to resistance to antibiotics 
irrespective of whether the resistance is intrinsic or acquired. Sometimes, multiple 
mechanisms, affecting the same group of antibiotics are required to achieve clinically 
relevant decrease in susceptibility (e.g., a reduction in intracellular concentration of the 
drug combined with the production of a moderately effective hydrolyzing enzyme 
(Dever and Dermody, 1991; Harvey et al., 2007; Murray et al., 2012). On the other 
hand, not infrequently, multiple mechanisms sufficiently effective on their own may be 
present in the same cell providing an apparent redundancy in achieving resistance (e.g., 
the presence of multiple carbapenemases) (Arnold et al., 2011; Bush, 2013; Opal and 
Pop-Vicas, 2015). Quite commonly, multiple mechanisms affecting different groups of 
antibiotics co-expressing in the same cell lead to MDR (Alekshun and Levy, 2007; 
Nikaido, 2009; Tortora et al., 2013). The most common mechanisms of antibiotic 
resistance are as follows (Blair et al., 2015; Lin et al., 2015; Shaikh et al., 2015): 
 
 producing  enzymes that destroys the antibiotic 
 altering antibiotic‘s target molecule (while preserving its functionality). 
 reducing the drugs uptake 
 increasing efflux of the compound 
 molecular shielding of the antibiotic‘s target resulting in preventing proper 
access of the antibiotic molecule 
 By-passing the metabolic steps the antibiotic is supposed to interfere with  
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Bacteria are often increasingly resistant to multiple antibiotics, representing an 
increased threat to health-care both in the community, as well as in the hospitals. 
Recently, the Centers for Disease Control and Prevention (CDC), USA have identified 
those organism which represent the most urgent threats of antibiotic resistance (Table 2.) 
(CDC, 2013) 
Table 2: Categories of urgent threats of antibiotic resistant bacteria 
 
1.3 Resistance to ß-Lactam Antibiotics 
 
Bacterial resistance to β-lactams can be mediated by: 
 altering the target of the drugs 
 decreasing the intracellular concentration of the compound  
 enzymatic destruction of the antibiotics 
 
Urgent 
threats 
 Clostridium difficile  
 Carbapenem-resistant Enterobacteriaceae (CRE)  
 Drug-resistant Neisseria gonorrheae 
 
 
 
 
 
 
 
Serious 
threats 
 Multidrug-resistant Acinetobacter  
 Drug-resistant Campylobacter  
 Fluconazole-resistant Candida (a fungus)  
 Extended spectrum β-lactamase producing Enterobacteriaceae 
  (ESBLs)  
 Vancomycin-resistant Enterococcus (VRE)  
 Multidrug-resistant Pseudomonas aeruginosa  
 Drug-resistant non-typhoidal Salmonella  
 Drug-resistant Salmonella Typhi 
 Drug-resistant Shigella 
 Methicillin-resistant Staphylococcus aureus (MRSA)  
 Drug-resistant Streptococcus pneumoniae  
 Drug-resistant tuberculosis  
 
Concerning 
threats 
Vancomycin-resistant Staphylococcus aureus (VRSA)  
Erythromycin-resistant Group A Streptococcus  
Clindamycin-resistant Group B Streptococcus  
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1.3.1 Target Alteration 
 
The first mechanism is common and highly effective in Gram-positive bacteria 
(e.g., in methicillin resistant Staphylococcus aureus, MRSA or in Streptoccoccus 
pneumoniae), and is also present in some Gram-negative organisms (e.g., the ß-
lactamase negative, ampicillin resistant (BLNAR) strains of Haemophilus influenzae 
(Dever and Dermody, 1991; Lambert, 2005; Tristram et al., 2007).  However, in 
converting Enterobacteriaceae to ß-lactam resistant, it has limited, if any role; hence it 
will not be discussed here. 
1.3.2 Decreasing Intracellular Concentration 
 
The intracellular concentration of a drug can be limited in two ways either by 
expelling molecules already taken up or by limiting their uptake. The first mechanism is 
usually achieved by the up-regulation of the expression of efflux pumps  (Poole, 2005; 
Webber and Piddock, 2003). These efflux pumps vary in the spectrum of compounds 
they are able to expel from the cell, but often they are multi-drug efflux pumps 
(Aeschlimann, 2003; Rouveix, 2007; Sun et al., 2014). Although this spectrum may 
include various ß-lactam drugs in Enterobacteriaceae, in their cephalosporin and 
carbapenem resistance efflux pumps, play a comparatively minor role, seldom leading to 
clinically significant level of resistance to these agents (Andersen et al., 2015; Pages et 
al., 2009). 
 
The other mechanism is the modification of porins in the outer membrane 
resulting in limited uptake of the drugs. This mechanism has considerable effectiveness 
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in Enterobacteriaceae, by lowering the susceptibility to cephalosporins and 
carbapenems (Pages et al., 2008; Wozniak et al., 2012) are porin loss (Yang et al., 
2010), narrowing channel of porins (Nikaido, 1989), and decreasing expression of porin 
(Doumith et al., 2009) the three distinct strategies of porin modification to limit the 
carbapenem uptake in Enterobacteriaceae (Pages et al., 2008). If alone, uptake 
restriction due to porin loss may not result in clinically significant loss of susceptibility; 
however, once, combined with the production of hydrolytic enzymes, even with limited 
carbapenemase activity on their own (see later), the combined effect of these two 
mechanisms can cause clinically significant carbapenem resistance. 
1.3.3 Enzymatic Degradation of ß-Lactams 
 
Enzymatic inactivation of β-lactam agents is the most common and most 
effective resistance mechanism among Enterobacteriaceae against this group of 
antibiotics (Forbes et al., 2002; Murray et al., 2012).  
 
Two classification schemes for ß-lactamases are currently in use (Bush and 
Jacoby 2010). The Ambler molecular system, based on conserved and distinguishing 
amino acid motifs, classifies ß-lactamases into four molecular classes, i.e., A, B, C, and 
D (Table 3 - see page 18). On the other hand, grouping by the Bush-Jacoby-Medeiros 
system is based on the functional similarities (including substrate spectrum and 
susceptibility to inhibitors, such as clavulanic acid, sulbactam and tazobactam) of the 
various enzymes forming four main, and multiple subgroups (Table 3.) (Ambler, 1980; 
Bush and Jacoby, 2010; Hall and Barlow, 2005). 
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The highest number of ß-lactamases are found in Ambler molecular class A. 
They can characteristically be inhibited by ß-lactamase inhibitors. Their genes are often 
located on plasmids; therefore, they have the ability to spread among members of the 
same species or even among different genera. The best known representatives of this 
group are Temoneira (TEM) and Sulfhydryl reagent variable enzyme (SHV) type 
enzymes. The original molecules had relatively narrow substrate spectrum. However, 
subsequent mutations have resulted in considerable extension of their spectrum, 
including 3
rd
 and 4
th
 generation cephalosporins (and in some cases a low activity also 
against carbapenems). Enzymes with such extended spectrum are called extended 
spectrum ß-lactamases (ESBLs) (Fong and Drlica, 2003; Harvey et al., 2007; Rupp and 
Fey, 2003). 
 
Beyond the TEM and SHV-type ESBLs, there are several other groups of such 
enzymes. Currently, the Cefotaximase (CTX-M) type of ESBLs, with characteristically 
high activity against cefotaxime, represents a new and rapidly growing family of 
molecular class A ESBLs. They have five distinct phylogenetic groups and several types 
have been described. In recent years, the CTX-M type ESBLs are now actually the most 
frequent ESBL type worldwide (Bonnet, 2004; Cantón et al., 2008; Eisner et al., 2006; 
Zowawi et al., 2013) 
 
Other important members of this group are the enzymes with an even further 
extended activity spectrum, i.e., carbapenemases. An important example is the K.   
pneumoniae carbapenemase (KPC), first detected in USA in 1996, that is currently the 
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most common carbapenemase in several parts of the world (Arnold et al., 2011; 
Nordmann et al., 2009; Sonnevend et al., 2015a; Won et al., 2011; Zowawi et al., 2014).  
 
Molecular class B enzymes are the so-called Metallo ß-lactamases (MBL) that 
require a divalent cation for their activity and hence, can be inactivated by chelators, 
such as EDTA or dipicolinic acid (DPA). There are several broad spectrum enzymes 
among them with activity against all ß-lactams (including carbapenems) with the 
exception of monobactams. Similar to group A enzymes, their genes can often be found 
on mobile genetic elements. They are commonly present in non-fermenting bacteria, 
such as Pseudomonas and Acinetobacter¸ but are spreading fast in Enterobacteriaceae. 
Examples of these enzymes are the Verona integron-encoded metallo-β-lactamase 
(VIM), Imipenem Metallo ß-lactamases (IMP) and the recently emerging New Delhi 
Metallo ß-lactamases (NDM) (Cornaglia et al., 2011; Ghazawi et al., 2012; Sonnevend 
et al., 2012; Walsh and Toleman, 2012). 
 
The most important types of class C enzymes are the AmpC-type enzymes. 
Some, if hyper-expressed, have broad spectrum activity which includes hydrolysis of 3
rd
 
and 4
th
 generation cephalosporins, and in some cases, have even a weal to moderate 
activity against carbapenems. In some species, the over expression of the ß-lactamase to 
achieve clinical resistance is inducible by ß-lactam drugs, while in others they are 
constitutively expressed (Hanson, 2003; Jacoby, 2009; Thomson, 2010). 
 
Molecular class D enzymes are primarily oxacillinases (OXA) that  vary in their 
spectrum considerably. An important group even has carbapenemase activity, although 
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some of these enzymes exhibit simultaneously no or moderate activity against 
cephalosporins (Evans and Amyes, 2014; Walther-Rasmussen and Høiby, 2006). They 
predominantly occur in various non-fermenting Gram-negative rods, but currently are 
fast spreading in Enterobacteriaceae.(Ahn et al., 2015; Cantón et al., 2012). 
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Table 3: Classification of β-lactamases 
(Bush and Jacoby, 2010; Bush et al., 1995) 
Molecular 
class 
Bush-
Jacoby-
Medeiros 
Active 
site 
Enzyme type Substrates Examples Inhibitors 
Gene 
Location 
A 
2a 
2b 
2be 
2br 
2c 
2e 
2f 
Serine 
Penicillinases 
Broad Spectrum 
Aminopenicillins TEM1 
SHV1 
Clavulanic 
acid 
Plasmid 
Chromosome 
Extended Spectrum ß-
lactamases (ESBL) 
Broad spectrum and 
aztroneam 
TEM-derived, 
CTX- derived 
Clavulanic 
acid 
Plasmid 
Carbapenemases 
 
Extended spectrum plus 
cephamycins 
KPC-2 
KPC-3 
Clavulanic 
acid 
Chromosome 
B 3 Zn
2+
 
Metallo-β-lactamases Extended spectrum plus 
cephamycins 
IMP,VIM, GIM, 
NDM 
EDTA Plasmid 
Chromosome 
C 
1 
1e 
Serine 
Cephalosporinases Extended spectrum plus 
cephamycins 
AmpC-type Cloxacillin 
Monobactam 
Plasmid 
Chromosome 
D 
2d 
 
Serine 
Oxacillinases 
Broad spectrum 
Cloxacillin, methicillin OXA-family in 
P. aeruginosa 
Clavulanic 
acid +/- 
Plasmid 
Chromosome 
Extended spectrum 
 
Broad spectrum and 
monobactams 
OXA-derived in 
P. aeruginosa 
Clavulanic 
acid +/- 
Plasmid 
Chromosome 
Carbapenemases Extended spectrum plus 
cephamycins 
 
OXA-derived in 
Acinetobacter 
Clavulanic 
acid +/- 
Plasmid 
Chromosome 
Not 
Determined 
4 
Not 
available 
Penicillinase from 
Pseudomonas 
cepacia 
Penicillins Not available Clavulanic 
acid – 
EDTA 
Not available 
 
1
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1.4 Fosfomycin Resistance  
 
Bacteria use several mechanisms to resist fosfomycin, including decreasing drug 
uptake, modification of the target site, and inactivation of the antibiotic (Castañeda-
García et al., 2013; Karageorgopoulos et al., 2011). There are two main fosfomycin 
transport systems in E. coli involving the glycerol-3-phosphate transporter (GlpT) and a 
hexose phosphate transporter (UhpT), respectively. Any mutations affecting either of 
these transporters can result in fosfomycin resistance. The GlpT transporter is 
constitutively expressed, while the UhpT is inducible, mainly in the presence of glucose-
6-phosphate (Cordaro et al., 1976; Huang et al., 2003).  
 
Modification of MurA, the target of the drug‘s action (Karageorgopoulos et al., 
2011), and overexpression of MurA (Horii et al., 1999) are also causing resistance to 
fosfomycin. These mechanisms have been reported in E. coli, Vibrio fischeri, 
Mycobacterium tuberculosis and Chlamydia trachomatis (Kumar et al., 2009; Nilsson et 
al., 2003; Takahata et al., 2010) 
 
Presence of specific genes can contribute to the development of resistance to 
fosfomycin. Three main genes have been described in pathogenic bacteria like fosA, 
fosB and fosX (Arca et al., 1988; Leon et al., 1985; Suárez and Mendoza, 1991). The 
fosA and fosB genes are typically found in plasmids of Gram-negative and Gram-
positive bacteria, respectively, while fosX is a chromosomal enzyme of Listeria 
monocytogenes. Novel resistance determinants that mediate transferable resistance to 
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fosfomycin through inactivation of the antibiotic have also been described (Ho et al., 
2013; Lee et al., 2012; Wachino et al., 2010) 
 
1.5 Disinfectants and Disinfectant Resistance 
 
Antibiotics are not the only agents with anti-microbial activity. Disinfectants and 
antiseptics are biocides, i.e., chemical substances acting on a broad variety of species. 
Disinfectants are applied on non-living surfaces, while antiseptics are used on live 
tissues to reduce the number, or in some cases, eliminate infecting microorganisms 
(McDonnell and Russell, 1999; Russell, 2002). 
 
Biocides are commonly used in medicine, agriculture, forestry and industry. 
However, the overuse or improper storage of the formulations lead to the development 
of  resistance to biocides due to decrease in the effective concentration (Chapman, 1998; 
Poole, 2002). This phenomenon has been reported and published since 1950s, 
particularly with the contamination of cationic biocide formulations (Chapman, 2003a; 
Russell, 2002). 
 
Biocides have been classified into four main groups with multiple subgroups 
(AccuStandard, 2014; EU, 2012): 1. Disinfectants and general biocidal products, 2. 
Preservatives, 3. Pest control agents and 4. Other biocidal products. Agents which are of 
prime importance in infection control belong to group 1.  
 
The quaternary ammonium compounds (QACs) like benzalkonium chloride 
(BENZ), cetylpyridinium chloride, cetrimide, proceine and detizor are routinely used in 
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both clinical and industrial settings, like disinfecting food-processing and production 
environments, in order to prevent the spread of pathogens (Russell, 2000; Sidhu et al., 
2002; Sidhu et al., 2001). Consequently, it has been suggested that QACs can play a role 
in promoting the development of antimicrobial resistance by co- or cross-resistance to 
antimicrobials (Chapman, 2003b). 
 
The mechanisms of action of the biocide depends on the bacterial structure that 
biocides interact with. Accordingly, three levels of interaction can be described: (i) 
interaction with outer cellular components, (ii) interaction with the cytoplasmic 
membrane, and (iii) interaction with cytoplasmic constituents (Busta et al., 2006). 
 
Intrinsic and acquired are two main mechanisms have been developed by 
bacteria to resist biocides. The first mechanism is intrinsic (inhered by bacterium) that 
include change in permeability, efflux pumps, degradation and modification of target 
sites. On the other hand, acquired (mutations or acquisition of mobile genetic elements) 
is the second mechanism. In both mechanisms, the concentration of intracellular of 
biocides are decreased to an extent that they lose effectiveness (Busta et al., 2006). 
There are some factors affecting biocides activity, notably concentration, period of 
contact, pH, temperature, the type, nature and numbers of microorganisms to be 
inactivated, and the presence of organic or other interfering materials (Chapman, 2003a; 
Cloete, 2003; Russell, 2002).  
 
Bacteria may become resistant to all known biocides (Chapman, 1998). In the 
health care setting, bacterial resistance to biocides has long been reported with 
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compounds such as: chlorhexidine (Stickler, 1974); quaternary ammonium compounds 
(Gillespie et al., 1986); bisphenol triclosan (Schmid and Kaplan, 2004); iodophor 
(Anderson, 1989); parabens (Flores et al., 1997; Valkova et al., 2001) ; and more active 
biocides such as glutaraldehyde (Vikram et al., 2015) and peroxygens (Eissa et al., 
2014). While biocides are effective against planktonic populations of bacteria, they 
could be ineffective against nosocomial pathogens growing in biofilms (Otter et al., 
2015). 
 
 
Regarding the most common efflux-related biocid resistance genes, sugE(c), 
emrE, ydgE/ydgF and mdfA are chromosomally encoded QAC resistance genes  (Bay 
and Turner, 2009; Edgar and Bibi, 1997; Zou et al., 2014).  The mdfA belongs to the 
major facilitator superfamily (MFS) of efflux pumps, while sugE(c) ,emrE and 
ydgE/ydgF are members of the small multidrug resistance (SMR) family. Additionally, 
five QAC resistance genes qacE, qacED1, qacF, qacG and sugE(p) have been identified 
on mobile genetic elements, e.g., on plasmids or on integrons, in Gram-negative 
organisms. They belong to the SMR family conferring efflux-mediated resistance to 
QACs  (Bay et al., 2008; K ücken et al., 2000; Russell, 1997; Zou et al., 2014). 
 
 It has been suggested that biocide and antibiotic resistance in bacteria might be 
linked by three main principles (Chapman, 2003a):  
 
1. Cross-resistance: genes that are encoding for resistance to both biocides and one 
or more antibiotic classes. This resistance can involve efflux pumps (Levy, 
2002a), changes in cell envelope that includes reduction or changes in porins, 
23 
 
 
 
LPS and other lipids (Denyer and Maillard, 2002), and finally, production of 
biofilm (SCENIHR, 2009).  
 
2. Co-resistance: genes encoding resistance or reduced susceptibility. These genes 
conferring resistance are presented on the same extra-chromosomal element, 
integrons, transposons or plasmids are transferred and expressed jointly in a new 
bacteria. For example, the qac-genes are often together with sul1 genes encoding 
sulphonamide resistance located as part of mobile genetic elements, which can 
also harbor various other resistance genes (Sidhu et al., 2002; Sidhu et al., 2001). 
This observation is similar to what other investigators have found. For example, 
a similar distribution of three qac resistance genes have been observed in clinical 
S. aureus and Coagulase-negative staphylococci  (CNS) (Mayer et al., 2001). 
 
3. Enhanced DNA repair, e.g., by activating  SOS response in bacteria, which 
promotes horizontal gene transfer of resistance genes (Maiques et al., 2006; 
Úbeda et al., 2005) 
 
1.6 The Spread of Resistance  
 
The spread of resistance is a highly complex phenomenon. It takes place at two 
distinct levels: at the level of the microorganism, and at the level of the niches providing 
an environment sustaining resistant cells. On the former level, on one hand, it includes 
the re-location of resistance gene-containing genetic elements, such as genomic islands, 
transposons, gene cassettes and integrons between various parts of the genome within 
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the cells (Forbes et al., 2002; Normark and Normark, 2002).  On the other hand 
resistance genes pass across cellular, often even across species borders, by horizontal 
gene transfer via transduction, conjugation and transformation (Gyles and Boerlin, 2014; 
Harvey et al., 2007). The combination of these mechanisms allows, as often has been the 
case for ß-lactamases, that resistance genes originally evolved in environmental bacteria 
eventually reaching human pathogens (Alekshun and Levy, 2007; Blair et al., 2015; 
Stokes and Gillings, 2011).  
 
The other level of spread of resistance takes place at the level of the 
environment, defined in a broader sense i.e., as the inanimate environment, as well as the 
host. This means the capacity of the strain to survive in and spread between susceptible, 
permissive niches, inanimate or alive.  It requires the delicate interaction between the 
microorganism and the particular niche. The latter one should provide conditions to 
sustain the microbe, i.e., it should be susceptible to be colonized by the particular strain.  
 
1.7 Fitness, Pathogenicity and Virulence 
 
The microbe should be fit enough to take the chances offered by a given 
environment, i.e., it should be fit enough to face the challenges. Importantly, if the niche 
also provides selective advantage to the resistant cells, e.g., it contains the antibiotic to 
which certain cells of the population are more resistant to than others, their rate in the 
population increases to the level of being exclusive. (Forbes et al., 2002; Harvey et al., 
2007; Murray et al., 2012).  Fitness is the capacity of a microorganism to maintain itself 
in a permissive environment either inanimate or alive. Pathogenicity is the capacity to be 
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maintained in a susceptible living host of a specific species in a way that is harmful to 
the latter organism. The extent of this capacity is expressed by the quantitative term 
―virulence‖ and its extent is determined by the presence, variety, and expression of 
specific microbial factors (i.e. ―virulence factors‖) needed for these specific parasite-
host interactions. The concept is summarized in Figure 2. 
 
 
 
 
  
 
 
 
 
 
Figure 2: An overview of bacterial mechanisms of pathogenicity  
(Tortora et al., 2013). 
 
 
Within a species there could be specific phylogenetic lineages with uneven 
distribution of virulence factors among them making one lineage more likely to be 
pathogenic than others. This is particularly well studied in E. coli. In 2000, a triplex PCR 
was developed to identify the major phylogenetic groups (A, B1, B2 and D) of this 
species (Clermont et al., 2000), which was further refined recently (Doumith et al., 
2012). The majority of E. coli strains causing extraintestinal infections (Extraintestinal 
Pathogenic E. coli, ExPEC) belong to phylogroup B2, and, less commonly, to 
phylogroup D (Dale and Woodford, 2015). 
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The set of virulence factors present in a cell determines the site of infection, as 
well as the ways of interaction with the host. Their presence and the level of their 
expression promote the fitness and survival for a given strain when it encounters specific 
environment. In certain species, i.e., E. coli, various pathotypes may exist, i.e., the 
several groups of enteropathogenic types and ExPEC types (Köhler and Dobrindt, 2011; 
Wilson et al., 2002; Wu et al., 2008).  The most common virulence factors of ExPEC are 
shown in Table 4. (Dale and Woodford, 2015).  
 
Beyond these specific virulence factors directly involved in host-parasite 
interactions, other cellular components may have an indirect, or still to be understood 
direct role, in the pathogenesis or fitness of the isolates. One such component is the core 
of the lipopolysaccharide molecule, a structure specifically studied in my project. 
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Table 4: ExPEC virulence factors 
  
Virulence Factors Gene (S) Gene (S) 
Adhesins  
Adhesion siderophore iha 
Dr binding adhesins afa/draBC 
E. coli common pilus ecpA 
F1C fimbriae foc gene cluster 
Heat-resistant haemagglutinin hra 
M fimbriae bmaE 
N-acetyl D-glucosamine-specific fimbriae gaf 
P fimbriae papACEFG 
S fimbriae sfa/sfaS 
Temperature sensitive haemagglutinin tsh 
Type 1 fimbriae fimH 
Iron acquisition systems  
Aerobactin receptor iutA 
Peri-plasmic iron binding protein sitA 
Salmochelin receptor iroN 
Siderophore receptor ireA 
Yersiniabactin receptor fyuA 
Protectins and invasins  
Colicin V cva 
Conjugal transfer surface exclusion protein traT 
Group 3 capsule kpsMT III 
Increased serum survival iss 
Invasion of brain endothelium ibeA 
K1/K2/K5 group 2 capsule variants K1/K2/K5 genes 
kpsM II group 2 capsule kpsM II 
Outer membrane protease T ompT 
Toxins  
α-haemolysin hlyD 
Cytolethal distending toxin cdtB 
Cytotoxic necrotising factor cnf1 
Enteroaggregative E. coli toxin astA 
Haemolysin A hlyA 
Secreted autotransporter toxin sat 
Serine protease pic 
Vacuolating toxin vat 
Others  
 ß-glucoronidase uidA 
Colibactin synthesis clb & clbB 
Uropathogenic-specific protein usp 
Flagellin variant  H7 fliC 
Maltose and glucose-specific PTS transporter subunit IICB malX 
Pathogenicity island marker malX 
D-serine deaminase DsdA 
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1.7.1 The Core Region of Lipopolysaccharide 
 
The lipopolysaccharide (LPS) of Gram-negative cell envelope forms the outer 
leaflet of the outer membrane (Figure 3.) (Donnenberg, 2015; Murray et al., 2012). 
Connecting the inner, highly conserved  Lipid A part, i.e., the endotoxin, to the 
outermost, highly variable O-specific side chain of LPS is the core. It is made of 
oligosaccharide components and commonly contains sugars such as heptose and 3-
deoxy-D-mannooctulosonic acid (also known as KDO, keto-deoxyoctulosonate) (Amor 
et al., 2000; Wang and Quinn, 2010). The core oligosaccharide (OS) forms a linear or a 
branched structure. The core-OS region can be divided into two regions: the inner and 
outer cores (Figure 3.). The inner core is attached directly to lipid A and is less variable 
and its composition is normally characteristic of a genus or family (Wang and Quinn, 
2010). 
 
The outer core region is more variable, being the part more exposed towards the 
external pressures. It is normally referred to as the hexose region, and is usually 
composed of neutral and basic hexoses (Frirdich and Whitfield, 2005; Wang and Quinn, 
2010). By comprehensive study and sequence analysis for the chromosomal waa loci, 
Amor et al. have developed a PCR-based LPS core typing system for E. coli isolates 
(Amor et al., 2000).  
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Figure 3: The envelope of Gram-negative bacteria   
(Beutler and Rietschel, 2003).  
 
 
In E. coli there are 5 core types distinguished: R1-4 and K-12 (Frirdich and 
Whitfield, 2005). Importantly, studies in the 1990s and early 2000s found that the 
distribution of these core types among commensal strains and those isolated from 
clinical cases were uneven. Among E. coli isolated from human blood stream infection 
(BSI) R1 (69.4%) was the most common followed by R2 (11.1%) , R3 (11.1%),  K-12 
(5.6%) and R4 (2.8%) respectively (Appelmelk et al., 1994; Gibb et al., 1992). These 
frequencies were well reflected by the distribution of core-type-specific antibodies in the 
population (Gibbs et al., 2004). However, it has been noticed lately that previously rare 
core types R4 and K-12 have become more common, at least in animal infections (Duda 
et al., 2011). More recently, it was found in our laboratory that strains isolated from 
urinary tract infections in the United Arab Emirates exhibited a  surprisingly high 
frequency of the K-12 core type (44.6%) among ESBL producing strains that was 
clearly associated with the ST131 MDR clone (see later) (Szijártó et al., 2012). Based on 
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these data, the possibility that newly emerging clones could have an advantage if 
expressing previously rare core types was raised (Szijártó et al., 2012). 
 
1.7.2 The Relationship Between Antimicrobial Resistance and Fitness/Virulence 
 
Antimicrobial resistance and bacterial virulence have developed independently; 
nevertheless, they share some common characteristics. Both are to counteract 
mechanisms which, if successful, could eliminate the microbe (Beceiro et al., 2013; 
Martínez and Baquero, 2002). In some cases, the association between fitness and 
resistant antimicrobial actions are caused by being shielded in unique niches, i.e., 
intracellularly or within the matt of biofilms (Patel, 2005). Some microbial mechanisms, 
e.g. efflux pumps, may affect both, resistance and fitness, as well, as they may eliminate 
from the cells not only compounds that could potentially prevent colonization of the 
host, but also antimicrobials (Opal and Pop-Vicas, 2015; Poole, 2002).  However, the 
connection is often inverse: an overexpression of an efflux pump or the down regulation 
or loss of porins might be needed for survival in an antibiotic rich environment, but may 
affect negatively the fitness of the cells (Doumith et al., 2009; Yang et al., 2010). 
 
A further, unique, way of linking drug resistance and virulence together is the co-
location of fitness/virulence and antibiotic resistance genes on the same, usually mobile, 
genetic elements, such as plasmids. Not only that in this case the two features could 
spread together horizontally, but also they are co-selected for, i.e., within the host the 
pressure to be fit also would also mean selection for being resistant (Beceiro et al., 
2013).  
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So, the possible links between fitness/virulence and antimicrobial resistance is 
not unidirectional, i.e., not necessarily the most fit/virulent strains are the most resistant 
ones and vice versa. What is clear is that certain resistant clones have a unique capacity 
to spread. They are often mentioned as the ―International High Risk MDR Clones‖ 
(Mathers et al., 2015). 
 
1.8 International High Risk MDR Clones 
 
During the past decade, an increasingly trend has been observed, i.e., a 
considerable part of the outbreaks by MDR Enterobacteriaceae being due to a limited 
number of related strains, i.e., clones. In some cases, the clones were clearly 
homogenous, while in others the level of heterogeneity regarding the features of the 
clones, including virulence, as well as the mechanism and spectrum of their antibiotic 
resistance varied (Mathers et al., 2015). 
 
1.8.1 E. coli High Risk Clones 
 
One of the best studied example of such clones is the E. coli ST131 (O25:H4) 
clone which has recently been responsible for the increasing proportion of extraintestinal 
infections caused by this species. Initially, the clone was associated with CTX-M type, 
mostly, but not exclusively the CTX-M-15 type ESBLs (Pitout, 2010; Pitout, 2012) 
significantly contributing to the global spread of this enzyme  (Naas et al., 2008) (Figure 
4.). Today, a substantial proportion of MDR ExPEC belong to ST131 and it is described 
as a ST-lineage pandemic (Al-Agamy et al., 2014; Blanco et al., 2011; Bonnet, 2004). 
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Figure 4: Global distribution of CTX-M genotypes  
(Hawkey and Jones, 2009). 
 
As a result, in many parts of the world 10–40% of E.coli and K. pneumoniae strains 
express ESBLs (Rupp and Fey, 2003). Most importantly, members of the same clone 
have been described to carry other type of ß-lactamases, such as carbapenemases 
(Peirano et al., 2011). Beyond ST131, several STs of  E. coli have been described as 
international clones: e.g. ST10, ST12, ST38,  ST73, ST95, ST127, ST393, ST405, and 
ST648 (Petty et al., 2014; Riley, 2014; Wirth et al., 2006; Woodford et al., 2011). 
 
The spread of E.coli lineages has been associated with certain resistance patterns. 
For example, ST69 is globally recognized as resistant primarily to trimethoprim-
sulphamethoxazole, but not regularly as an ESBL-producing clone. Other, very common 
ExPEC lineages, like ST73 and ST95, are common causes of UTI, but are rarely 
multidrug resistant (Riley, 2014). The ST405 was recently described as an E. coli clone 
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disseminating CTX-M-15 ESBL on a global scale (Coque et al., 2008; Hrabák et al., 
2009). The ST393 has also emerged as a MDR ExPEC. It is considered as member of 
the ST131 complex where it is associated with CTX-M-type ESBLs without losing 
virulence (Olesen et al., 2009). As mentioned earlier, the ST131 is associated closely 
with ESBL-production and quinolone resistance (Olesen et al., 2013). However, while 
most ST131 isolates belong to serotype O25, a sub-group has recently been identified as 
O16 (Banerjee and Johnson, 2014; Zhong et al., 2015). O25b:H4 serotype strains are 
commonly resistant to fluoroquinolones, aminoglycosides, trimethoprim-
sulfamethoxazole and extended-spectrum cephalosporins (Banerjee et al., 2013; Dashti 
et al., 2014).  
 
1.8.2 K. pneumoniae High Risk Clones 
 
Clonality is not restricted to E. coli. Most MDR K. pneumoniae isolates, which 
produce ESBLs and carbapenemases, often in combination with quinolone and 
aminoglycoside resistance, belong to particular clones. There are a number of STs of  K. 
pneumoniae strains associated with multidrug resistance: ST23, ST26, ST101, ST380, 
ST86, ST57, ST65, ST375, ST11, ST14, ST15, ST258 and ST512 (Baraniak et al., 2013; 
Bialek-Davenet et al., 2014; Breurec et al., 2013; Brisse et al., 2009; Woodford et al., 
2011).  Isolates that express capsule serotype K1 and are associated with pyogenic liver 
abscess belong to ST23 and ST57 and placed to Clonal Group (CG) 23 (Brisse et al., 
2009; Merlet et al., 2012; Turton et al., 2007). On the other hand, STs associated with 
serotype K2 were distributed into 3 main CGs: CG86, CG375, and CG380. In fact, K2 
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isolates associated with severe community-acquired infections are genetically more 
diverse than K1 isolates (Bialek-Davenet et al., 2014). 
 
Large outbreaks caused by successful clones of K. pneumoniae have been 
reported since the early 1990s in several countries (Arena et al., 2013). Inn Hungary, 
epidemic K. pneumoniae clones with CTX-M-15 were assigned to ST11, ST15 and 
ST147  (Damjanova et al., 2008). In the USA, Klebsiella pneumoniae carbapenmase 
(KPC) producing isolates belonging to ST258 were identified in 10 of the 19 states 
reporting such strains (Kitchel et al., 2009). In addition, ST258 have been reported from 
Brazil, China, Argentina, Colombia, Hungary, France, Greece, Poland, India, Israel, 
Norway, Scotland, and Sweden (DeLeo et al., 2014; Munoz-Price et al.; Nordmann et 
al., 2011) 
 
1.8.3 The Virulence of High Risk E. coli Clones 
 
Although the clonal dissemination of ExPEC and that of ESBL producing or 
carbapenem resistant K. pneumoniae (CRKP) strains is globally recognized and 
reported, the mechanism of their spread is not well understood. Usually, these strains are 
associated with both community-onset and healthcare-associated infections, in particular 
urinary tract and bloodstream infections (Hrabák et al., 2009; Riley, 2014). 
 
E. coli ST131 (O25b:H4) exhibit a wide array of virulence factors (Johnson, 
1991; Pitout et al., 2005). However, the relationship between virulence and drug 
resistance is rather complex (Beceiro et al., 2013). A study found that resistance to 
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quinolones, i.e., a common feature within this clone, is linked to a loss of virulence 
factors. At the same, time the low virulent phylogenetic groups might be more prone to 
acquire resistance to quinolones (Chakraborty et al., 2015; Da Silva and Mendonça, 
2012). Another study found that the rate of virulence factors among pathogenic E. coli 
strains isolated from human blood and urine was higher in the phylogenetic group B2. 
Alpha-hemolysin, yersiniabactin receptor (fyuA), serum resistance-associated outer 
membrane protein (traT) and aerobactin receptor (iutA) were found to be independent 
predictors for pathogenicity. Of these virulence factors, iutA and traT were significantly 
more common in strains producing the blaCTX-M-1 group and the blaCTX-M-9 group ESBLs, 
respectively (Lee et al., 2010). In contrast, another report found that the production of a 
CTX-M-1 enzyme does not appear to affect virulence (Dubois et al., 2009). 
Furthermore, the B2 epidemic strains circulating in the United Kingdom expressing 
CTX-M-15 did not appear to be more virulent, despite iutA and fyuA being more 
prevalent in these than in non-clonal CTX-M-15 producing isolates (Branger et al., 
2005; Lee et al., 2010). In fact, it seems that there are significant differences in the 
prevalence of individual virulence factors among CTX-M producers and non-producers 
(Karisik et al., 2008; Pitout et al., 2005). 
 
 
Certain ExPEC STs associate simultaneously with both high level of resistance 
and virulence, enabling them to cause major outbreaks at different locations (Table 5.) 
(Riley, 2014). This combination certainly provides a competitive advantage and ability 
for the clonal dissemination worldwide (Naseer and Sundsfjord, 2011; Van der Bij et al., 
2012). The dissemination of the resistant strains takes place either by medical tourism or 
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other human activities, or by contaminated vehicles or food products  (Adams-Sapper et 
al., 2012; Dale and Woodford, 2015; Riley, 2014) 
 
 
Table 5: Phenotypic and genotypic characteristics of pandemic ExPEC E. coli clonal 
lineages 
 
MLST Serogroups, 
serotypes 
phylogenetic 
group 
Prototypic virulence factor genes 
ST393 O15b:K52:H1 D 
iha (adhesin-siderophore), fimH (type 1 
fimbriae), fyuA (yersiniabactin 
receptor), 
iutA (aerobactin receptor), and kpsM II 
(group 2 capsule) 
 
ST131 
O25b:H4, O16:H5, 
NT:H4, O157 
B2 
iha and fimH (adhesins), sat (toxin), 
fyuA/irp2 and iutA/iucD (siderophore 
systems), 
kpsM II, usp (uropathogenic specific 
protein), traT (serum resistance-
associated), 
ompT (outer membrane protease), and 
malX (pathogenicity island marker) 
ST69 
O11, O15, O17, 
O44, O73, 
O77, O86, O125ab, 
O25b 
D 
F10 and F16 papA alleles, papG allele 
II, sfa/focDE (S and F1C fimbriae), 
focG 
(F1C fimbriae adhesin), iha, hlyD, cnf1, 
fyuA, iutA, iroN, malX, and afa/dra 
(Dr antigen-binding adhesins), cdtB, 
and K1 kpsMT 
ST95 
O1:K1:H7, 
O2:K1:H7, 
O18:K1:H7, 
O45:K1:H7 
B2 
fimH, fimAvMT78, papG II, iucD, iroN, 
kpsM II-K1, cvaC, iss, traT, malX, usp, 
and tsh 
ST73 O6:H B2 
papC, papEF, papG, sfa/foc, fimH, hra, 
hlyA, cnf1, pic, vat, iroN, fyuA, kpsM II, 
usp, and ompT 
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1.8.4 The Virulence of High Risk K. pneumoniae Clones 
 
The virulence-related genes of globally distributed clonal groups of K. 
pneumoniae has also been investigated in several studies. The type-3 fimbriae cluster 
mrkABCDF was almost universally present, and plasmid-associated clusters 
pcoABCDERS (copper-resistance) and silCERS (silver-resistance) were widely 
distributed. In contrast, some other genes were mainly associated with particular Clonal 
Groups (CGs). The allantoinase cluster was present only in members of CG23 and ST25. 
Some or all isolates of the major CGs associated with community-acquired invasive 
infections (CG23, CG86, CG375, and CG380) harbored the 2 well-recognized virulence 
factors, iucABCDiutA (aerobactin synthesis) and rmpA (the positive regulator of mucoid 
phenotype), in addition to the yersiniabactin siderophore cluster and, except for CG23, 
the 2-component regulatory system kvgAS. These results reinforce the view that CG23, 
CG86, CG375, and CG380 represent hypervirulent CGs of K. pneumoniae (Bialek-
Davenet et al., 2014; Bialek-Davenet et al., 2013). Several other STs and CGs (ST25, 
CG65, ST66, ST90 and ST382) also harbored virulence genes, suggesting additional 
hypervirulent clones, which is also supported by the clinical origin of some isolates of 
these STs. In contrast, CG258 was almost entirely devoid of virulence genes (Bialek-
Davenet et al., 2014; Bialek-Davenet et al., 2013; Bogaerts et al., 2010; Woodford et al., 
2011) 
 
On the other hand, a study found that the ability of ESBL producing and non-
producing K. pneumoniae strains to express type 1 and 3 fimbrial adhesins were not 
different significantly (Sahly et al., 2008). Conversely, the ability of ESBL producers 
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strains to invade ileocecal and bladder epithelial cells was significantly higher (81% and 
27.6%, respectively) than non-ESBL producers (61% and 10%, respectively), possibly 
due to the capacity to up regulate the expression of one or more invasion related genes. 
Nevertheless, it is still unclear whether this effect resulted from the direct expression of 
the blaSHV-type ESBL gene or from the expression of another plasmid-borne gene(s) 
(Beceiro et al., 2013; Sahly et al., 2008). 
 
As seen from the existing controversies, contrary to the abundance of data, still, 
very little is understood on the association between virulence and resistance, resistance 
and the ability to spread, and resistance to antibiotics and disinfectants. This study aimed 
to shed some lights on these questions, from the local, i.e., Arabian Gulf, perspective. 
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Chapter 2: Aims and Objectives 
 
2.1 Long Term Aims 
 
 The long term aim of the project is to contribute to a better understanding of the 
epidemiology of multidrug resistant Klebsiella pneumoniae and Escherichia coli in the 
Arabian Peninsula by understanding the dominant clones and the features in which 
clonal isolates differ from their sporadic counterparts.  
 
2.2 Specific Objectives 
 
A. To characterize blood-stream E. coli isolates by: 
- genotyping by PCR targeting virulence and antibiotic resistance genes 
- assessing their antibiotic resistance 
- establishing the clonal structure of the collection by macrorestriction analysis 
and multilocus sequence typing 
 
B. To characterize the virulence, antibiotic susceptibility and clonal structure of 
carbapenem resistant K. pneumoniae collected in the Arabian Peninsula by: 
- genotyping by PCR targeting virulence and antibiotic resistance genes 
- assessing their antibiotic resistance 
- subjecting the strains to macrorestriction analysis and multilocus sequence typing 
- assessing their serum sensitivity and biofilm forming capacity 
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C. To compare the biocide susceptibility of carbapenem resistant and susceptible E. 
coli and K. pneumoniae isolates by: 
- determining the quantitate susceptibility to chlorhexidine, benzalkonium and 
irgasan 
- testing for the presence of a panel of chromosomally coded, as well as plasmid 
located genes associated with disinfectant resistance 
 
D. To compare the susceptibility of carbapenem resistant and susceptible K 
pneumoniae strains to fosfomycin, i.e., an antibiotic currently not available in the 
UAE for parenteral use by: 
- determining the quantitative susceptibility of the isolates to fosfomycin and 
comparing it to susceptibilities to tigecycline and colistin, i.e., the other ―last 
resort‖ drugs 
- investigating the genetic background of fosfomycin resistant strains encountered 
by PCR-genotyping 
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Chapter 3: Material and Methods 
 
3.1 Bacterial Strains  
 
A total of 337 strains including 172 E. coli and 165 K. pneumoniae were 
included in various parts of the study. The specific numbers used for each project and 
their actual selection criteria and sources are detailed when describing the actual results. 
Duplicate isolates from the same patients were excluded and only the first isolate from 
each case was included. The strains were speciated by the laboratories of the 
participating hospitals using standard microbiological procedures (e.g. API or VITEK 2 
identification panels). When strains with a specific resistance type were collected (e.g. 
strains non-susceptible to carbapenems), this was done based on the results of tests run 
in the submitting laboratories. However, the resistance patterns were always confirmed 
by us (see later). All isolates were stored in duplicates in Tryptic Soy Broth (TSB), 
(MAST, UK) containing 10% glycerol (Univar, USA) in two separate -80
o
C freezers 
being on independent electrical circuits. Prior to each experiment, strains were revived 
onto Tryptic Soy Agar (TSA), (MAST, UK) by incubating for 24 h at 37 C. 
 
3.2 Antibiotic Susceptibility Testing  
 
All tests were carried out and evaluated by the Clinical Laboratory Standard 
Institute (CLSI) standards (CLSI, 2014), except for tigecycline, for which no breakpoint 
values are currently available in this system. In this case we used the ones recommended 
by EUCAST (www.eucast.org/clinical-breakpoints).  
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Qualitative antibiotic susceptibility testing was conducted by the Kirby-Bauer 
(disc diffusion) method. Fresh cultures grown on TSA plates were suspended in sterile 
1xPBS to 0.5 McFarland density and applied onto ready-made Mueller-Hinton agar 
(MHA) plates (Pangulf Lab Solution, UAE) with a swab (Citoswab, China) to provide 
semi-confluent growth. Antibiotic disks (MAST, UK) were applied using an applicator, 
seven discs per/ 90 mm dish. Plates were incubated for 18 h at 37
o
C. The diameters of 
the zone of inhibition were measured with a caliper. Susceptibilities were established 
against amikacin (AK), ampicillin (AP), augmentin (AUG), aztreonam  (AZT), 
ceftazidime (CAZ), chloramphenicol (CHL), ciprofloxacin (CIP), colistin (COL), 
cefpodoxim (CPD), cefotaxime (CTX), cefuroxime (CXM), doxycycline (DXT), 
ertapenem (ERT), fosfomycin (FOS), cefoxitin (FOX), gentamicin (GN), imipenem 
(IMP), meropenem (MEM), netilmicin  (NET), piperacillin-tazobactam (PTZ), 
trimethoprim-sulphamethoxazole (SXT), tigecycline (TGC), ticarcillin/clavulanic acid 
(TIM) and tobramycin (TOB).  
 
For quantitative assay the broth microdilution assay was used. Antibiotics were 
serially diluted in 100 µl volume of Muller Hinton Broth (MHB), (MAST, UK)  in 96 
well microplates (Nunc, USA) and inoculated by a Multipoint inoculator (MAST, UK) 
to give a final concentration of 5 x 10
5
 colony forming units (CFU)/ml. After 18 hours of 
incubation at 37 
o
C, the growth was visually assessed and the Minimum Inhibitory 
Concentration of the drug (MIC) was determined as the lowest concentration preventing 
visible growth of the organism tested. The quantitative susceptibility test was established 
against: imipenem (IMP), meropenem (MEM), ertapenem (ERT), ceftazidime (CAZ) 
and cefotaxime (CTX) respectively. For fosfomycin (FOS), tigecycline (TGC), colistin 
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(COL), the agar dilution method was used to determine the MIC. Different 
concentrations of antibiotics were prepared in 1 ml and added to 24 ml of MHA plate 
(MAST, UK). A 1:10 dilution of bacteria was prepared by adding 100 µl of 0.5 
McFarland to 900 µl of 1XPBS, to give a final concentration of 10
4
/µl. One µl of this 
suspension was delivered by the multipoint inoculator, i.e., approximately 10
4
 CFU/dot 
was inoculated. 
 
For all sensitivity assays, Escherichia coli ATCC 25922 strain was used as a 
susceptible control.  
 
3.3 Detection of MIC of Disinfectants 
 
Pure substances of triclosan (Irgasan) (IRG) (5-chloro-2-(2,4-dichlorophenoxy) 
phenol), chlorhexidine (CHEX) (1,1′-Hexamethylenebis[5-(4-chlorophenyl) biguanide], 
and benzalkonium chloride (BENZ) (Alkylbenzyldimethylammonium chloride) were 
purchased from (SIGMA, USA). The MIC of disinfectants was determined by agar 
dilution assay. Different concentrations of biocides were prepared in 1 ml and added to 
24 ml of MHA plate (MAST, UK). 1:10 dilution of the bacteria was prepared by adding 
100 µl of 0.5 McFarland to 900 µl of 1XPBS to give a final concentration of 10
4
/µl. 
 
3.4 Detection of ESBL Production 
 
This test was performed based on the CLSI criteria (CLSI, 2014) using MHA 
plates (Oxoid, Basingstoke, UK). The double disc synergy test was used to confirm 
ESBL production using a disc containing amoxicillin/clavulanic acid placed in the center 
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of the inoculated plate and discs containing various cephalosporins and aztroneam 
placed around 20 mm apart from the central disc. The strains exhibiting the ―keyhole‖ 
were considered as an ESBL producer (Apfalter et al., 2007; Bell et al., 1999).  
 
3.5 Detection of Carbapenemase Production (Modified Hodge Test) 
 
The general presence of carbapenemases were assessed by the modified Hodge 
Test (CLSI, 2014). MHA plates (Pangulf Lab Solution, UAE) were inoculated with a 0.5 
McFarland suspension of E.coli ATCC 25922. Ertapenem susceptibility disks were 
placed on the center of the plate. The test strain, a carbapenemase non-producing 
negative control strain (E. coli K-12 J53), and a KPC producing positive control (GR-
KPC2) were streak-inoculated towards the disc. The plate was incubated overnight at 
37
o
C. After 16-24 hours, the plate was examined for a cloverleaf-type indentation at the 
intersection of the test organism and E.coli 25922.  
 
3.6 Carba NP Test 
 
Carba NP test was performed as described (Nordmann et al., 2012b). One 
calibrated loop (10 μL) of the test strain was suspended in a Tris-HCl 20 mmol/L lysis 
buffer (B-PERII, Bacterial Protein Extraction Reagent; Thermo Scientific Pierce, 
Rockford, IL, USA), vortexed for 1 minute and further incubated at room temperature 
for 30 minutes. This bacterial suspension was centrifuged at 10,000 × g at room 
temperature for 5 minutes. Thirty μL of the supernatant, corresponding to the enzyme-
containing extract, was mixed in a 96-well plate with 100 μL of a 0.3% of Imipenem 
monohydrate solution (Sigma, Saint-Quentin Fallavier, France). Plates were incubated at 
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room temperature for a maximum of 2 hours. For carbapenemase producers, the color of 
the wells turned from red to orange or yellow. On the other hand, the color of the wells 
remained red if no carbapenemase activity was present.  
 
3.7 Detection of Biofilm Production by Klebsiella pneumoniae 
 
Klebsiella pneumoniae were sub-cultured on TSA plates and incubated at 37 
o
C. 
Next day 2 ml of Luria Broth (LB), (Invitrogen, USA) was inoculated and incubated 
with this bacterial strain overnight at 37 
o
C. On the third day, 2 ml aliquots of 1X M63 
broth supplemented with 20% Casamino Acid (CA), (BD, USA) and 0.2% glucose were 
inoculated with 10 μl of the bacterial suspension. Hundred μl aliquots of these 
suspensions were distributed into 96-wells plate (Nunc, USA), 4 wells per strain, and 
incubated overnight at 37 
o
C for 18 hours. Un-inoculated wells containing medium only 
served as negative controls. On the day four, 25 μl of 1% crystal violet were added to all 
wells. The plates were incubated at room temperature for 15 minutes. After the 
incubation period, the content of the wells was aspirated and washed 3X with 200 μl 
with distilled water. After that, the 96-wells plates were air dried at room temperature 
overnight. Next, 200 μl of lysing solution (1% SDS, 50% Ethanol, 1% PBS) were added 
and plates were gently shaken on a tilting table for 30 minutes. The optical density of the 
dissolved, dye-binding masses of biofilm forming bacteria was measured at 570 nm. 
 
The results were evaluated using an arbitrary scheme (Novais et al., 2012) 
defining the cut-off optical density value (ODc) for biofilm production as the mean + 
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three standard deviations of OD of the sterility control. The strength of biofilm 
production was scored as seen on Table 6. 
 
Table 6: Scoring system for the extent of biofilm production 
Score OD 
Nonadherent ≤ODc  
Weakly ODc  < OD ≤ 2 ODc 
Moderately 2 ODc < OD  ≤ 4 ODc 
Strongly > 4 ODc 
ODc – Cut-off optical density 
3.8 Detection of Serum Resistance  
 
Serum resistance were assayed by method of King et al. (King et al., 2009). 
Briefly, fresh cultures grown on TSA plates at 37°C were suspended in sterile 0.9% 
NaCl to 0.5 McFarland density. Normal human serum (NHS) was prepared from the 
blood of 4 healthy individuals. After clotting at room temperature, serum was separated 
by centrifugation for 30 minutes at 3,500 rpm at 37C. Sera was pooled and stored in 
aliquots at -80°C until use.  
 
0.5 McFarland bacterial suspensions were diluted 50 times to get 2x10
6 
CFU/ml 
by adding 40 μl of 0.5 McFarland suspension to 1960 μl 0.9% saline. 25 μl of 50 X 
bacterial suspension were mixed with 75 μl pre-warmed (37 oC) NHS in a microtitre 
plate (Nunc, USA), in parallels . Immediately after mixing, 20 μl of the first parallel was 
taken for 10X serial dilutions (-1, -2, -3) to determine the original germ count (zero 
time). The plate then was incubated at 37 °C for 3 hours. Again, a 20 μl of the 3 parallels 
were taken for serial dilutions (-1, -2, and -3) to determine the germ count after 3 hours 
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of incubation. Viable counts were determined after 18 hours of incubation by plating 25 
μl of each serial dilution on TSA plate for colony counts. In every experiment, a serum 
sensitive (K. pneumoniae 1321) and a highly resistant strain (K. pneumoniae 1023) were 
included. Serum sensitivity of strains was evaluated according to Sharma et al., 1999. 
Strains were considered susceptible if the initial count was reduced to <1% of the 0 time 
CFU, while if >90% survived, the strain was considered resistant. Strains between these 
two values were considered intermediate.  
 
3.9 Extraction of Bacterial Genomic DNA for PCR 
 
Three to five colonies of strains grown overnight on TSA plates were picked by 
toothpick and suspended into two 200 μl aliquots of sterile distilled water in Eppendorf 
tubes. The tubes were incubated for 10 minutes at 99˚C in a thermo-block (Eppendorf) 
and centrifuged for 10 minutes at 14,800 rpm. Supernatant of both tubes was collected 
without touching the pellet, combined in a new autoclaved Eppendorf tube and kept at 
4˚C. This material was used for most experiments as the DNA target. Whenever doubts 
were raised on the quality of DNA material (e.g. fuzzy amplicons, unexpected results), 
DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Germany) according to 
the manufacturers‘ instruction. 
 
3.10 Genotyping by PCR 
 
Before subjecting DNA samples for further testing, a PCR reaction targeting the 16S 
ribosomal RNA gene was carried out to establish the presence of bacterial DNA (Louie 
et al., 2002). The entire gene was amplified using flanking forward primer 5‘-
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GACGTACTCGCAGAATAAGC-3‘ and reverse primers, 5‘- 
TTAGTCTTGCGACCGTACTC-3‘. 
 
PCR reactions were performed on Applied Biosystems 2700 and 2720 
thermocyclers. In all reactions, E. coli J53RAZ genomic DNA and ultra-pure distilled 
water were used as negative controls. All positive reactions first obtained were 
confirmed by direct sequencing. The genes targeted and the primers and parameters used 
in different PCR reactions with respective references are listed in Table 7. Amplified 
DNA was loaded on 1-2% agarose gels (Promega, US) in the presence of ethidium 
bromide dye (Sigma, USA), and the gels were examined and photographed at 302 nm 
using the Biometra Gel Documentation System (Biometra, Göttingen, Germany). To 
assess the molecular mass of the amplicons, Gene Ruler 100 bp DNA ladder 
(Fermentas) standards were run on each gel. 
 
3.11 Conjugation  
 
For conjugation experiments, J53RAZ (a Na-azide resistant in-house derivative of 
the rifampin resistant J53 E. coli K-12) was used as the recipients. Four hour TSB 
cultures of the donor and recipient were combined in a 1:4 ratio and were incubated for 
4 hours at 37
o
C without shaking. The mixture was centrifuged at 3500 rpm for 15 
minutes and the pellet was re-suspended in 200 μl of TSB. 100 μl of the suspension was 
dropped onto a TSA plate to continue conjugation, this time on a solid surface. Next 
day, the growth was collected in PBS. Serial dilutions were plated onto plates containing 
150 μg/ml azide plus the antibiotic selection marker. In our case, this was 4μg/ml 
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fosfomycin and 25 μg/ml glucose-6 phosphate. Next day, colonies were collected and 
subjected to plasmid electrophoresis to ensure that transconjugants and not mutants of 
the donor or recipient were obtained.  
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Table 7: Primers and PCR protocols used in this study 
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Detection of ESBL genes singleplex  PCR to detect TEM, SHV, CTX-M & GES 
 
blaTEM 
C 
D 
TCG GGG AAA TGT GCG CG 
TGC TTA ATC AGT GAG GCA CC 
 
971bp 
 
5‘at 
94˚C 
30 X (30‖ at 
94˚C- 30‖ at 
60˚C and 
60‖ at 72˚C) 
 
10‘ at 
72˚C 
 
 
 
 
 
 
(Cao et al., 
2002) 
 
blaSHV 
OS-5 
OS-6 
TTA TCT CCC TGT TAG CCA CC 
GAT TTG CTG ATT TCG CTC GG 
 
798bp 
 
5‘ at 
94˚C 
30X(45‖ at 
94˚C, 55‖ at 
60˚C and 
60‖ at 72˚C) 
 
5‘at 
72˚C 
 
blaPER 
PER-A 
PER-B 
ATG AAT GTC ATT ATA AAA GC 
AAT TTG GGC TTA GGG CAG AA 
 
925bp 
 
5‘at 
94˚C 
35X (45s at 
94˚C, 60‖ at 
52˚C and 
60‖ at 72˚C) 
10‘at 
72˚C 
 
blaCTX-M 
MA-1 
MA-2 
SCS ATG TGC AGY ACC AGT AA 
CCG CRA TAT GRT TGG TGG TG 
 
543bp 
 
5‘ at 
94˚C 
30X (30‖ at 
94˚C, 30‖ at 
55˚C and 
60‖ at 72˚C) 
10‘ at 
72˚C 
blaGES 
GES-1A 
GES-1B 
ATG CGC TTC ATT CAC GCA C  
CTA TTT GTC CGT GCT CAG G  
 
 
774bp 
 
5‘ at 
94˚C 
35X (45‖ at 
94˚C, 60‖ at 
52˚C and 
60‖ at 72˚C) 
7‘ at 
72˚C 
 
Detection of AmpC gene multiplex PCR  
MOX-1, 
MOX-2, 
CMY-1, 
CMY-8 to 
CMY-11  
 
MOXMF  
MOXMR  
 
GCT GCT CAA GGA GCA CAG GAT  
CAC ATT GAC ATA GGT GTG GTG C  
520 
bp  
 
 
 
 
5‘ at 
94˚C  
 
 
 
 
 
 
30 X (30‖ at 
94˚C, 30‖ at 
64˚C and 
60‖ at 72˚C)  
 
 
 
 
 
 
10‘ at 
72˚C  
 
 
 
 
 
 
(Pérez-
Pérez and 
Hanson, 
2002) 
 
 
 
LAT-1 to 
LAT-4, 
CMY-2 to 
CMY-7, 
BIL-1  
 
CITMF  
CITMR 
TGG CCA GAA CTG ACA GGC AAA  
TTT CTC CTG AAC GTG GCT GGC  
 
462 
bp  
 
5
0
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DHA-1, 
DHA-2  
DHAMF  
DHAMR 
AAC TTT CAC AGG TGT GCT GGG T  
CCG TAC GCA TAC TGG CTT TGC  
 
405bp  
 
 
 
 
 
 
5‘ at 
94˚C  
 
 
 
 
 
 
30 X (30‖ at 
94˚C,  30‖ at 
64˚C and 
60‖ at 72˚C)  
 
 
 
 
 
 
10‘ at 
72˚C  
 
 
 
 
 
 
(Pérez-
Pérez and 
Hanson, 
2002) 
 
ACC  
ACCMF  
ACCMR 
AAC AGC CTC AGC AGC CGG TTA  
TTC GCC GCA ATC ATC CCT AGC  
346bp  
 
MIR-1, 
ACT-1  
EBCMF  
EBCMR 
TCG GTA AAG CCG ATG TTG CGG  
CTT CCA CTG CGG CTG CCA GTT  
302bp  
 
FOX-1 to 
FOX-5b  
FOXMF  
FOXMR 
AAC ATG GGG TAT CAG GGA GAT G  
CAA AGC GCG TAA CCG GAT TGG  
190bp  
 
Detection of carbapenemase genes 
 
blaOXA-48-like 
OXA-F 
OXA-R 
GCGTGGTTAAGGATGAACAC 
CATCAAGTTCAACCCAACCG  
 
438bp  
 
5‘ at 
94˚C  
40X (30‖at 
94˚C, 40‖ at 
52˚C, 50‖ at 
72˚C)  
10‘at 
72˚C  
(Poirel et 
al., 2011b) 
 
blaKPC 
KPC-F  
KPC-R 
CGTCTAGTTCTGCTGTCTTG  
CTTGTCATCCTTGTTAGGCG  
 
798bp  
 
blaVIM 
VIM-F  
VIM-R 
GATGGTGTTTGGTCGCATA  
CGAATGCGCAGCACCAG  
 
390bp  
 
blaIMP 
IMP-F  
IMP-R 
GGAATAGAGTGGCTTAAYTCTC  
GGTTTAAYAAAACAACCACC  
 
232bp  
 
 
blaNDM-1 
 
NDM1-Fo 
NDM1-Re 
 
TGCCGAGCGACTTGGCCTTG 
ACCGATGACCAGACCGCCCA 
 
379bp 
 
 
5‘ at 
94˚C 
30X (30‖at 
94˚C, 30‖ at 
60˚C, 60‖ at 
72˚C) 
 
7‘ at 
72˚C. 
 
 
(Ghazawi et 
al., 2012) 
Detection of plasmid mediated quinolone resistance genes 
 
qnrA 
QnrAm-F 
QnrAm-R 
AGAGGATTTCTCACGCCAGG 
TGCCAGGCACAGATCTTGAC 
580 
bp 
 
 
 
10‘ 
at 
94˚C 
 
 
35 X (1‘ at 
94˚C, 1‘ at 
54˚C and 1‘ 
at 72˚C) 
 
 
 
10‘ at 
72˚C 
 
 
 
(Cattoir et 
al., 2007; 
Fritsche et 
al., 2008) 
 
 
qnrB 
 
QnrBm-F 
QnrBm-R 
GGMATHGAAATTCGCCACTG 
TTTGCYGYYCGCCAGTCGAA 
264 
bp 
 
5
1
 
52 
 
 
 
qnrS 
 
QnrSm-F 
QnrSm-R 
GCAAGTTCATTGAACAGGGT 
TCTAAACCGTCGAGTTCGGCG 
428 
bp 
 
 
 
 
 
10‘ 
at 
94˚C 
 
 
 
 
 
35 X (1‘ at 
94˚C, 1‘ at 
54˚C and 1‘ 
at 72˚C) 
 
 
 
 
 
 
10‘ at 
72˚C 
 
 
 
 
 
 
(Cattoir et 
al., 2007; 
Fritsche et 
al., 2008) 
qepA 
 
QepA-F 
QepA-R 
CTGCAGGTACTGCGTCATG 
CGTGTTGCTGGAGTTCTTC 
403 
bp 
 
 
aac-6’-Ib-
cr 
 
AAC6′-Ib-cr1 
AAC6′-Ib-cr2 
 
TTGCAATGCTGAATGGAGAG 
CGTTTGGATCTTGGTGACCT 
 
218 
bp 
 
Detection of aminoglycoside 16S methyltransferase genes 
armA armA-f 
armA-r 
TATGGGGGTCTTACTATTCTGCCTAT 
TCTTCCATTCCCTTCTCCTTT 
 
514 
bp 
 
 
 
 
 
 
 
 
5‘ at 
94 
˚C 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 X (15‖ at 
94˚C, 30‖ at 
58˚C, and 1‘ 
at 72˚C) 
 
 
 
 
 
 
 
 
 
 
 
10‘ at 
72˚C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fritsche et 
al., 2008) 
 
 
 
 
 
 
rmtA rmtA-f 
rmtA-r 
CTAGCGTCCATCCTTTCCTC 
TTTGCTTCCATGCCCTTGCC 
 
635 
bp 
rmtB rmtB-f 
rmtB-r 
TCAACGATGCCCTCACCTC 
GCAGGGCAAAGGTAAAATCC 
 
459 
bp 
 
rmtC rmtC-f 
rmtC-r 
GCCAAAGTACTCACAAGTGG 
CTCAGATCTGACCCAACAAG 
 
752 
bp 
rmtD rmtD-f 
rmtD-r 
CTGTTTGAAGCCAGCGGAACGC 
GCGCCTCCATCCATTCGGAATAG 
 
376 
bp 
Detection of E. coli phylogenetic typing  
 
Chu 
ChuA.1 
ChuA.2 
GACGAACCAACGGTCAGGAT 
TGCCGCCAGTACCAAAGACA 
 
279 
bp 
 
 
 
 
5‘ at 
94˚C 
 
 
 
 
 
35X (30‖ at 
94˚C, 30‖ at 
55˚C and 
30‖ at 72˚C) 
 
 
 
 
 
 
7‘at 
72˚C 
 
 
 
 
 
 
 
(Clermont 
et al., 2000) 
 
 
 
 
YjaA 
Yja.A.1 
Yja.A.2 
TGAAGTGTCAGGAGACGCTG 
ATGGAGAATGCGTTCCTCAAC 
 
211 
bp 
 
TspE4C2 
TspE4C2.1 
TspE4C2.2 
GAGTAATGTCGGGGCATTCA 
CGCGCCAACAAAGTATTACG 
 
152 
bp 
5
2
 
53 
 
 
 
Detection of E. coli LPS core typing 
 
R1 
R1C3 
R1K15 
GGGATGCGAACAGAATTAGT 
TTCCTGGCAAGAGAGATAAG 
551 
bp 
 
 
 
1‘ at 
94˚C 
 
 
 
 
 
 
35X (20‖ at 
94˚C, 30‖ at 
50˚C and 
135‖ at 
72˚C) 
 
 
 
 
 
5‘at 
72˚C 
 
 
 
 
 
(Amor et 
al., 2000) 
 
 
 
 
R2 
R2C4 
R2K9 
GATCGACGCCGGAATTTTTT 
AGCTCCATCATCAAGTGAGA 
699 
bp 
 
R3 
R3C2 
R3K13 
GGCCAAAACACTATCTCTCA 
GTGCCTAGTTTATACTTGAA 
1141 
bp 
 
R4 
R4C4 
R4K14 
TGCCATACTTTATTCATCA 
TGGAATGATGTGGCGTTTAT 
1785 
bp 
 
K12 
K12-1 
K12-2a 
TTCGCCATTTCGTGCTACTT 
TAATGATAATTGGAATGCTGC 
916 
bp 
Detection of E. coli rfbO25b  
 
 
rfbO25b 
 
rfb.1bis 
rfbO25.r 
 
ATA CCG ACG ACG CCG ATC TG  
TGC TAT TCA TTA TGC GCA GC 
 
 
300 
bp 
 
5‘ at 
94˚C 
 
35X (30‖ at 
94˚C, 30‖ at 
60˚C and 
45‖ at 72˚C) 
 
7‘at 
72˚C 
 
(Clermont 
et al., 2008) 
 
Detection of E. coli rfbO16 
 
 
rfbO16 
 
gndbis.f 
rfbO16.r 
 
ATACCGACGACGCCGATCTG 
GGATCATTTATGCTGGTACG 
 
 
450 
bp 
 
5‘ at 
94˚C 
 
35X (30‖ at 
94˚C, 30‖ at 
59˚C and 
60‖ at 72˚C) 
 
7‘at 
72˚C 
 
(Clermont 
et al., 2007) 
E.coli MLST 
adk adk F 
adk R 
ATTCTGCTTGGCGCTCCGGG 
CCGTCAACTTTCGCGTATTT 
 
583 
bp 
 
 
 
 
5‘ at 
94˚C 
 
 
 
 
 
 
 
 
 
 
35X (60‖ at 
94˚C, 60‖ at 
56˚C and 
60‖ at 72˚C) 
 
 
 
 
 
 
 
 
10‘at 
72˚C 
 
 
 
 
 
 
 
 
 
 
(Wirth et 
al., 2006)  
 
 
 
 
 
 
fumC 
 
fumC F 
fumC R 
TCACAGGTCGCCAGCGCTTC  
GTACGCAGCGAAAAAGATTC  
806 
bp 
 
gyrB 
 
gyrB F 
gyrB R 
TCGGCGACACGGATGACGGC  
ATCAGGCCTTCACGCGCATC  
911 
bp 
 
icd 
 
icd F 
icd R 
ATGGAAAGTAAAGTAGTTGTTCCGGCACA  
GGACGCAGCAGGATCTGTT  
878 
bp 
 
5
3
 
54 
 
 
 
mdh 
 
mdh F 
mdh R 
ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG  
TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT  
932 
bp 
 
 
 
 
5‘ at 
94˚C 
 
 
 
 
35X (60‖ at 
94˚C, 60‖ at 
56˚C and 
60‖ at 72˚C) 
 
 
 
 
 
 
10‘at 
72˚C 
 
 
 
 
 
 
 
 
(Wirth et 
al., 2006)  
 
 
 
 
 
purA 
 
purA F 
purA R 
CGCGCTGATGAAAGAGATGA  
CATACGGTAAGCCACGCAGA  
816 
bp 
 
recA 
 
 
recA F 
recA R 
 
CGCATTCGCTTTACCCTGACC  
TCGTCGAAATCTACGGACCGGA  
 
780 
bp 
 
Klebsiella pneumoniae MLST 
 
rpoB 
VIC3 
VIC2 
GGC GAA ATG GCW GAG AAC CA 
GAG TCT TCG AAG TTG TAA CC 
 
501 
bp 
5‘ at 
94˚C 
35X (60‖ at 
94˚C, 60‖ at 
50˚C and 
60‖ at 72˚C) 
 
10‘at 
72˚C 
 
 
 
 
 
 
 
 
 
 
 
(Diancourt 
et al., 2005) 
 
 
 
 
 
 
 
 
 
 
gapA 
 
gapA173 
gapA181 
 
TGA AAT ATG ACT CCA CTC ACG G 
 CTT CAG AAG CGG CTT TGA TGG CTT 
 
450 
bp 
 
5‘ at 
94˚C 
 
35X (60‖ at 
94˚C, 60‖ at 
60˚C and 
60‖ at 72˚C) 
 
10‘at 
72˚C 
 
mdh 
 
mdh130 
mdh867 
 
CCC AAC TCG CTT CAG GTT CAG 
CCG TTT TTC CCC AGC AGC AG 
 
 
477 
bp 
 
 
 
 
 
5‘ at 
94˚C 
 
 
 
 
 
35X (60‖ at 
94˚C, 60‖ at 
50˚C and 
60‖ at 72˚C) 
 
 
 
 
 
10‘at 
72˚C 
pgi pgi1F 
pgi1R 
GAG AAA AAC CTG CCT GTA CTG CTG GC 
CGC GCC ACG CTT TAT AGC GGT TAA T 
 
432 
bp 
phoE phoE604.1 
phoE604.2 
ACC TAC CGC AAC ACC GAC TTC TTC GG 
TGA TCA GAA CTG GTA GGT GAT 
 
420 
bp 
infB infB1F 
infB1R 
CTC GCT GCT GGA CTA TAT TCG 
CGC TTT CAG CTC AAG AAC TTC 
 
318 
bp 
 
tonB 
 
tonB1F 
tonB2R 
 
CTT TAT ACC TCG GTA CAT CAG GTT 
ATT CGC CGG CTG RGC RGA GAG 
 
414 
bp 
 
5‘ at 
94˚C 
 
35X (60‖ at 
94˚C, 60‖ at 
45˚C and 
60‖ at 72˚C) 
 
10‘at 
72˚C 
5
4
 
55 
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hly hly f 
hly r 
AACAAGGATAAGCACTGTTCTGGCT 
ACCATATAAGCGGTCATTCCCGTCA 
1177 
bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
papC PapC f 
PapC r 
GTGGCAGTATGAGTAATGACCGTTA 
ATATCCTTTCTGCAGGGATGCAATA 
220 
bp 
 
papAH 
PapA f 
PapA r 
ATGGCAGTGGTGTCTTTTGGTG 
CGTCCCACCATACGTGCTCTTC 
720 
bp 
papEF PapEF f 
PapEF r 
GCAACAGCAACGCTGGTTGCATCAT 
AGAGAGAGCCACTCTTATACGGACA 
336 
bp 
fimH FimH f 
FimH r 
TGCAGAACGGATAAGCCGTGG 
GCAGTCACCTGCCCTCCGGTA 
508 
bp 
PAI RPAi f 
RPAi r 
GGACATCCTGTTACAGCGCGCA 
TCGCCACCAATCACAGCCGAAC 
930 
bp 
fyuA FyuA f 
FyuA r 
TGATTAACCCCGCGACGGGAA 
CGCAGTAGGCACGATGTTGTA 
880 
bp 
bmaE bmaE-f 
bmaE-r 
ATGGCGCTAACTTGCCATGCTG 
AGGGGGACATATAGCCCCCTTC 
507 
bp 
sfa/focDE sfa1 
sfa2 
CTCCGGAGAACTGGGTGCATCTTAC 
CGGAGGAGTAATTACAAACCTGGCA 
410 
bp 
iutA AerJ f 
AerJ r 
GGCTGGACATCATGGGAACTGG 
CGTCGGGAACGGGTAGAATCG 
300 
bp 
 
 
 
5‘at 
94˚C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25X (30‖ at 
94˚C, 30‖ at 
63˚C and 
120‖ at 
72˚C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
10‘at 
72˚C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Johnson 
and Stell, 
2000) 
 
 
 
 
 
 
 
 
 
 
 
 
gafD gafD-f 
gafD-r 
TGTTGGACCGTCTCAGGGCTC 
CTCCCGGAACTCGCTGTTACT 
952 
bp 
cvaC ColV-Cf 
ColV-Cr 
CACACACAAACGGGAGCTGTT 
CTTCCCGCAGCATAGTTCCAT 
680 
bp 
focG FocG f 
FocG r 
CAGCACAGGCAGTGGATACGA 
GAATGTCGCCTGCCCATTGCT 
360 
bp 
traT TraT f 
TraT r 
GGTGTGGTGCGATGAGCACAG 
CACGGTTCAGCCATCCCTGAG 
290 
bp 
afa/draBC Afa f 
Afa r 
GGCAGAGGGCCGGCAACAGGC 
CCCGTAACGCGCCAGCATCTC 
559 
bp 
Cnf1 cnf1 
cnf2 
AAGATGGAGTTTCCTATGCAGGAG 
CATTCAGAGTCCTGCCCTCATTATT 
498 
bp  
sfaS SfaS f 
SfaS r 
GTGGATACGACGATTACTGTG 
CCGCCAGCATTCCCTGTATTC 
240 
bp 
K5 K5-f 
kpsIIr 
CAGTATCAGCAATCGTTCTGTA 
CATCCAGACGATAAGCATGAGCA 
159 
bp 
5
5
 
56 
 
 
 
rfc rfc-f 
rfc-r 
ATCCATCAGGAGGGGACTGGA 
AACCATACCAACCAATGCGAG 
788 
bp 
 
 
5‘at 
94˚C 
 
 
25X (30‖ at 
94˚C, 30‖ at 
63˚C and 
120‖ at 
72˚C) 
 
 
10‘at 
72˚C 
 
 
(Johnson 
and Stell, 
2000) 
 
nfaE nfaE-f 
nfaE-r 
GCTTACTGATTCTGGGATGGA 
GCTTACTGATTCTGGGATGGA 
559 
bp 
 
KpsMT II 
kpsII f 
kpsII r 
GCGCATTTGCTGATACTGTTG 
GCTTACTGATTCTGGGATGGA 
272 
bp 
 
KpsMT III 
kpsIII f 
kpsIII r 
TCCTCTTGCTACTATTCCCCCT 
AGGCGTATCCATCCCTCCTAAC 
392 
bp 
 
 
5‘ at 
94˚C 
 
 
25X (30‖ at 
94˚C, 30‖ at 
63˚C and 
120‖ at 72˚C) 
 
 
10‘at 
72˚C 
 
 
(Johnson and 
Stell, 2000) 
 
ibeA 
ibe10 f 
ibe10 r 
AGGCAGGTGTGCGCCGCGTAC 
TGGTGCTCCGGCAAACCATGC 
170 
bp 
 
K1 
K1-f 
kpsIIr 
TAGCAAACGTTCTATTGGTGC 
CATCCAGACGATAAGCATGAGCA 
153 
bp 
iha iha-I 
iha-II 
CAG TTC AGT TTC GCA TTC ACC 
GTA TGG CTC TGA TGC GAT G 
1305 
bp 
 
5‘at 
94˚C 
 
35X (30‖ at 
94˚C, 30‖ at 
53˚C and 
90‖ at 72˚C) 
 
 
10‘at 
72˚C 
 
 
(Toma et 
al., 2004) 
 
Saa SAADF 
SAADR 
CGT GAT GAA CAG GCT ATT GC 
ATG GAC ATG CCT GTG GCA AC 
119 
bp 
toxB toxB911F 
toxB1468 R 
ATA CCT ACC TGC TCT GGA TTG A 
TTC TTA CCT GAT CTG ATG CAG C 
602 
bp 
UpaH upaH f 524 
upaH r 525 
AGT GAA GGG GCA AAA ACC TT 
TGA AAC CAC CAC CAT TCT GA 
328 
bp 
 
5‘at 
94˚C 
30X (30‖ at 
94˚C, 30‖ at 
50˚C and 
60‖ at 72˚C) 
 
7‘at 
72˚C 
(Allsopp et 
al., 2012; 
Allsopp et 
al., 2010) 
UpaB CO426.s-5 
CO426.s-3 
GGA AAG GCA AAG TTT CAG GG 
GGT GGT ATG TTT CTG TTT AC 
462 
bp 
Sat sat-f 
sat-r 
ATG CCG TAT GAG TCC CAT TG 
GTT GCC GGT ACA GTA AAT GC 
586 
bp 
 
 
 
 
5‘at 
94˚C 
 
 
 
 
35X (30‖ at 
94˚C, 40‖ at 
51˚C and 
60‖ at 72˚C) 
 
 
 
10‘at 
72˚C 
 
 
 
(Toma et 
al., 2004) 
 
 
ireA ireA-f 
ireA-r 
GAA TGC CCA GGG CGA AAT AC 
CAG CGA CTT GCC ATT GAG AC 
844 
bp 
ironN ireN-f 
ireN-r 
AGC CAT TGC CTT TCG AGT AG 
CGC CAA TTT CAG CCT TAG TG 
908 
bp 
Usp  usp-f 
usp-r 
CAG TAT CCG GAG TTG ATA GC 
CCG CCA CTA TAT TCA ATC GC 
161 
bp 
 
cdt B 
 
cdt S1 
cdt a1 
 
GAAAGTAAATGGAATATAAATGTCCG 
AAATCACCAAGAATCATCCAGTTA 
 
430 
bp 
 
5‘at 
94˚C 
25X (30‖ at 
94˚C, 30‖ at 
˚C 63 and 
60‖ at 72˚C) 
 
10‘at 
72˚C 
 
(Johnson 
and Stell, 
2000) 
Detection of Klebsiella pneumoniae virulence factors 
 
mag A 
mag A-F 
mag A-R 
GGT GCT CTT TAC ATC ATT GC 
GCA ATG GCC ATT TGC GTT AG 
1280 
bp 
 
5‘at 
94˚C 
 
35X (30‖ at 
94˚C, 60‖ at 
˚C 50 and 
60‖ at 72˚C) 
 
7‘at 
72˚C  
 
 
(Brisse et 
al., 2009) 
 
 
allS 
1416R 
336F2 
CCG TTA GGC AAT CCA GAC 
TCT GAT TTA (A/T)CC CAC ATT 
1090 
bp 
5
6
 
57 
 
 
 
 
mrkD 
mrkD-1 
mrkD-2 
TAT (T/C)G(G/T) CTT AAT GGC GCT GG 
TAA TCG TAC GTC AGG TTA AAG A(C/T)C 
920 
bp 
 
 
5‘at 
94˚C 
 
 
 
35X (30‖ at 
94˚C, 60‖ at 
˚C 50 and 
60‖ at 72˚C) 
 
 
7‘at 
72˚C  
 
 
 
 
(Brisse et 
al., 2009) 
 
 
 
rmp A 
rmpA-F 
rmpA-R 
ACT GGG CTA CCT CTG CTT CA 
CTT GCA TGA GCC ATC TTT CA 
535 
bp 
 
kfu BC 
kfuB-F1179 
kfuC-R649 
GAA GTG ACG CTG TTT CTG GC 
TTT CGT GTG GCC AGT GAC TC 
797 
bp 
 
fim H 
 
fim-1 
fim-2 
 
GCT CTG GCC GAT AC(C/T) AC(C/G) ACG G 
GC(G/A)(A/T)A(G/A)TAACG(T/C) GCC TGG AAC 
GG 
 
423 
bp 
 
5‘at 
94˚C 
35X (30‖ at 
94˚C, 60‖ at 
˚C 55 and 
60‖ at 72˚C) 
 
7‘at 
72˚C 
 
(Brisse et 
al., 2009) 
 
cf29a 
 
cf29a-F 
cf29a-R 
 
GAC TCT GAT TGC ACT GGC TGT G 
GTT ATA AGT TAC TGC CAC GTT C 
 
862 
bp 
 
5‘at 
94˚C 
35X (30‖ at 
94˚C, 60‖ at 
˚C 51 and 
60‖ at 72˚C) 
 
7‘at 
72˚C 
 
(Brisse et 
al., 2009) 
 
uge 
 
uge-F 
uge-R 
 
GAT CAT CCG GTC TCC CTG TA 
TCT TCA CGC CTT CCT TCA CT 
 
534 
bp 
 
 
 
 
5‘at 
94˚C 
 
 
 
 
35X (30‖ at 
94˚C, 60‖ at 
˚C 53 and 60‖ 
at 72˚C) 
 
 
 
 
7‘at 
72˚C 
 
 
 
 
 
 
(Brisse et 
al., 2009) 
 
 
 
 
wabG 
 
wabG-F 
wabG-R 
 
CGGACTGGCAGATCCATATC 
ACCATCGGCCATTTGATAGA 
 
 
683 
bp 
 
clp K 
 
clpK-F 
clpK-R 
 
GGGGGGGGATCCGAACCTGCCTGACGACGCCAACCA 
GGGGGGGTCGACGCAGCCTCGCCCGCCATCAAGA 
 
437 
bp 
5‘at 
94˚C 
35X (30‖ at 
94˚C, 60‖ at 
˚C 53 and 
60‖ at 72˚C) 
 
7‘at 
72˚C 
 
(Bojer et al., 
2010) 
 
ure A 
 
ureA-F 
ureA-R 
 
GCT GAC TTA AGA GAA CGT TAT G 
GAT CAT GGC GCT ACC T(C/T) A 
 
337 
bp 
 
5‘at 
94˚C 
35X (30‖ at 
94˚C, 60‖ at 
˚C 55 and 
60‖ at 72˚C) 
7‘at 
72˚C 
 
(Brisse et 
al., 2009) 
Capsule 
type K2 
K2wzy-F1 
K2wzy-R1 
GACCCGATATTCATACTTGACAGAG 
CCTGAAGTAAAATCGTAAATAGATGGC 
641 
bp 
 
 
 
 
5‘at 
94˚C 
 
 
 
 
 
 
 
 
35X (30‖ at 
94˚C, 90‖ at 
˚C 58 and 
90‖ at 72˚C) 
 
 
 
 
 
 
10‘at 
72˚C 
 
 
 
 
 
 
 
 
(Turton et 
al., 2010) 
 
 
 
 
Capsule 
type K5 
K5wzxF360 
K5wzxR639 
TGGTAGTGATGCTCGCGA 
CCTGAACCCACCCCAATC 
280 
bp 
Capsule 
type K54 
wzxK54F 
wzxK54R 
CATTAGCTCAGTGGTTGGCT 
GCTTGACAAACACCATAGCAG 
881 
bp  
Capsule 
type K57 
wzyK57F 
wzyK57R 
CTCAGGGCTAGAAGTGTCAT 
CACTAACCCAGAAAGTCGAG 
1037 
bp 
Capsule 
type K20 
wzyK20F 
wzyK20R 
CGGTGCTACAGTGCATCATT 
GTTATACGATGCTCAGTCGC 
741 
bp 
5
7
 
58 
 
 
 
 
wcaC 
wcaGF 
wcaGR 
GGTTGGKTCAGCAATCGTA 
CTATTCCGCCAACTTTTGC 
169 
bp 
 
5‘at 
94˚C 
 
35X (30‖ at 
94˚C, 90‖ at 
˚C 58 and 
90‖ at 72˚C) 
 
10‘at 
72˚C 
 
(Turton et 
al., 2010) k.pneumoniae  
16S-23S 
ITS 
K.pneumoniae 
Pf 
K.pneumoniae 
Pr1 
 
ATTTGAAGAGGTTGCAAACGAT 
TTCACTCTGAAGTTTTCTTGTGTTC 
130 
bp 
Detection of disinfectant resistance genes 
 
cepA 
 
cepA-F 
cepA-R 
 
CAACTCCTTCGCCTATCCCG 
TCAGGTCAGACCAAACGGCG 
 
1051 
bp 
 
5‘at 
94˚C 
30X (30‖ at 
94˚C, 60‖ at 
˚C 66 and 
120‖ at 
72˚C) 
 
7‘at 
72˚C 
 
(Fang et al., 
2002) 
 
qac∆E1 
 
qac∆E1_Zou-F 
qac∆E1_Zou-R 
 
AATCCATCCCTGTCGGTGTT 
CGCAGCGACTTCCACGATGGGGAT 
 
175 
bp 
 
5‘at 
94˚C 
30X (30‖ at 
94˚C, 30‖ at 
˚C 56 and 
30‖ at 72˚C) 
 
7‘at 
72˚C 
 
 
 
 
 
(Zou et al., 
2014) 
 
qacE 
 
qacE_Zou-F 
qacE_Zou-R 
 
AAGTAATCGCAACATCCG 
CTACTACACCACTAACTATGAG 
 
 
258 
bp 
 
5‘at 
94˚C 
30X (30‖ at 
94˚C, 30‖ at 
˚C 50 and 
30‖ at 72˚C) 
 
5‘at 
72˚C 
 
qacF/H/I 
 
qacF/H/I-F 
qacF/H/I-R 
 
GTCGTCGCAACTTCCGCACTG 
TGCCAACGAACGCCCACA 
 
229 
bp 
 
5‘at 
94˚C 
30X (30‖ at 
94˚C, 35‖ at 
˚C 60 and 
60‖ at 72˚C) 
 
5‘at 
72˚C 
 
qacG 
qacG-F 
qacG-R 
TCGCCTACGCAGTTTGGT 
AACGCCGCTGATAATGAA 
122 
bp 
 
 
 
 
 
 
5‘at 
94˚C 
 
 
 
 
 
 
 
30X (30‖ at 
94˚C, 35‖ at 
˚C 55 and 
60‖ at 72˚C) 
 
 
 
 
 
 
5‘at 
72˚C 
 
 
 
 
 
 
 
(Zou et al., 
2014) 
 
emrE 
emrE-F 
emrE-R 
TATTTATCTTGGTGGTGCAATAC 
ACAATACCGACTCCTGACCAG 
195 
bp 
 
mdfA 
mdfA-F 
mdfA-R 
GCATTGATTGGGTTCCTAC 
CGCGGTGATCTTGATACA 
284 
bp 
 
sugE(c) 
sugE(c)-F 
sugE(c)-R 
CTGCTGGAAGTGGTATGGG 
GCATCGGGTTAGCGGACT 
226 
bp 
 
sugE(p) 
sugE(p)-F 
sugE(p)-R 
GTCTTACGCCAAGCATTATCACTA 
CAAGGCTCAGCAAACGTGC 
190 
bp 
 
ydgE 
ydgE-F 
ydgE-R 
GGCAATCGTGCTGGAAAT 
CGACAGACAAGTCGATCCCT 
149 
bp 
 
 
ydgF 
ydgF-F 
ydgF-R 
TAGGTCTGGCTATTGCTACGG 
GGTTCACCTCCAGTTCAGGT 
330 
bp 
 
5
8
 
59 
 
 
 
 
class I 
Intragrase  
 
intI-F2 
intI-R2 
 
GCT GCG TTC GGT CAA GGT TC 
GCA CAG CAC CTT GCC GTA GA 
 
256 
bp 
 
5‘at 
94˚C 
 
30X (45‖ at 
94˚C, 45‖ at 
˚C 56 and 
45‖ at 72˚C) 
 
5‘at 
72˚C 
 
(Lin et al., 
2009) 
Detection of fosA& fosC 
 
fosA 
 
fosA3/4-fo 
fosA3/4-re 
 
TGA ATC ATC TGA CGC TGG 
TCA ATC AAA AAA GAC CAT C 
 
404 
bp 
 
5‘at 
94˚C 
30X (30‖ at 
94˚C, 30‖ at 
˚C 50 and 
60‖ at 72˚C) 
 
1‘at 
72˚C 
 
(Nakamura 
et al., 2014) 
 
fosC 
 
fosC2-fo 
fosC2-re 
 
CGT TCC GTG GAG TTC TAT AC 
CTT GAT AGG GTT TAG ACT TC 
 
339 
bp 
 
5‘at 
94˚C 
30X (30‖ at 
94˚C, 30‖ at 
˚C 53 and 
60‖ at 72˚C) 
 
1‘at 
72˚C 
 
(Nakamura 
et al., 2014) 
 
5
9
 
60 
 
 
 
3.12 Plasmid Profile Analysis  
 
For routine detection and isolation of large and small plasmids, the method of 
Kado and Liu was used with minor modifications (Kado et al., 1981). The strains were 
inoculated on TSA plates to obtain confluent growth and incubated overnight at 37
o
C. 
Next day, cells were collected by toothpicks from an area of approximately 4 cm
2
 and 
suspended gently into 250 μl of lysing solution (3% SDS, 50 mM Tris, pH 12.57), and 
mixed by gentle agitation until the suspension became homogenous and viscous. The 
lysed cells were incubated at 60 °C in a thermoblock (Eppendorf) for 45 minutes with 
gentle mixing every 15 minutes. After the incubation period, equal volume of 1:1 
phenol:chloroform was added and the solution was emulsified by gentle shaking. The 
emulsion was broken by centrifugation at 13,000 rpm for 15 minutes. The top aqueous 
layer (approximately 60 μl) was transferred to clean tubes without disrupting the 
precipitate at the interface. Samples were subjected to electrophoresis for 3 hours at 120 
V in 0.8% agarose gel. The gels were stained with ethidium bromide, destained and 
photographed using the Biometra gel documentation system.  
 
3.13 Hybridization 
 
Plasmid gels were de-purinated in 0.25 M HCl, followed by denaturation in 0.5 
M NaOH, 1 M NaCl and finally neutralized in 1 M Tris, 0.6 M NaCl. All treatment steps 
were 15 minutes long at room temperature with gentle shaking and were repeated twice. 
Between each steps, gels were rinsed in sterile distilled water. The gel was capillary-
transferred to Hybond N+ membranes (Roche) by soaking overnight in 20X SSC (saline 
sodium citrate). Next day the membranes were UV cross-linked at 70,000 micro-joules.  
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Hybridization probes were generated by PCR amplification of fosA3/A4 genes of 
genomic DNA of strains KW11, followed by DNA purification (Promega kit, USA), and 
quantitation using the ND-1000 spectrophotometer (Nano Drop Technologies, USA). 
The DNA fragments were labeled using the DIG DNA labeling kit (Roche). In brief, 200 
ng of purified fragment was boiled for 10 minutes in a boiling water bath and quickly 
chilled on ice. The denatured DNA was conjugated with digoxigenin according to the 
manufacturer‘s instructions. Membranes were pre-hybridized at optimal hybridization 
temperature, which was calculated based on the size of the probe and GC ratio, using the 
formula recommended by the manufacturer. (Topt.=Tm-20
o
C with 
Tm=49.82+0.41(%G+C)-600/L (L=length of the probe in base pairs)) in a pre-warmed 
hybridization buffer (5X SSC 1% blocking solution, 0.1 % N-lauryl sarcosine, 0.02% 
SDS) for 30 minutes followed by the addition of the hybridization buffer containing the 
probe. According to previous calculations, the membranes were hybridized overnight 
with gentle shaking at 53
o
C. 
 
For post hybridization, the blots were washed twice with 2X SSC/0.1% SDS 
(Sigma) at room temperature (RT) for 5 minutes with gentle shaking followed by two 
subsequent washings in 0.1X SSC/0.1 % SDS at 68
o
C for 15 minutes also with constant 
agitation. The membrane was briefly rinsed in washing buffer at room temperature, 
incubated in blocking solution for 30 minutes, and again incubated in antibody solution 
provided with the kit for 30 minutes. The blots were washed twice in washing buffer, 
equilibrated in detection buffer and finally incubated without shaking in the color 
substrate solution for various lengths of time in the dark till the desired spot or band 
intensity was seen. The reaction was stopped using TE buffer (10mM Tris, 1mM EDTA 
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pH 8 (Sigma, USA)). The blot was digitized using the Biometra gel documentation 
system.  
 
3.14 Pulsed Field Gel Electrophoresis (PFGE) 
 
We used the method of Gautom (Gautom, 1997). Briefly, bacterial strains grown 
on TSA plates were suspended in 2ml of cell suspension buffer (100 mM Tris, 100 mM 
EDTA, pH8.0) up to a density of 3 McFarland units. Suspensions were kept on ice. 
Simultaneously, 1% plug (low melting point) agarose (Sigma, USA) was melted in 1% 
SDS in TE buffer (10mM Tris:1mM EDTA pH 8) and kept at 54˚C. 500 μl bacterial 
suspensions, 25 μl of proteinase K (Invitrogen) (20 mg/ml) and 525 μl of 1% plug 
agarose were combined, mixed carefully, quickly transferred into 1 ml syringes and kept 
for 15-30 minutes at room temperature to allow the solidification of the agarose. 
Aliquots of 5 ml cell lysis buffer (50 mM Tris:50 mM EDTA pH 8, 1% Sarkosyl) and 25 
μl of 20 mg/mL proteinase K were distributed into 50 ml tubes and 1mm thick slices of 
agarose plugs were directly cut into them. They were incubated for 2 hours at 50˚C in a 
shaker water bath (200 rpm). Subsequently, the plugs were washed twice with 10 ml of 
preheated sterile MilliQ water for 20 minutes in a 50˚C shaker water bath. Plugs were 
washed four times for 20 minutes with 10 ml of preheated TE buffer. Finally, plugs were 
stored in 5 ml of fresh TE buffer at 4˚C.  
 
Genomic DNA within the plugs was digested overnight at 37˚C in a 100 μl 
restriction mixture made up of 10 μl of NE buffer 4 (New England Biolabs, UK), 1 μl of 
BSA (New England Biolabs, UK), 30 U (1.5 μl) of XbaI enzyme (New England Biolabs, 
UK) and 87.5 μl of sterile distilled water. Following digestion, the restriction mixtures 
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were removed and the plugs were incubated in 250 μl of 0.5X TBE buffer for 30 
minutes at room temperature. Subsequently, plugs were inserted into wells of 1.4% of 
agarose gel (Pulse Field Running Agarose A2929, Sigma, USA) prepared in 0.5xTBE 
buffer. The two wells at the two sides of each gels contained a lambda-ladder PFGE 
molecular mass marker (New England Biolabs, UK) for standardization. Gels were run 
in CHEF Mapper (Biorad, USA) electrophoresis chamber in 0.5X TBE buffer pre-
chilled to 14˚C. The running program consisted of 26 hours run at 6 V/cm with 120˚ 
angle and an initial switch time of 2.2 seconds and a final switch time of 54.2 seconds 
with linear ramp.  
 
The gels were stained with ethidium bromide for 20 minutes, followed by de-
staining in MilliQ water. Bands were detected and photographed under UV light in a 
Biometra gel documentation system. Gel pictures were stored as .tif files for further 
analysis. The GelCompare II software (Applied Maths, Sint-Martens-Latem, Belgium) 
was used to analyze the banding patterns. The Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) tree graphically showing the level of relatedness between 
the isolates was created based on the Dice similarity coefficient (SD) (with a 1.5% 
position tolerance). Depending of the specific tasks, strains showing patterns with SD ≥ 
80% or 90% were arbitrarily considered to represent a pulsotype. 
 
3.15 Multilocus Sequence Typing (MLST)  
 
In order to study the relatedness of the E. coli strains and K. pneumoniae strains, 
their genomic DNA were typed by MLST method based on the protocol described by 
Wirth et al. 2006 and Brisse et al. 2009, respectively (Brisse et al., 2009; Wirth et al., 
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2006). The seven housekeeping genes of E. coli (adk, fumC, gyrB, icd, mdh, pur, recA) 
and the seven housekeeping genes of K. pneumoniae (ropB, gapA, mdh, pgi, phoE, infB, 
tonB) were amplified by the primers shown in Table 7. In some cases the MLST typing 
was carried out commercially (ID Genomics, Seattle, WA, USA) for which we provided 
purified genomic DNA. 
 
E. coli isolates were assigned to sequence types using the tools on the E. coli 
MLST webpage (http://mlst.ucc.ie/mlst/dbs/Ecoli). For K. pneumoniae the MLST 
webpage (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html) was 
used. 
 
3.16 Sequencing 
 
PCR products were purified either by the EXO-SAP or PCR purification kit 
(QIAGEN, Germany) prior to sequencing. Sequencing was done using the Big Dye 
Cycle Terminator V.3.1 (Applied Biosystems, USA) according to the manufacturer's 
instructions. The samples were sequenced in both directions using the 3130X Genetic 
Analyzer (Applied Biosystems, USA). Sequences were analyzed using the MEGA5 
(http://www.megasoftware.net/mega4/mega.html) and the Clone Manager (Sci-
Edsoftware) software. 
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3.17  ERIC PCR 
 
The Enterobacterial Repetitive Intergenic Consensus Polymerase Chain Reaction 
(ERIC-PCR) (Versalovic et al., 1991) method was used to rapidly confirm differences 
between donor and recipient strain for conjugation and/or transformation. It was 
performed by using the ERIC2 primer (5‘-AAG TAA GTG ACT GGG GTG AGC G-
3‘). A 7-minute initial denaturation at 94˚C was followed by 30 cycles of denaturation 
for 30 seconds at 90˚C, annealing for 60 seconds at 50˚C and extension for 8 minutes at 
65˚C. The final step was an extension for 16 minutes at 65˚C. The patterns obtained with 
different strains (strictly amplified in the very same experiment only) were compared 
visually.  
 
3.18 Statistical Analysis 
 
If clustering was considered extensive, to investigate the association between 
groups of strains and specific features,  we used the generalized linear mixed effect 
model (GLMM) with a binomial distribution (Breslow and Clayton, 1993). This model 
is used to take into account the potential correlation that may occur between members in 
the same family. We used the R software version 3.2.2 for data analysis (Team, 2014). 
The function glmmPQL (Breslow and Clayton, 1993; Schall, 1991) from the package 
MASS was used to fit the GLMM model with binomial distribution for our data. This 
analysis was kindly carried out by Dr. Abderrahim Oulhaj, Institute of Public Health, 
CMHS, UAEU. For assays not affected by clustering, Fisher‘s exact test and the Student 
t test were used.  
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Chapter 4: Results 
 
4.1 Characterization of Blood Stream E. coli Isolates Recovered in the UAE 
 
4.1.1 General Characteristics of the Collection 
Altogether, 172 Escherichia coli bloodstream isolates, all independent and 
clinically relevant strains recovered at Tawam Hospital, Al Ain, UAE between 2010 and 
2011 were included in the study. The basic demographic and clinical data available are 
summarized in Table 8. No further details on the patients and on the clinical details, i.e. 
nationality, outcome etc., were available. 
Table 8: Demographic and basic clinical data 
Specifics  
n 172 
Age (x ± SD) 51.9±26.1 
Male: Female ratio 88:84 
Malignancy present     n (%) 72 (41.9) 
Of these solid tumor     n (%) 49 (68.1) 
Hematological malignancy  n (%) 23 (31.9) 
Urosepsis*  n (%) 64 (37.2) 
Line infection   n (%) 10 (5.81) 
 
*As substantiated by simultaneous E. coli isolated from the urine 
(strains from urine were not available to compare to blood isolate) 
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PFGE studies of the 167 (97.1%) typable isolates revealed a heterogeneous 
population exhibiting 98 distinct PFGE patterns even if (SD ≥80%) coefficient was used 
as a similarity threshold (Figure 5.). The clustering is shown in Table 9. 
Figure 5: Pulsed Field Gel Electrophoresis patterns of the isolates 
The dashed line represent the threshold of 80% similarity, red boxes identify clusters 
 
Table 9: Cluster size distribution of the isolates 
 
 
 
 
No. of 
clusters 
Size of the cluster (No. of isolates in cluster) 
1 2 3 4 5 6 7 8 
54 30 10 1 1 1 0 1 
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4.1.2 Antibiotic Susceptibility 
  
The antibiotic resistance of the isolates was assessed by disc diffusion and the 
results, together with the rate of ESBL production, are summarized in Table 10. 
 
Table 10: Antibiotic Resistance of the Isolates 
 
 
 
 
 
 
 
 
 
 
 
 
AP-Ampicillin, AUG-Augmentin, CIP-Ciprofloxacin, CAZ-Ceftazidime, CPD-
Cefpodxim, CTX-Cefotaxime, CXM-Cefuroxime, FOX-Cefoxitin, TIM-
Ticracillin/clavulanic acid, PTZ-Pipracillin-tazobactam, ERT-Ertapenem, IMP-
Imipenem, MEM-Meropenem, DXT-Doxycycline, CHL-Chloramphenicol, GN-
Gentamicin, AK-Amikacin, NET-Netilmicin, SXT-Trimethoprim-Sulphamethoxazole.    
Antibiotic 
Resistant  
(%) 
Intermediate 
(%) 
AP 75.6 0.0 
AUG 18.6 27.9 
CIP 47.1 5.8 
CAZ 26.7 3.5 
CPD 36.0 9.3 
CTX 39.5 11.0 
CXM 37.2 2.9 
FOX 4.7 2.3 
TIM 33.1 20.3 
PTZ 8.1 14.0 
ERT 0.6 0.6 
IMP 0.0 0.6 
MEM 0.0 0.0 
DXT 55.2 8.1 
CHL 13.4 1.2 
GN 21.5 0.6 
AK 2.9 5.2 
NET 5.8 5.2 
SXT 55.8 1.2 
ESBL production 32.6 
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In nearly one third of the isolates (32.6%)  ESBL production was detected by the 
key-hole test. In all 56 ESBL producing strains the enzyme was of the CTX-M type. 
Within this group, with the exception of 6 blaCTX-M-27 and 1 each of blaCTX-M-1 and 
blaCTX-M-14, all others represented blaCTX-M-15. The resistance to 3
rd
 and 4
th
 generation 
cephalosporins reflected this ratios (Table 10). One strain, carrying the blaOXA-48-like 
carbapenemase gene exhibited resistance to ertapenem, while two others were not fully 
susceptible to carbapenems. One exhibited intermediate susceptibility to ertapenem, 
while another exhibited intermediate susceptibility to meropenem,. These two also did 
not show any carbapenemase activity, and common carbapenemase genes were not 
detected within them. 
 
The high rate of resistance (exceeding 50%) to doxycycline and trimethoprime-
sulphamethoxasole, and similarly high resistance rate to ciprofloxacin (47.1%) was 
noteworthy. While only a few strains carried plasmid-associated qnrA, B, S and qepA 
genes (1, 4, 2 and 4 strains, respectively), 69 of them harbored acc (6’)-Ib-cr exhibiting a 
strong correlation between this gene and resistance to ciprofloxacin (P<0.0001) (data not 
shown). 
 
4.1.3 Phylogentetic Groups, Core Types and Virulence Factors 
 
The rate of the different phylogenetic types, core type and virulence factors are 
shown in Table 11. 
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Table 11: Phylogenetic groups distribution, core types and virulence factors of the 
strains 
Specifics n (%) 
Phylogenetic Groups  
A 31 (18.02) 
B1 22 (12.79) 
B2 69 (40.12) 
D 50 (29.07) 
Core Types  
R 1 58 (33.72) 
R 2 14 (8.14) 
R 3 31 (18.02) 
R 4 30 (17.44) 
K-12 39 (22.67) 
Virulence Factors  
PAI 79 (45.93) 
hlyA 34 (19.77) 
sat 72 (41.86) 
CDT 0 (0.00) 
Cnf1 23 (13.37) 
tox B 0 (0.00) 
paP C 59 (34.30) 
paP AH 60 (34.88) 
paP EF 57 (33.14) 
tra T 123 (71.51) 
ibe A 2 (1.16) 
cva C 15 (8.72) 
fim H 154 (89.53) 
bma E 2 (1.16) 
sfa/foc DE 18 (10.47) 
foc G 9 (5.23) 
sfaS 5 (2.91) 
gaf D 2 (1.16) 
nfa E 3 (1.74) 
afa/dra 18 (10.47) 
iha 51 (29.65) 
upa B 79 (45.93) 
upa H 68 (39.53) 
usp 96 (55.81) 
ire A 24 (13.95) 
iro N 55 (31.98) 
fyu A 129 (75.00) 
iut A 121 (70.35) 
 Cont. 
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Cont.  
rfc  2 (1.16) 
KpsMT III 10 (5.81) 
KpsMT II 92 (53.49) 
K1 20 (11.63) 
K5 54 (31.40) 
Virulence factor score (x ± SD) 8.45 ± 4.6 
 
The high frequency of core types R4 and K-12 was surprising as these core types 
are usually rare among ExPEC (Amor et al., 2000; Appelmelk et al., 1994; Gibb et al., 
1992).  Furthermore, as the rate of strains belonging to phylogenetic group D was higher 
than reported earlier for bloodstream isolates (Szijártó et al., 2012), we analyzed these 
features with attention focused on these two groups ( Tables 12.). 
 
Table 12: Distribution of phylogenetic groups within different core types 
 
  Core type n 
Phylogenetic group    n (%) 
A B 1 B 2 D 
R 1 58 
12 
(20.7) 
14 
(24.1) 
29 
(50.0) 
3 
(5.12) 
R 2 14 
14 
(100.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
R 3 31 
2 
(6.5) 
7 
(22.6) 
2 
(6.5) 
20 
(64.5) 
R 4 30 
2 
(6.7) 
1 
(3.3) 
1 
(3.3) 
26 
(86.7) 
K-12 39 
1 
(2.6) 
0 
(0.0) 
37 
(94.9) 
1 
(2.6) 
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The analysis clearly showed that more than half of the group D strains had R4 
core type genes and nearly 90% of the strains carrying this core type belonged to group 
D, showing a highly significant correlation between and R4 core type and group D 
(P<0.0001) (Table 12.). Furthermore, more than half of the B2 strains carried a K-12 
core and nearly all (94.9%) K-12 core type strains belonged to the B2 phylogenetic 
group. Only 1-1 strains belonged to groups A and D (Table 12.), also indicating a very 
strong correlation between the K-12 core structure and the B2 group (P<0.0001). 
 
Taking PFGE clustering into consideration when conducting statistical analysis 
the following features exhibited association at varying levels of significance (P≤0.05) 
with strains of different core types (Table 13.). 
 
Table 13: Significant association of specific features with core types 
Core 
type 
n 
Feature with significant (P=>0.05) association 
Source 
Genotype Non-
susceptibility 
R 1 58 - 
qnrB, iroN, ireA, usp, 
upaH, upaB, sfa-foc-DE, 
cvaC, PaPAH, PaPEF, 
cnf1, HlyA 
- 
R 2 14 - - - 
R 3 31 Line infections 
K5, KpsMTII, KpsMTIII, 
iha 
 
R 4 30 
Line infections, 
malignancy, 
solid tumors 
K5, KpsMTII,   
K-12 39 Urosepsis 
acc (6’)-Ib-cr, K5, 
KpsMTII, traT, PaPEF, 
PaPC, PAI    
CTX, CAZ, GN 
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4.1.4 Characterization of B2/K-12 and D/R4 Strains 
 
Next, the homogeneity of the group B2/core K-12 strains (n=37) and that of the 
group D/R4 strains (n=26) was investigated by determining their MLST. The results are 
shown in Table 14. 
 
 Table 14: Distribution of sequence types among strains with rare phylogenetic group/ 
core type combinations 
*phylogeny group/core type 
While the association of the ST131 type with the K-12 core type was anticipated 
from our previous studies (Szijártó et al., 2012), the link of other common ExPEC clones 
to a previously relatively rare core type needed further confirmation. In order to validate 
our PCR results suggestive of R4 core type in strains belonging to these three common 
MDR STs the entire sequence of the outer core oligosaccharide operon (GenBank 
AF019747,1 (Heinrichs et al., 1998) was blasted against the whole-genome shotgun 
contigs (wgs) available in the NCBI database (Kindly carried out by Dr. Valeria 
Szijartó, Arsanis, Vienna, Austria).  On the first 100 whole genome sequences showing 
100% coverage and a minimum of 99% identity with the query sequence multilocus 
Strain 
type* 
n 
% of 
all 
Sequence type  n (% within strain type) 
ST 38 ST 131 ST 362 ST 405 ST 648 
ST 
1882 
B2/K-12 37 21.51 
0 
(0.00) 
37 
(100.00) 
0 
(0.00) 
0 
(0.00) 
0 
(0.00) 
0 
(0.00) 
D/R4 26 15.11 
8 
(30.76) 
0 
(0.00) 
1 
(3.84) 
7 
(26.92) 
9 
(34.61) 
1 
(3.84) 
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sequence typing (MLSA) was performed in silico. Of these 21, 20 and 18 belonged to 
ST38, ST405 and ST 648, respectively, i.e., to the STs identified as carrying the R4 core 
type in the current study (Table 14.). 
 
Next, to study the internal structure of these clones their PFGE patterns were re-
analyzed omitting any isolates with different STs and using the stricter SD≥90% 
similarity threshold. Also, macrorestriction patterns of strains not belonging to any of 
these STs (i.e. ST38, ST131, ST405 and ST648) were also re-analyzed as one group. 
The data are presented in Figures 6.-10. and Table 15. 
 
Figure 6: Macrorestriction patterns of ST38 isolates 
The dashed line represent the threshold of 90% similarity, red boxes identify clusters. 
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Figure 7: Macrorestriction patterns of ST131 isolates 
The dashed line represent the threshold of 90% similarity, red boxes identify clusters. 
 
 
Figure 8: Macrorestriction patterns of ST405 isolates 
The dashed line represent the threshold of 90% similarity, red boxes identify clusters. 
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Figure 9: Macrorestriction patterns of ST648 isolates 
The dashed line represent the threshold of 90% similarity, red boxes identify clusters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Macrorestriction patterns of isolates not belonging to the four MDR STs 
The dashed line represent the threshold of 90% similarity, red boxes identify clusters. 
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Table 15: Cluster size distribution of strains within and outside the MDR STs 
STs 
 
n* 
Number of 
patterns 
Number of clusters containing members 
of 
1 2 3 
ST38 8 7 6 1 0 
ST131 37 29 21 8 0 
ST405 5 4 3 1 0 
ST648 9 9 9 0 0 
Others 108 97 91 4 2 
n* - No. of typable strains 
These data showed that within the clonal group ST131 strains and, particularly 
strains beyond the 4 major STs were, as expected, rather heterogeneous.   
 
 The strains belonging to these 4 STs were considerably more resistant than the 
other isolates combined. The rates of resistance to selected antibiotics within these STs, 
as compared to other isolates and shown in Figure 11. The resistance rates against all 
these antibiotics were significantly higher in the group combining the emerging STs 
compared to strains outside of these sequence types (P<0.01), although variations among 
the four STs existed, particularly when none-ß-lactams were considered. For instance, 
strains in the ST38 group exhibited similarly low rates of resistance against 
ciprofloxacin and gentamicin as the strains outside these STs did, while among members 
of the other 3 STs resistance even to these drugs was very common. 
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Figure 11: Rate of resistance to selected antibiotics within and outside of the common 
sequence type 
CXM – cefuroxime, CTX – cefotaxime, CAZ – ceftazidime, CPD – cefpodoxim, CIP – 
ciprofloxacin, GN – gentamicin, SXT – trimethoprim-sulphamethoxazole, DXC – 
doxycycline. MDR STs – strains belonging to either ST38, 131, 405 or 648 sequence 
types. Others – strains beyond these STs. 
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Summarizing the characteristics of the clones, Table 16. shows that while they 
were more resistant than other isolates, with the exception of the ST131 clone, they 
carried less virulence-related genes.  
Table 16: Characteristics of the four common clones 
ST Phylogeny Core 
Non-
susceptibility* 
Genotype* 
Virulence 
score** 
ST131 B2 K-12 
CXM, TIM, 
DXT, SXT, AP, 
CIP, CAZ, 
CPD, CTX, 
Acc (6’)-Ib-cr, PAI, 
traT, fimH, iha, 
upaB, upaH, usp, 
fyuA, iutA, KpsMTII 
11.22 ± 1.83 
ST38 D R4 
CXM, TIM, 
DXT, SXT, AP, 
AUG, CIP, 
CAZ, CPD, 
CTX, 
traT, fimH, usp, 
fyuA, iutA, KpsMTII, 
6.88 ± 2.3 
ST405 D R4 
CXM, FOX, 
TIM, PTZ, 
DXT, SXT, AP, 
AUG, CIP, 
CAZ, CPD, 
CTX, 
Acc (6’)-Ib-cr, traT, 
fimH, fyuA, 
KpsMTII, k5 
5.43 ± 0.98 
ST648 D R4 
CXM, TIM, 
PTZ, DXT, 
SXT, AP, 
AUG, CIP, 
CAZ, CPD, 
CTX, 
Acc (6’)-Ib-cr, traT, 
fyuA, iutA, KpsMTII, 
4.44 ± 1.81 
All 
others 
Mixed Mixed 
DXT, AP 
traT, fimH, fyuA, 
iutA, 
8.15± 5.14 
* Feature or gene present in at least 50% of the isolates 
**The average number of virulence genes present/strain 
 
Taken together, our results showed that three of the recently emerging ExPEC 
clones (ST38, ST405 and ST648) carry a core type previously relatively rarely 
encountered among bloodstream isolates. These clones, while highly resistant, were less 
virulent that other strains. 
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4.2 Characterization of Carbapenem Resistant Klebsiella pneumoniae (CRKP) 
Clones and Sporadic Isolates Recovered in the Arabian Peninsula 
 
4.2.1 Identification of Clones 
Our laboratory received 165 CRKP strains between 2011 and 2013 from various 
countries from the Arabian Peninsula to determine their carbapenemase types. All 
repeated isolates were eliminated from the same patients. Additionally, few isolates 
carrying the blaVIM carbapenemase gene were also eliminated since they were 
encountered rarely.  The distribution of the strains according to country, specimen type 
and the carbapenemase carried is shown in Table 17. 
 
Table 17: Origin, source and carbapenemases produced by CRKP 
 
 
 
 
 
 
 
 
 
 
 
* KW-Kuwait 
** OM-Oman 
*** Screening- Infection control screening samples 
  % 
Country of origin 
UAE 38.8 
KW* 7.9 
OM** 25.5 
KSA 27.9 
   
Specimen type 
Blood 13.9 
Respiratory  33.3 
Urine 20.0 
Wound 17.6 
Screening *** 10.9 
Others  4.2 
   
Carbapenemase produced 
NDM 49.1 
OXA-48-like 31.5 
NDM-OXA 10.3 
None 9.1 
81 
 
 
 
In order to assess any clustering within this pool of isolates, they were subjected 
to macrorestriction analysis using a tolerant, (SD >80%) similarity threshold. The PFGE 
patterns of the isolates are shown on Figure 12. 
 
 Of the 165 isolates, 163 (97.8%) were typable. The strains exhibited 70 PFGE 
types. The cluster distribution is shown in Table 18. 
 
Table 18: Distribution of PFGE clusters 
 Size of cluster (n) 
 1 2 3 7 9 11 15 23 
Number of 
clusters 
38 21 6 1 1 1 1 1 
 
In order to establish clonal groups, strains were subjected to multi-locus 
sequence typing (MLST). For PFGE clusters, the following approach was applied: for 
each cluster up to 3 members at least one strain with each specific carbapenemase 
production type was MLST-ed. For larger clusters, the same rule was applied with larger 
numbers (i.e., usually 2-4 for each carbapenemase type, if present) of strains tested. 
Sequence types differing in a single allele only were assigned to clonal groups as shown 
in Table 19. Strains with the same sequence type or within the same clonal complex 
were considered a clone if containing more than 3 members. Strains outside of clones 
were considered sporadic. By these rules, 2 sequence types and 4 clonal complexes were 
identified to represent clones (Table 19). 
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Figure 12: PFGE clusters of the 163 K. pneumoniae isolates 
The dashed line represent the threshold of 90% similarity, red boxes identify clusters. 
 
8
2
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Table 19: Allele types of clonal complexes and sequence types 
CC** ST*** 
Allele types* 
gapA infB mdh pgi phoE rpoB tonB 
11 
11 3 3 1 1 1 1 4 
340 3 3 1 1 1 1 18 
15 
14 1 6 1 1 1 1 1 
15 1 1 1 1 1 1 1 
709 1 1 1 1 1 1 4 
17 
16 2 1 2 1 4 4 4 
17 2 1 1 1 4 4 4 
336 2 1 1 1 72 4 4 
2103 2 1 1 1 13 4 4 
147 
147 3 4 6 1 7 4 38 
273 3 4 6 1 7 4 4 
392 3 4 6 1 7 4 40 
- 101 2 6 1 5 4 1 6 
- 152 2 3 2 1 1 4 56 
 
*Numbering of alleles is according to the Klebsiella pneumoniae MLST website 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html). 
Boxes indicate allele differences within clonal complexes 
** CC- Clonal Complex they are differing in 1 allele, only 
*** ST- Sequence Type is a unique string of numbers 
 
4.2.2 General Characterization of the Clones 
 
 The distribution of country of origin and specimen type of the clones they were 
recovered from are shown in Tables 20. and 21. It should be noted that there were clones 
represented by strains isolated in multiple countries. 
  
 As can be seen, representatives of all clones had been recovered from multiple 
specimens, for most also including screening samples. It was noteworthy that the blood-
stream isolates were absent in the two smallest clones, only. 
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Table 20: Country of origin of the clones 
Groups n 
Country of origin (%) 
UAE KW* OM** KSA 
All 165 38.8 7.9 25.5 27.9 
CC11 20 35.0 0.0 55.0 10.0 
CC15 37 75.7 5.4 10.8 8.1 
CC17 7 0.0 57.1 0.0 42.9 
ST101 5 40.0 0.0 0.0 60.0 
CC147 30 23.3 6.7 50.0 20.0 
ST152 23 0.0 0.0 0.0 100.0 
Sporadic 43 46.5 11.6 27.9 14.0 
* KW-Kuwait 
** OM-Oman 
 
 
Table 21: Distribution of the strains assigned to clones according to the types of 
specimen 
Groups 
 
n 
Specimen types (%) 
Blood Resp Urine Wound Screening* Others 
All 165 13.9 33.3 20.0 17.6 10.9 4.2 
CC11 20 25.0 20.0 20.0 15.0 15.0 5.0 
CC15 37 18.9 24.3 24.3 16.2 16.2 0.0 
CC17 7 0.0 42.9 28.6 14.3 14.3 0.0 
ST101 5 0.0 60.0 20.0 0.0 20.0 0.0 
CC147 30 16.7 23.3 20.0 23.3 13.3 3.3 
ST152 23 4.3 78.3 13.0 4.3 0.0 0.0 
Sporadic 43 11.6 25.6 18.6 25.6 7.0 11.6 
*Screening- Infection control screening samples 
 
4.2.3 Comparison of Carbapenemases Produced by Clones and Sporadic Isolates 
 
 The type of carbapenemase produced by clones and sporadic isolates is shown in 
Table 22. It was noteworthy that all clones carried blaNDM as a single carbapenemase 
gene at a higher, and with the exception of CC17, blaOXA-48-like at a lower rate than did 
sporadic isolates. For the four more frequently observed clones, where statistical 
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analysis was possible, the higher rate of NDM carriage significantly exceeded that found 
among sporadic isolates (Fisher test, P varying between 0.0268 and <0.0001). 
Conversely, with the exception of clone C11 (P=0.2838) the rate of blaOXA-48-like 
carriership was significantly less common among members of the larger clones.  
 
Table 22: Carbapenemase genes in the strains assigned to clones 
Groups n 
Carbapenemase (%) 
NDM OXA NDM-OXA None 
All 165 49.1 31.5 10.3 9.1 
CC11 20 55.0 35.0 5.0 5.0 
CC15 37 43.2 27.0 24.3 5.4 
CC17 7 28.6 71.4 0.0 0.0 
ST101 5 40.0 40.0 0.0 20.0 
CC147 30 66.7 20.0 10.0 3.3 
ST152 23 95.7 0.0 4.3 0.0 
Sporadic 43 18.6 51.2 7.0 23.3 
 
Another noteworthy observation was that the rate of strains without detectable 
carbapenemase genes was considerably higher in the sporadic group than among the 
clones identified. The differences, regarding the large clones, with the exception of 
CC11 (P=0.1505) did even reach the level of statistical significance (P varying between 
0.0124 and 0.0308). 
 
 The PFGE cluster distribution within the clones is shown in Figures 13.-18. 
together with the carbapenemases produced. The cluster structure of the clones is 
presented in Table 23. The homogeneity of the clones varied with ST152 being the most 
homogenous. This was supported by the approximate value of variability comparing the 
size of a clone to the number of clusters present within Table 23. It was also noteworthy 
that in all clones strains producing different carbapenemase, at least in addition to the 
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one dominating in the particular clone (see NDM, NDM and OXA in ST152) were 
present. As expected, sporadic isolates were highly heterogeneous (Figures 19.).  
 
 
 
 
 
 
 
 
 
 
 
Figure 13: PFGE clusters of CC11 strains 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: PFGE clusters of CC15 strains  
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Figure 15: PFGE clusters of CC17 strains 
 
 
 
 
 
 
 
 
Figure 16: PFGE clusters of ST101 strains 
Figure 17: PFGE clusters of CC147 strains 
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Figure 18: PFGE Clusters of ST152 strains 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: PFGE clusters of sporadic strains 
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Table 23: Cluster structure of clones and sporadic strains 
Groups n 
Number of  
patterns 
Variability© 
Size of clusters (n) 
1 2 3 4 6 13 15 
CC11 20 15.0 1.33 12 2 0 1 0 0 0 
CC15 37 18.0 2.06 14 3 0 1 0 1 0 
CC17 7 5.0 1.40 3 2 0 0 0 0 0 
ST101 5 4.0 1.25 3 1 0 0 0 0 0 
CC147 30 21.0 1.43 16 4 0 0 1 0 0 
ST152 23 4.0 5.75 2 1 0 1 0 0 1 
Sporadic 41* 39.0 1.05 37 2 0 0 0 0 0 
*2 out of the 43 strains were non-typable. © defined as n/patterns 
 
4.2.4 Virulence of Clones and Sporadic Isolates 
 
 The results of testing the presence of 16 virulence-related genes in the isolates 
are summarized in Table 24. 
 
Table 24: Frequencies of virulence-related genes in the isolates 
Genes 
Frequency of virulence genes (%) in 
All CC11 CC15 CC17 ST101 CC147 ST152 Sporadic 
fyuA 52.7 25.0 83.8 14.3 80.0 30.0 78.3 44.2 
iutA 2.4 0.0 2.7 0.0 0.0 0.0 0.0 7.0 
ireA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
iroN 3.6 5.0 0.0 14.3 0.0 3.3 0.0 7.0 
kfuBC 26.7 15.0 89.2 0.0 40.0 3.3 0.0 11.6 
magA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
allS 1.8 0.0 0.0 0.0 0.0 0.0 0.0 7.0 
cf29A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
mrkD 95.8 100.0 97.3 100.0 100.0 93.3 100.0 90.7 
Cont. 
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Cont. 
fimA 98.8 100.0 100.0 100.0 100.0 96.7 100.0 97.7 
rmpA 1.2 0.0 0.0 0.0 0.0 0.0 0.0 4.7 
ugeA 98.8 100.0 100.0 100.0 100.0 96.7 100.0 97.7 
wabG 90.9 80.0 94.6 100.0 80.0 86.7 95.7 93.0 
cnf1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
traT 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
clpK 43.0 60.0 81.1 71.4 20.0 6.7 8.7 44.2 
 
Strains in all groups, including the sporadic isolates contained almost uniformly, 
the biofilm formation-linked type 3 fimbria gene mrkD, the adhesion-related type 1 
fimbria gene fimA and the ugeA and wabG genes associated with the synthesis of cell 
wall. Considerable variations between groups were observed regarding the presence of 
fyuA, kfuBC and clpK genes. Some of the clones carried these genes at much higher 
frequencies than the sporadic isolates (e.g. CC15, ST152 for yersiniabactin iron binding 
outer membrane protein fyuA,  and iron uptake related kfuBC genes, or CC11, CC15 for 
heat-shock resistance associated clpK genes). On the other hand, for some other clones 
the very opposite trend could be observed, i.e., they carried these genes at a lower rate 
than their sporadic counterparts (e.g. CC11 and CC147 for fyuA, ST152 for kfuBC, or 
CC147 and ST152 for clpK, respectively). 
 
 When the combined impact of virulence-related genes was investigated by 
comparing the virulence scores (i.e. the sum of positive virulence gene PCRs) between 
the groups, it was found that only CC15 strains had a considerably higher score than 
sporadic isolates (P=<0.0001) and in case of CC147 it was even significantly lower 
(P=0.0009) Table 25. 
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 Similarly varying results were obtained when investigating the serum sensitivity 
of the isolates. Comparing the actual survival rate after 3 hours of serum exposure did 
not show any significant differences between sporadic strains and the larger clones, 
although the rate of strains sensitive to serum was more common among sporadic strains 
(Table 25.).  
 
 Regarding biofilm production, in general, most strains were commonly 
producing strong biofilms. The rate of strong producers was the lowest among sporadic 
strains but even among them is was almost 75% (Table 25.). The optical densities 
indicating the amount of attached bacteria in the biofilm matt were significantly higher 
for CC15 and CC147 strains (P=0.0226 and P<0.0001, t-test). Moderate to non-
producers occurred in every clone with the exception of the small (n=7) CC17 where all 
isolates produced a strong biofilm. 
 
Importantly, only 5 isolates of the entire collection, 2 among CC11, in CC15, 1 
in CC17 and 1 among the sporadic strains exhibited the hyperviscous phenotype 
characteristic to highly invasive strains (Shon and Russo, 2012).  
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Table 25: Virulence-related features of the strains 
 
Groups n 
Virulence 
score 
Serum 
survival 
rate 
Rate (%) of serum  
Biofilm 
OD570±SD 
Rate (%) of biofilm formation 
Resistant Sensitive Strong Moderate Weak None 
All 165 5.16 ± 1.23 1.21 ± 2.68 34.5 21.2 1.5 ± 0.75 84.8 7.3 5.5 2.4 
CC11 20 4.85 ± 0.99 0.68 ± 1.29 15 20 1.26 ± 0.53 85 15 0 0 
CC15 37 6.49 ± 0.93 0.70 ± 1.09 27 24.3 1.63 ± 0.85 81.1 2.6 16.2 0 
CC17 7 5.0 ± 0.00 0.08 ± 0.16 0 57.1 1.51 ± 0.41 100 0 0 0 
ST101 5 5.2 ± 1.48 8.39 ± 10.49 60 20 1.17 ± 0.65 80 0 0 20 
CC147 30 4.17 ± 0.99 1.50 ± 2.81 43.3 3.3 2.08 ± 0.75 96.7 0 0 3.3 
ST152 23 4.83 ± 0.65 1.45 ± 1.29 69.6 8.7 1.32 ± 0.68 91.3 4.3 0 4.3 
Sporadic 43 5.05 ± 1.11 0.9 ± 1.58 27.9 32.6 1.24 ± 0.63 74.4 16.3 7 2.3 
 
9
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4.2.5 Antibiotic Resistance of Clones and Sporadic Isolates 
 
 The antibiotic susceptibility of sporadic isolates and strains within clones were 
also compared. Regarding ß-lactam drugs, with the exception of CC17, i.e,. one of the 
two smaller clones, no real differences were noted regarding the MIC values. While 
being above the clinical breakpoint (i.e. ≥ 2 mg/L), CC17 strains had a considerably 
lower MIC50 value compared to some of the other clones, reaching 64 mg/L against 
ertapenem (Table 26.).   
  
The rate of resistance to the different antibiotics was also established (Table 27.). 
As expected (considering the selection criteria of the strains, i.e., being non-susceptible 
to at least one carbapenem), the rate of resistance to any ß-lactam drugs at least 
approached 100% in all groups. However, a much less uniform picture emerged when 
comparing the resistance rates to non-beta lactam antibiotics (Table 27.). 
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Table 26: MIC values of antibiotics against the different clones 
 
Antib. Range 
MIC (mg/L) against different groups (n) 
All 
(165) 
CC11 
(20) 
CC15 
(37) 
CC17 
(7) 
ST101 
(5) 
CC147 
(30) 
ST152 
(23) 
Sporadic 
(43) 
ERT 
MIC50 16 32 64 8 64 16 16 16 
MIC90 64 64 64 TFC TFC 64 32 16 
IMP 
MIC50 8 8 16 8 8 8 16 8 
MIC90 64 32 64 TFC TFC 64 32 32 
MEM 
MIC50 32 64 128 16 64 32 32 32 
MIC90 128 128 128 TFC TFC 128 128 128 
CAZ 
MIC50 128 128 128 128 128 128 128 128 
MIC90 128 128 128 TFC TFC 128 128 128 
CTX 
MIC50 128 128 128 64 128 128 128 128 
MIC90 128 128 128 TFC TFC 128 128 128 
AZT 
MIC50 128 128 128 64 128 128 128 128 
MIC90 128 128 128 TFC TFC 128 128 128 
TGC 
MIC50 1.5 1 2 1 1 2 1 1.5 
MIC90 4 2 6 TFC TFC 6 1 4 
COL 
MIC50 0.19 0.125 0.19 0.25 0.125 0.19 0.19 0.19 
MIC90 0.5 0.5 4 TFC TFC 6 0.38 0.5 
TFC – Too few to calculate 
ERT- Ertapenem, IMP- Imipenem, MEM- Meropenem, CAZ-Ceftazidime, CTX-
Cefotaxime, AZT- Aztreonam, TGC- Tigecycline, COL- Colistin  
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Table 27: The rate of resistance to antibiotics 
 
Antibiotics 
Rate (%) of resistance in groups (n) 
All 
(165) 
CC11 
(20) 
CC15 
(37) 
CC17 
(7) 
ST101 
(5) 
CC147 
(30) 
ST152 
(23) 
Sporadic 
(43) 
ERT 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
IMP 93.9 100.0 94.6 100.0 80.0 100.0 100.0 83.7 
MEM 99.4 100.0 100.0 100.0 100.0 100.0 100.0 97.7 
CAZ 94.5 95.0 97.3 85.7 100.0 96.7 100.0 88.4 
CTX 95.2 95.0 97.3 85.7 100.0 96.7 100.0 90.7 
AZT 87.9 95.0 91.9 71.4 100.0 80.0 95.7 83.7 
TGC 23.6 5.0 37.8 14.3 0.0 43.3 0.0 23.3 
COL 7.3 5.0 10.8 0.0 20.0 13.3 4.3 2.3 
CIP 92.7 100.0 100.0 71.4 100.0 100.0 100.0 76.7 
SXT 83.0 90.0 83.8 85.7 80.0 80.0 100.0 72.1 
GN 76.4 85.0 89.2 14.3 100.0 86.7 100.0 48.8 
AK 55.8 45.0 62.2 42.9 60.0 70.0 100.0 23.3 
TOB 86.7 95.0 91.9 71.4 80.0 96.7 100.0 67.4 
CHL 49.1 65.0 70.3 28.6 0.0 83.3 4.3 32.6 
DXT 58.8 60.0 51.4 71.4 80.0 63.3 47.8 62.8 
 
ERT- Ertapenem, IMP- Imipenem, MEM- Meropenem, CAZ-Ceftazidime, CTX-
Cefotaxime, AZT- Aztreonam, TGC- Tigecycline, COL- Colistin, CIP- Ciprofloxacin, 
SXT- Trimethoprim-Sulphamethoxazole, GN- Gentamicin, AK- Amikacin, TOB- 
Tobramycin, CHL- Chloramphenicol, DXT- Doxycycline 
 
 
With a few exceptions, notably the relatively sensitive small clone, CC17, the 
rate of resistance to non-ß-lactam drugs was considerably higher among the clones than 
among sporadic isolates. This was particularly obvious in case of colistin, ciprofloxacin 
and aminoglycoside antibiotics, e.g., gentamicin, amikacin and tobramycin, respectively 
(Table 27.). 
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The difference between clonal and sporadic strains were even more obvious 
when the results were expressed as a ―resistance score‖, defined as the number of drugs 
a strain expressed resistance to (Table 28.). 
 
Table 28: Resistance scores of the groups 
  Resistance score 
  
 N of 
strains 
All antibiotics  
(n=15) 
Non-ß-lactam antibiotics 
(n=9) 
All 165 11.04 ± 2.09 5.33 ± 1.72 
CC11 20 11.35 ± 1.69 5.5 ± 1.15 
CC15 37 11.78 ± 1.16 5.97 ± 1.07 
CC17 7 9.43 ± 1.72 4.00 ± 0.82 
ST101 5 11.0 ± 1.0 5.2 ± 1.1 
CC147 30 12.10 ± 1.88 6.37 ± 1.71 
ST152 23 11.52 ± 0.67 5.57 ± 0.59 
Sporadic 43 9.53 ± 2.68 4.09 ± 2.11 
 
 As seen, members of all clones, with the exception of the small CC17, were more 
resistant to antibiotics, and notably more non-ß-lactam antibiotics, than the sporadic 
isolates, which, in case of the larger clones analyzed, reached the level of statistical 
significance (P between 0.0072 and <0.0001). 
 
 These findings were in line with our results regarding the presence of non-
carbapenemase-coding resistance genes. With the exception of the low rate of blaTEM 
seen in the small clone ST101, TEM, SHV and CTX-M coding genes were commonly 
present in each groups. However, testing a limited number of fluoroquinolone and 
aminoglycoside resistance genes showed that sporadic strains less commonly carried 
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these genes than, with the exception of the small CC17 clone, their clonal counterparts 
(Table 29.). This was particularly noteworthy when the comparison regarding the 
presence of any 16S methylases causing broad spectrum aminoglycoside resistance was 
made. In all clones, with the exception of CC17 that did not contain any, these genes 
were present at much higher frequencies than in sporadic isolates, reaching the level of 
statistical significance in CC15, CC147 and ST152 (P between 0.0002 and <0.0001). 
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Table 29: Frequencies of resistance genes encountered in CRKP 
 
Groups n 
Frequency of resistance genes (%) 
ß-lactamase 16S methylases 
Any 16S 
methylase 
aac(6')-
Ib-cr TEM SHV CTX-M armA rmtA rmtB rmtC rmtD 
All 165 72.1 80.6 80.0 21.2 0.0 1.8 18.8 0.0 40.0 86.7 
CC11 20 80.0 60.0 90.0 20.0 0.0 0.0 10.0 0.0 20.0 95.0 
CC15 37 64.9 83.8 78.4 37.8 0.0 0.0 5.4 0.0 43.2 97.3 
CC17 7 42.9 71.4 42.9 0.0 0.0 0.0 0.0 0.0 0.0 71.4 
ST101 5 20.0 80.0 80.0 0.0 0.0 0.0 40.0 0.0 40.0 80.0 
CC147 30 70.0 93.3 76.7 46.7 0.0 10.0 6.7 0.0 63.3 86.7 
ST152 23 91.3 69.6 91.3 4.3 0.0 0.0 95.7 0.0 95.7 100.0 
Sporadic 43 76.7 86.0 79.1 4.7 0.0 0.0 2.3 0.0 7.0 69.8 
 
9
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4.3 Biocide Susceptibility of K. pneumoniae and E. coli strains 
 
The next part of the project we studied the resistance of carbapenem resistant K. 
pneumoniae (CRKP) and E. coli (CREC) isolated from blood to various biocides and 
compared them to features of isolates from other sources, as well as to carbapenem 
susceptible isolates (CSKP and CSEC) cultured from blood. 
 
4.3.1 The Collection 
Strains were collected between 2011 and 2014 from countries of the Arabian 
Peninsula. Carbapenem susceptible strains originated from blood, while their resistant 
counterparts were from a variety of sources. During analysis the sources, i.e. blood or 
non-blood, were taken into consideration. The distribution of the strains is shown in 
Table 30. 
 
The strains were subjected to macrorestriction analysis using the stringent 
SD>90% similarity threshold to assess any clustering within the carbapenem resistant 
and susceptible pools (Figures 20.–23.). As these studies did not reveal any significant 
clustering (i.e., the pools were heterogeneous), its potential effect was not considered in 
further statistical evaluations. 
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Table 30: The source of the isolates 
 
Strain 
type 
Source n 
Sample type Country of origin 
Resp. Wound Urine Screen* Other UAE KW** KSA OM*** 
CRKP 
Blood 16 - - - - - 7 4 3 2 
Non-blood 72 23 15 15 14 5 21 10 17 24 
CSKP Blood 35 - - - - - 35 0 0 0 
CREC 
Blood 8 - - - - - 8 0 0 0 
Non-blood 35 4 5 14 5 7 21 7 0 7 
CSEC Blood 25 - - - - - 25 0 0 0 
 
CRKP – Carbapenem resistant K. pneumoniae 
CSKP – Carbapenem susceptible K. pneumoniae 
CREC – Carbapenem susceptible E. coli 
CSEC– Carbapenem susceptible E. coli 
* Screen: Infection control screening samples 
**KW: Kuwait 
***OM: Oman 
 
1
0
0
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Figure 20: Marcorestriction analysis of carbapenem susceptible E. coli  strains 
The dashed line represent the threshold of 90% similarity; red boxes identify clusters. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Marcorestriction analysis of carbapenem resistant E. coli  strains 
The dashed line represent the threshold of 90% similarity; red boxes identify clusters. 
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Figure 22: Marcorestriction analysis of carbapenem susceptible K. pneumonaie strains 
The dashed line represent the threshold of 90% similarity; red boxes identify clusters. 
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Figure 23: Marcorestriction analysis of carbapenem resistant K. pneumonaie strains 
    The dashed line represent the threshold of 90% similarity; red boxes identify clusters. 
 
1
0
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 The carbapenem resistant isolates produced a variety of carbapenemases, while 6 
of the K. pneumoniae and 12 of the E. coli strains were carbapenemase non-producers 
(Table 31.). 
 
Table 31: Distribution of various carbapenemase types among carbapenem resistant 
strains 
 
In general, comparison between strains of the two species revealed that K. 
pneumoniae strains exhibited significantly higher MIC values against benzalkonium 
chloride (BENZ) and chlorhexidine (CHEX) (P<0.0001) than E. coli isolates did, while 
no significant difference was seen for irgasan (IRG). Similar results were obtained when 
comparing the carbapenem resistant subsets of the two species, only (Table 32. and 
Table 33.). 
 
4.3.2 Biocide Susceptibility of K. pneumoniae and its Link to Carbapenem 
Resistance and Genotype  
 
The susceptibility of the strains to disinfectants, as well as the frequency of genes 
potentially associated with biocide resistance is shown in Tables 32. and 33. 
 
Regarding K. pneumoniae strains, bloodstream CRKP isolates exhibited 
significantly higher MIC values to chlorhexidine (CHEX) (P=0.0031) than their CSKP 
Species All 
Type of carbapenemase produced 
NDM OXA NDM-OXA VIM None 
K. pneumoniae 88 32 35 10 5 6 
E. coli 43 17 13 0 1 12 
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counterparts, and the difference was also significant when all CRKP strains were 
compared to the susceptible ones (P=0.0007).  In this later case similar difference was 
found for benzalkonium chloride (BENZ), as well (P=0.0031). On the other hand, no 
significant differences in susceptibility to any biocides between bloodstream and non-
bloodstream CRKP strains were noted (Table 32.). 
 
Three genes, qacδE1, qacE and sugE (P) were present in considerable higher 
frequencies in CRKP than in CSKP strains suggesting an association with increased 
resistance (Table 33.). 
 
Table 32: MIC values of K. pneumoniae strains against different biocides 
BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan 
 
qacδE1 was significantly associated with CRKP isolates (P=0.0151, Fisher‘s 
exact test). The role of qacδE1 in conferring resistance to chlorhexidine (CHEX) was 
also highlighted by the fact that the difference between the MIC values against this 
  
  
  
  
 CRKP  
CSKP   
 
All Non-blood Blood 
n 88 72 16 35 
BENZ 
 
 
x ± SD 40.36 ± 16.98 40.89 ± 17.79 38.0 ± 12.9 33.83 ± 7.54 
median 32 32 32 32 
MIC90 64 64 64 32 
CHEX x ± SD 26.18 ± 11.99 25.67 ± 11.85 28.5 ± 12.72 18.17 ± 10.14 
  median 32 32 32 16 
  MIC90 32 32 32 32 
IRG x ± SD 7.35 ± 54.83 7.92 ± 60.24 4.75 ± 15.81 1.37 ± 5.42 
  median 1 1 0.75 0.5 
  MIC90 2 1 2 1 
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disinfectant among qacδE1 positive versus negative strains (26.52 ± 12.51 vs. 21.86 ± 
11.28, respectively) reached the level of significance (P=0.0321). No such difference 
was seen regarding the other biocides in this comparison.  
 
MIC values of benzalkonium chloride (BENZ) in strains positive for sugE(P) 
(n=10) (51.2 ± 30.91) were significantly (P=0.0133) higher than in the negative isolates 
(n=78, 37.87 ± 12.86). However, although sugE(P) positivity was more common among 
CRKP strains, this genotype did not show a significant association with this phenotype 
(P=0.069). No similar differences regarding other disinfectants were found comparing 
these two groups.  
 
 
Table 33: Frequency of biocide resistance genes in K. pneumoniae 
Genes 
CRKP 
CSKP 
All Non-blood Blood 
n 88 72 16 38 
emrE 0.0 0.0 0 2.9 
qacδE1 51.1 44.4 81.25 25.7 
qacE 4.5 5.6 0 0.0 
mdfA 1.1 1.4 0 0.0 
ydgE 1.1 1.4 0 0.0 
ydgF 1.1 1.4 0 0.0 
sugE( c ) 1.1 1.4 0 0.0 
cepA 97.7 97.2 100 94.3 
qacC 0.0 0.0 0 0.0 
sugE (P) 11.4 8.3 25 0.0 
qacF 0.0 0.0 0 0.0 
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As the number of qacE positive strains was too low, i.e. 4 in the CRKP and 0 in 
the CSKP group, they were omitted from this analysis. 
 
4.3.3 Biocide Susceptibility of E. coli and its Link to Carbapenem Resistance and 
Genotype 
 
For E. coli, as far as MIC values to biocides were concerned, no significant 
difference between carbapenem resistant and susceptible blood culture isolates, or in 
general, carbapenem resistant and susceptible isolates could be established Table 34.  
 
Table 34: MIC values of E. coli  strains against different biocides 
  
  
  
  
 CREC  
CSEC   
 
All Non-blood Blood 
n 43 35 8 25 
BENZ x ± SD 26.23 ± 8.61 25.37 ± 8.99 30.0 ± 5.66 25.6 ± 8.0 
  median 32 32 32 32 
  MIC90 32 32 TFC 32 
CHEX x ± SD 1.80 ± 1.21 1.87 ± 1.24 1.5 ± 1.07 1.68 ± 0.99 
  median 1 1 1 1 
  MIC90 4 4 TFC 2 
IRG x ± SD 0.16 ± 0.06 0.16 ± 0.06 0.16 ± 0.06 0.14 ± 0.04 
  median 0.13 0.13 0.125 0.13 
  MIC90 0.25 0.25 TFC 0.125 
TFC – Too few to calculate 
BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan 
 
The mdfA, ydgE, ydgF, and sugE( C ) genes, while almost completely missing 
from the K. pneumoniae isolates, were close to uniformly present in all E. coli strains. 
On the other hand, similarly to K. pneumoniae, qacδE1 and sugE(P) were more common 
in the carbapenem resistant strains and they both showed a highly significant association 
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with the carbapenem resistant phenotype (P=0.0001) (Table 35.). Isolates carrying the 
qacδE1 gene exhibited a significantly higher MIC to chlorhexidine (CHEX) (P=0.0329), 
but not to the other biocides and, just like in K. pneumoniae, no such correlation was 
observed with sugE(P). 
 
Table 35: Frequency of biocide resistance genes in E. coli 
 
 
 
 
 
 
 
 
 
 
 
 
In E. coli, emrE occurred more commonly in carbapenem resistant strains, but 
this association did not reach the level of statistical significance and the MIC values of 
strains positive for this gene did not exhibit significantly higher MICs to any of the 
disinfectants. 
 
Genes 
CREC 
CSEC 
All Non-blood Blood 
n 43 35 8 25 
emrE 67.4 68.6 62.5 52.0 
qacδE1 76.7 80.0 62.5 28.0 
qacE 2.3 0.0 12.5 0.0 
mdfA 97.7 97.1 100.0 100.0 
ydgE 97.7 100.0 87.5 96.0 
ydgF 97.7 100.0 87.5 96.0 
sugE(c) 95.3 97.1 87.5 100.0 
cepA 0.0 0.0 0.0 0.0 
qacC 0.0 0.0 0.0 0.0 
sugE (P) 39.5 42.9 25.0 0.0 
qacF 7.0 5.7 12.5 4.0 
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4.3.4 Biocide Susceptibility in Relation to the Carbapenemases Produced 
 
 The relationship between susceptibility to disinfectants and the type of 
carbapenemase produced by carbapenem resistant strains was also investigated. The 
results are summarized in Tables 36. and 37.  
 
Table 36: MIC of biocides against K. pneumoniae strains producing different 
carbapenemases 
 MIC (mg/L) 
CPase  NDM OXA NDM-OXA VIM None 
n 32 35 10 5 6 
BENZ 38.0 ± 12.69 40.69 ± 15.2 40.00 ± 17.28 64.0 ± 39.19 32.0 ± 0.0 
CHEX 27.25 ± 13.15 24.69 ± 11.04 25.6 ± 8.26 32.0 ± 19.6 25.33 ± 10.63 
IRG 0.88 ± 0.52 0.8 ± 0.41 58.3 ± 160.63 0.7 ± 0.27 0.58 ± 0.34 
BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan 
 
 
Table 37: MIC of biocides against E. coli strains producing different carbapenemases 
NA – Not applicable 
BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan 
 
 
 
 MIC (mg/L) 
CPase  NDM OXA NDM-OXA VIM None 
n 17 13 0 1 12 
BENZ 27.29 ± 7.51 28.31 ± 7.02 NA NA 22.0 ± 10.85 
CHEX 1.71 ± 0.99 1.69 ± 1.32 NA NA 2.13 ± 1.45 
IRG 0.17 ± .06 0.16 ± 0.06 NA NA 0.15 ± 0.05 
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Statistical analysis of the different carbapenemase producing groups with at least 
10 members revealed no significant difference between them regarding the MIC values 
of different biocides in E. coli. In K. pneumoniae, applying the same criteria, irgasan had 
significantly higher MIC to NDM-OXA producing strains that to those producing these 
two enzymes alone (P=0.0439 and 0.0345, respectively). 
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4.4 Fosfomycin Susceptibility of K. pneumoniae Strains 
 
Since intravenous fosfomycin is currently not available in the UAE, routine 
testing of susceptibility to this drug is not carried out for Enterobacteriaceae causing 
infections beyond the urinary tract. Consequently, local resistance data for K. 
pneumoniae isolates are not available. As previously our laboratory studied the 
fosfomycin resistance rate of E. coli strains (Amna Baloushi, PhD thesis, manuscript in 
preparation) we extended these investigations to K. pneumoniae. During these studies 
the same group of CRKP and CSKP strains were used as for the investigations on 
susceptibilities to disinfectants (see 4.3 in this Thesis). The cluster structure of the pools 
of strains are provided there.  
 
Using the MIC≤32 mg/L EUCAST clinical breakpoint of fosfomycin the 
resistance rate we found were different in the CRKP and CSKP collections; 69 of the 88 
CRKP (78.4%) and 32 of the 35 CSKP (91.2%) showed susceptibility to this antibiotic. 
However, this difference was not statistically significant (Fischer‘s exact test; 
P=0.1822). If we compared the different subgroups of CRKP, i.e. isolates from sources 
other than blood, blood isolates and urine isolates, we found that blood CRKP isolates 
were significantly more likely to be resistant to fosfomycin than non-blood (P=0.0002) 
or urine (P=0.0059) CRKP isolates, whereas the resistance rate was similar in non-blood 
CRKP (11%) and CSKP (8.5%) isolates. If the blood isolates were compared to each 
other, i.e., CRKP blood vs. CSKP, carbapenem resistance was significantly associated 
with fosfomycin resistance (P=0.0005). The MIC50 and MIC90 values of the respective 
strain collections are shown in Table 38.  
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Table 38: Fosfomycin, colistin and tigecycline MIC of K. pneumoniae strains 
 
 
Mg/L 
 
CRKP 
CSKP 
 
All Non-blood Blood Urine 
n 88 72 16 15 35 
FOS 
MIC50 16 8 64 8 8 
MIC90 64 64 256 32 16 
COL 
MIC50 0.5 0.5 0.5 0.5 0.25 
MIC90 4 4 64 32 0.5 
TGC 
MIC50 1 1 1 1 0.5 
MIC90 8 8 2 8 1 
FOS-Fosfomycin, COL- Colistin, TGC- Tigecycline 
 
It is noteworthy that while over 90% of the CSKP isolates were susceptible to the 
three antibiotics tested, the MIC90 value of the CRKP collection to all three 
antimicrobials was higher than the clinical breakpoint of these antibiotics, respectively. 
 
Since fosfomycin therapy is considered as an alternative in case of CRKP 
infection, but not recommended as monotherapy in case of a non-urinary tract infection, 
we assessed the association in the CRKP collection between resistance to fosfomycin 
and resistance to antimicrobials, which may be used in combination, i.e. colistin or 
tigecycline. It was found that resistance to neither of these antibiotics is associated with 
fosfomycin resistance (fosfomycin vs. colistin P=0.0963 and fosfomycin vs. tigecycline 
P=0.42, respectively). However, when evaluating the association in blood isolates 
(CSKP and CRKP together) between the resistance to the two antibiotics, which could 
be used in bloodstream infections, i.e. fosfomycin and colistin, a significant association 
was found (P=0.0106).  
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As the majority of clinically relevant fosfomycin resistance observed nowadays 
is due to the fosfomycin inactivating resistance genes (fosA-type or fosC genes) we 
tested the presence of these in our collection by PCR. We found that while none of the 
strains were positive for fosC, more than ¾ of both CRKP and CSKP collection 
harbored the fosA gene (78.4% and 77.1%, respectively). However, the presence of the 
gene did not show any association with the phenotypic fosfomycin resistance. Sequence 
of the fosA PCR products of two fosfomyin resistant (ABC189 MIC>1024 mg/L and 
KW11 MIC=128 mg/L) and one fosfomycin susceptible strain (ABC52 MIC=4 mg/L) 
revealed 99-100% identity with fosA genes of 43 K. pneumoniae whole genomes 
deposited in the GenBank. A comparison of partial fosA of the above three strains and a 
plasmid-borne fosA gene of E. coli HKU1 (KC960485) and a chromosomally located 
fosA of K. pneumoniae 30660/NJST258 (CP006923) is shown, as a screenshot, on 
Figure 24. 
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Figure 24: Alignment of partial fosA genes of KC960485 and CP006923 (GenBank) to 
sequenced fosA PCR products of K. pneumoniae strains ABC52, KW11 and ABC189 
 
These findings suggest that fosA may be present on the chromosome of a 
majority of K.  pneumoniae, but not always expressed. Study of the possible expression 
differences of fosA gene was beyond the scope of our project. However, we tested 
whether the fosA gene was plasmid-borne in the strains showing phenotypic fosfomycin 
resistance by Southern blotting of plasmid gels and hybridizing the positively charged 
nylon membranes with digoxigenin labeled fosA probe.  
 
We did not observe any hybridization signal on the membrane (data not shown). To 
further prove that the fosfomycin resistance determinant was not transferable, we 
attempted to conjugate the resistance feature from K. pneumoniae ABC189, which 
exhibited the highest MIC to fosfomycin in the collection (MIC>1024 mg/L), with E. 
coli J53RAZ at 30
o
C and at 37
o
C. We also isolate plasmid DNA from the same K. 
pneumoniae isolate and transformed it in E. coli DH5α. None of these experiments 
resulted in fosfomycin resistant E. coli derivatives. 
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Chapter 5: Discussion 
 
An important feature of the recent epidemiology of infections due to members of 
the Enterobacteriaceae family, particularly E. coli and K. pneumoniae  strains, is that a 
considerable part of the cases are attributed to particular clones, i.e., strains closely 
related to each other implying that they stem from common ancestors. As clinically one 
of the most relevant feature of these strains is their often increased antibiotic resistance, 
and as they are disseminated globally, they are commonly referred to as multi-drug 
resistant, MDR pandemic clones (Pitout, 2012). 
 
 Although their epidemiology has been extensively studied, we still do not 
understand what makes certain strains capable of expanding and spreading while others 
are confined to sporadic infections, only. As we believe that a better understanding of 
the basis of their propagation and spread would help to mount a better control system 
against them, we studied such isolates recovered in the Arabian Peninsula using a 
variety of genotyping and fingerprinting methods and phenotypic assays. These studies 
were not only meant to address the above global questions, but also to characterize such 
local strains, i.e., a field having been considerably neglected, so far.  
 
Blood-stream infections are the most serious ones among extraintestinal E. coli 
(ExPEC) infections. The characterization of the 172 local blood-stream isolates mostly 
yielded the expected results, at least initially. The most common phylogenetic type was 
B2 followed by D (Dale and Woodford, 2015; Riley, 2014). Also, the strains exhibited a 
relatively high rate of resistance to a variety of antibiotics and the over 30% of the 
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strains produced ESBL, mostly of the CTX-M-15 type. The spectrum of virulence factor 
genes encountered was also in line with anticipation: a high frequency of presence of 
pathogenicity island (PAI), secreted autotransporter cytopathic toxin sat, the C5b6 
complex inhibiting, serum resistance associated traT, the type 1 fimbria gene fimH, 
group II capsule gene KpsMTII, yersiniabactin  fyuA and iron uptake gene iut were all 
anticipated to be common among extraintestinal isolates and have been broadly 
documented earlier (Dale and Woodford, 2015; Johnson et al., 2009; Pitout, 2012; Riley, 
2014). 
 
 On the other hand, PCRs targeting various core biosynthesis genes yielded, at 
least partly, unexpected results. Based on previous reports (Amor et al., 2000; 
Appelmelk et al., 1994; Gibb et al., 1992; Gibbs et al., 2004), one could have anticipated 
an overpowering dominance of strains with an R1 core type (Table 39.). The high rate of 
the previously rare K-12 core type was to some extent already anticipated as we have 
previously shown that members of the global ST131 clone carries this core type (Szijártó 
et al., 2012). However, the comparatively high rate of the R4 core type was considerably 
different from previous observations.  
 
The fact that the overwhelming majority (86.7%) of R4 core type strains 
belonged to phylogenetic group D lead us to the assumption that clustering of strains 
into clones could be responsible for the phenomenon. MLST studies confirmed this 
hypothesis and we identified three, well known international clones (ST38, ST405 and 
ST648) present among local isolates with a group D phylogeny and R4 core. Actually, 
all major STs identified in the current study consisted of strains expressing a previously 
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rare core type: the ST131 the K-12 type, as described earlier, the ST38, ST405 and 
ST648 strains the R4 core type.  
 
Table 39: Comparison of core type distribution found in this study to previous 
observations 
* ECOR: A reference collection of E. coli strains found in nature 
**ST38, ST131, ST405 and ST648 combined 
 
These STs have all been recognized to cause extraintestinal infections around the 
globe. Often they are known to produce, just as observed in the current study, various 
alleles of CTX-M type ESBLs (Pitout, 2012). 
 
The best documented global outbreak is clearly caused by ST131 strains (Peirano 
and Pitout, 2010).  However, CTX-M-9,-14, and -15-producing ST38 strains have been 
reported form Japan (Suzuki et al., 2009), from the Netherlands (van der Bij et al., 
2011), from Korea (Kim et al., 2011), and from Tanzania (Mshana et al., 2011). Strains 
Sample 
Core type (%) 
Reference 
R1 R2 R3 R4 K-12 
Non-
R1-3 
Blood 
Urine 
Feces 
61 7 15 - - 16 
(Gibb et al., 1992) 
 
81 5 5 - - 10 
52 19 10 - - 19 
Blood 68 6.5 8.7 5.1 3.2 - 
(Appelmelk et al., 
1994) 
*ECOR 69.4 11.1 11.1 2.8 5.6 - (Amor et al., 2000) 
Feces 
(human) 
Feces 
(cattle) 
63 15 4 14 4 - 
(Gibbs et al., 2004) 
49 11 11 25 4 - 
All Blood 
Main ST** 
Others 
33.72 8.14 18.02 17.44 22.67 - 
This study 0 0 0 39.34 60.66 - 
52.25 12.61 27.93 5.41 1.80 - 
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associated with OXA and NDM type carbapenemase production have also been 
described (Poirel et al., 2011a.; Yamamoto et al., 2011). CTX-M producing ST405 and 
ST648 have also been observed globally (Coque et al., 2008; Jones et al., 2008; Mihaila 
et al., 2010; Smet et al., 2010; van der Bij et al., 2011; Zong and Yu, 2010) and their 
carbapenemase producing varieties have also been documented (Hornsey et al., 2011; 
Mushtaq et al., 2011).  
 
The clones we encountered in the current study differed from each other 
substantially. On the one, hand all clones were resistant to a broader spectrum of 
antibiotics than isolates not clustered into clones (Table 17.). However, with the 
exception of ST131, they were less virulent than strains not belonging to any of the 
clones, as substantiated by their lower virulence score (Table 17.). Actually, ST131 
strains are known to be uniquely virulent compared to other ExPEC isolates (Johnson et 
al., 2009; Pitout, 2012).  
 
As far as resistance to antibiotics is concerned, while the clones we encountered 
locally were definitely more resistant that sporadic isolates, it is not clear if this is the 
reason or the consequence of their emergence. Theoretically it would be logical to 
assume that strains with more resistance have better survival chance in antibiotic-soaked 
environments. However, on the other hand susceptible, highly successful clones, such as 
ST95 and ST393 are known (Riley, 2014). Furthermore, the fact that some of these 
clones are also more common in community acquired cases (i.e., environments still less 
challenged by antibiotics that in hospital settings) argues against this reasoning (Riley, 
2014). Alternatively, one may assume that as fit clones expand, they are increasingly 
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exposed and hence become more resistant. Currently, based on the data in the literature 
and our own observations, we cannot exclude either scenarios.  
 
We believe that our finding, i.e., that in addition to the K-12 core of ST131 
strains previously described (Szijártó et al., 2012) three further clones express a 
previously relatively rare core type, i.e. R4, is worth further attention.  One may 
speculate that the previously low rate of K-12 and relatively low rate of R4 core type 
strains could leave the population less exposed to, and hence less primed by this 
antigens. In fact, a relation between the frequencies of various core types encountered 
and the level of specific antibodies found has been documented (Gibbs et al., 2004). 
Theoretically, this could lead to a naïve population with increased susceptibility to 
strains expressing these antigens.  
 
The obvious question is whether immune mechanisms specific to core antigens 
could lower the chance of infection or colonization with strains expressing them? It 
should be kept in mind, that the presence of serum, or even that of mucosal antibodies 
does not have a protective effect per se particularly, if the antigen targeted is such a 
relatively hidden antigen, as the core epitopes are. This is one of the main reasons why 
the possible role of core, as a potentially ―protective antigen‖ is not without 
controversies.  
 
But being located ―deep‖ in the cell wall may not completely eliminate the 
possibility that these antigens are targeted by immune mechanisms. Our earlier studies 
with rough shigella vaccines (Szijártó et al., 2013) have shown that epitopes located 
121 
 
 
 
deep in smooth strains are accessible to immune mechanisms to the extent that immune 
response targeting them can result in protection in in vivo models (Szijártó et al., 2013). 
One of the most likely protective epitopes were those located in the core.  
 
Some studies failed to show a protective effect of core specific antibodies (Russo 
et al., 2009; Van Dijk et al., 1981), while others argue the opposite (Cross et al., 2004; 
Di Padova et al., 1993; Müller-Loennies et al., 2007), although it should be noted that in 
some of these studies neither the epitope nor the mode of action were clearly defined, 
and in some cases, it was likely the anti-endotoxin, instead of the anti-bacterial effect 
which was evaluated. Nevertheless, in line with our own suggestion, it is noteworthy 
that based on their sero-epidemiological studies, Currie et al postulated that the anti-R3 
core mucosal immune response could play a role in preventing either the infection or the 
colonization by E. coli O157 strains (Currie et al., 2001).   
 
In conclusion, with the understanding that the majority of extraintestinal 
infections are due to strains previously permanently or temporarily colonizing the gut, 
based on our findings regarding the dominance of K-12 and R4 core type, we propose as 
a hypothesis for further studies, that the relative naivety of the population towards K-12 
and R4 core antigens could have contributed to the emergence of these clones by making 
easier for these strains to colonize the gut and hence, eventually cause infections. It is 
clear to us that proving this hypothesis needs further studies, which would reveal 
whether other clones spreading globally also carry some of the previously rare core 
types. Also, their frequencies in the gut flora of healthy carriers should be studied and 
finally, their increased colonizing potentials, if present, should be assessed in 
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experimentally challenged immune and non-immune hosts. These are the questions, as 
outcomes of this project, our laboratory is planning to address in the future. 
 
Next we characterized carbapenem resistant K. pneumoniae strains encountered 
in the Arabian Gulf countries. In the past few years, this group of pathogens have 
endemic in the region (Zowawi et al., 2014) with high incidence rates of (approximately 
6% of K. pneumoniae strains in Abu Dhabi – Dr. Jens Thomsen, Health Authority Abu 
Dhabi, personal communication) and mortality and, as our laboratory showed it recently, 
with extensive autochthonous transmission (Sonnevend et al., 2015b).  
 
With regards of study of 165 CRKP strains, the first important observation was 
that 26.1% of them could not be linked to clusters forming known STs or CCs (Table 
18.). Members of CCs and STs encountered locally have been well known for their 
outbreak potential (Arena et al., 2013; Baraniak et al., 2015; Del Franco et al., 2015; 
Hasan et al., 2014; Nagasaka et al., 2015; Park et al., 2015). However, beyond 
describing STs 14, 147 and 152 in the Arabian Peninsula (Sonnevend et al., 2015b), very 
little has been known earlier about the characteristics of locally spreading lineages. 
Furthermore, the local detection of CC11, CC17, ST 101 are new observations. These 
clones were not evenly distributed among the countries (Table 20.)  although the large 
were represented in multiple countries. This indicates their cross-border spreading 
potential with the implication that proper tracing the routes of their dissemination, and to 
interfere with it, is unlikely to succeed without international cooperation. One exception 
from this pattern was an outbreak of ST152 present exclusively in Riyadh, KSA, 
affecting multiple hospitals.  
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A noteworthy observation is the higher rate of NDM producers and the lower 
rate of carbapenemase non-producers among clonal strains compared to non-clonal, 
sporadic isolates (Table 22.). Theoretically, such distribution could imply the possibility 
that expressing certain type of carbapenemase would automatically provide 
epidemiological advantage to these strains. We would like to disagree with such 
arguments. Outbreaks with strains producing OXA-48-like carbapenemases are known 
to occur (Poirel et al., 2012) and clustered occurrence of such strains have even been 
reported even from the Middle East before (Zowawi et al., 2014).  Even in the current 
collection, one of the clones (CC17) were dominated by OXA-producing isolates (Table 
22.). Furthermore, with the notable exception of the highly homogenous ST152 clone 
producing almost exclusively NDM, our results have shown that most clones, sometimes 
even PFGE clusters within clones, can produce different carbapenemases (Figures 13.-
18.). This can easily be attributed to the known plasmid coded nature of the majority of 
carbapsenemases (Mathers et al., 2015).  
 
One may argue, that MBL enzymes, such is NDM, unlike OXA-type enzymes, 
are also hydrolyzing broadly used cephalosporins (El Salabi et al., 2013) and this could 
provide an advantage for NDM-positive isolates. However, its effect could be rather 
limited as over 80% of the isolates also expressed some kind of ESBL enzymes causing 
resistance to 3
rd
 and 4
th
 generation cephalosporins on their own (Table 29.). We believe 
that the explanation for NDM being more associated with the clones in this study could 
be the geographical location of the current investigation: despite the role of 
autochthonous acquisition of a considerable number of CRE infections, the area could 
still have closer epidemiological connection to the Indian Subcontinent dominated by 
124 
 
 
 
NDM producers rather than to the Mediterranean region more characterized by OXA 
positive isolates (Sonnevend et al., 2015b). In fact, in this study, it was observed that 
cases linked to previous foreign hospitalization, mostly in India, were almost exclusively 
due to NDM producing isolates. However, only further, more detailed epidemiological 
studies could validate this speculation.  
 
 The limited outbreak potential of carbapenem resistant, but carbapenemase non-
producing strains have been known (Drew et al., 2013). In the fact that these isolates 
were more common among those not clustered into clones was not surprising. 
 
 When investigating the virulence-related features of the clones, a picture rather 
similar to that observed with E. coli blood-stream isolates emerged. The general 
frequencies of the virulence genes (Table 24.) were similar to those found in previous 
studies (Candan and Aksöz, 2014; El Fertas-Aissani et al., 2013), the most commonly 
encountered ones being fimbrial adhesins (mrkD, fimA), cell wall synthesis genes (ugeA 
and wabG) and those related to iron acquisition (fyuA). Importantly, no noticeable 
difference were noted between clonal and sporadic isolates.   
 
On the other hand, some considerable differences in the distribution of virulence 
factors were noticed between clones, a variability noticed earlier as well (Lascols et al., 
2012). In this study certain clones, as assessed by their by virulence-score, were found to 
be more virulent than other ones or sporadic strains (e.g. members of CC15), while 
others scored lower (e.g. CC147). It was noteworthy that the highly virulent CC15 
strains had the highest carriage rate of iron-uptake related kfuBC while it was almost 
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completely missing from low-virulence type CC147. The same applied to heat tolerance 
associated clpK gene (Bojer et al., 2010). However, while these genes were the most 
common in the most, and least common in the least virulent clones, they were also 
encountered among sporadic isolates, and some where even completely missing from 
some clones (Table 24.). Consequently, their mere presence or absence is unlikely to be 
the single reason of clonal spread. 
 
Similarly varying results were obtained when investigating serums resistance and 
biofilm forming capacity. On one hand clones considerably varied in these features and 
did not differ in these respects from sporadic isolates to the extent that these features 
could account for the epidemiological fitness (Table 25.). Even though there were more 
members of the clones scored as ―strong biofilm producer‖ than encountered among 
sporadic isolates, this feature was also present in the latter group in nearly 75% of the 
strains, and if strong and moderate biofilm producers were counted together, sporadic 
isolates were not inferior (Table 25.). 
 
Clones were not homogenous regarding the biofilm producing capacities of their 
members. However, studying to what intra-clonal differences these phenomenon was 
due to went beyond the scope of the current study.  
 
 Recently, a hypervirulent variety of K. pneumoniae associated with the highly 
mucoid phenotype emerged (Shon and Russo, 2012). It was noteworthy that only 5 
strains in our entire collection exhibited this feature showing no association with any of 
the clones. This is was supported by the fact that the K1 or K2 associated genes, magA 
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and rmpA (Yeh et al., 2007) were rarely encountered among the isolates (Table 24.). On 
one hand it shows that this type is still rather rare in the region and on the other it 
suggest that this cannot be considered as a feature providing epidemiological fitness.  
 
 In general, the strains studied were highly resistant to multiple antibiotics (Table 
27.). One should keep in mind, that the pool studied was a highly selected collection, i.e. 
the inclusion criteria was ―non-susceptibility to carbapenems‖. This could explain their 
uniformly high resistance rate to all ß-lactams (Table 27.). As we did not have group A 
carbapenemase (e.g. KPC) producing strains in our collection, and as MBLs and group 
D enzymes, i.e., NDM and OXA-type enzymes, are inactive against it (Tzouvelekis et 
al., 2012), the high rate of resistance to aztreonam found across the entire collection 
suggests the wide-spread presence of ESBLs which was confirmed by the common 
presence of TEM, SHV and CTX-M specific genes (Table 29.).  
 
 Unlike the above uniformity, a notable difference between groups regarding 
resistance to non-ß-lactam antibiotics was observed. With the exception of the small 
clone CC17, all clones were more resistant to these heterogeneous group of agents, than 
sporadic isolates (Table 28.). These strains carried somewhat more frequently the 
fluoroquinolone modifying gene aac(6')-Ib-cr  than their non-clonal counterparts (Table 
29.). This, however, in itself is unlikely to provide an explanation for the less explosive 
spread of sporadic isolates. This is just one possible mechanism of resistance to these 
drugs beyond target alteration and target shielding (Redgrave et al., 2014) and the gene 
was present, although less frequently, but still by almost 70% in the sporadic isolates, as 
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well. Indeed, more than 3 quarter of the sporadic strains were also resistant to 
ciprofloxacin (Table 27.).  
 
The most striking difference between clonal and non-clonal isolates was 
encountered in the aminoglycoside class. Clonal groups, except CC17, were highly 
resistant to gentamicin, and to a considerable extent to amikacin, as well, while much 
lower resistance rates were observed in the non-clonal group (Table 27.). This correlated 
well with the wide-spread presence of various, mostly armA and rmtC type 16S 
ribosomal subunit modifying enzymes (Table 29.). Several mechanisms exist conferring 
resistance to aminoglycosides by producing enzymes with relatively narrow spectrum, 
i.e., being active against one or a few aminoglyocosides, only (Ramirez and Tolmasky, 
2010). However, target modifying 16S ribosomal methylases, often coded by mobile 
elements, confer resistance to a broader spectrum of aminoglycosides (Wachino and 
Arakawa, 2012). The fact that with the exception of the small CC17 clone, at least some 
members of all clones (varying between 21.0 and 95.7%) carried at least one of those 
genes  suggests a close association with clonal spread as these genes were present in 
only 7% among sporadic isolates (Table 29.). 
 
Aminoglycosides are commonly used, usually in combination with other drugs to 
treat infections caused by carbapenem resistant strains (Morrill et al., 2015). Hence, 
resistance could certainly provide a considerable advantage to spread in hospitals. It 
should also be kept in mind, however, that representatives of the group are also 
commonly applied in severe infections due to strains not (yet) resistant to carbapenems 
(Leibovici et al., 2009).  
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As mentioned earlier, relatively susceptible E. coli clones spreading globally are 
known (Riley, 2014). In the current study we did not encounter such CRKP clones, as 
the selection criteria, i.e. non-susceptibility to carbapenems does obviously strongly 
favor the MDR phenotype. Even the small CC17 clone lacking any 16S methylase genes 
was more resistant to amikacin and tobramycin then sporadic isolates, probably due to 
various aminoglycoside modifying enzymes. The detection of those was beyond the 
scope of the project.  
 
Although the current study has not addressed the determination of the possible 
sequence of events, i.e. resistance to aminoglycosides first followed by resistance to 
carbapenems or vice versa, the fact the carbapenems are usually used when ―more 
common drugs had failed‖ supports the first scenario. Obviously, a strain, even a 
relatively susceptible one, could easily acquire a plasmid coding for a carbapenemase in 
the gut of a patient, even if the patient is not under any therapy. However, if the strain is 
resistant to a broader panel of drugs (among others to aminoglycoside) it could have a 
better chance to spread, i.e. develop into a wide-spread clone, once exposed to different 
antibiotics. In that sense, resistance to a broader spectrum of non-ß-lactam drugs could 
facilitate to become clonally wide-spread.  
 
The rates of resistance to colistin and tigecycline should be mentioned separately 
as these are drugs used almost exclusively to treat CRKP and not CSKP infections and 
for colistin, until very recently (Liu et al., 2015) resistance was considered 
chromosomally located, not transferable. With considerable variation between clones 
some had clearly higher resistance rate to these drugs than sporadic isolates (Table 27.). 
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We surmise, however, that the still relatively low rate of these resistance to these drugs 
(however alarming their increase and their effect on the outcome of the specific cases 
could be), argues that these phenotypes are not factors determining whether out of a 
particular strain a globally spreading clone develops or not.   
 
Taken together, analyzing CRKP isolates, our conclusion is similar to the one we 
reached regarding E. coli: no specific virulence traits seem to be associated with the 
clonal nature, and there are apparently successful clones with rather low virulence 
scores. The resistance to a broader range of drugs are more associated with clonal 
isolates, and in case of CRKP, we believe that this is particularly clear regarding 
aminoglycoside drugs. As with E. coli, however, the chance that this is a consequence 
rather than the reason of becoming clonal, can only be established by investigations 
studying outbreaks due to susceptible clones. 
 
While all hospital laboratories regularly monitor resistance to antibiotics, such 
studies for disinfectants are not part of the routine. However, emerging resistance to 
these agents may have direct impact on the spread of pathogens. This is certainly true for 
microbes known to colonize surfaces and often causing exogenous infections (e.g. 
MRSA), but could equally be true for agents primarily causing endogenous infections, 
such as Enterobacteriaceae. While, to a large extent, gut colonizer MDROs spread by 
food (Riley, 2014), the role of direct or indirect contacts in their transmission, both to be 
controlled by the application of disinfectants, should not be underestimated. Therefore, 
we studied the biocide resistance of carbapenem resistant E. coli and K. pneumoniae and 
compared it to the figures seen in their carbapenem susceptible counterparts. It should be 
130 
 
 
 
noted that the only differentiating marker between these groups was the susceptibility to 
carbapenems, i.e. some of the members of the latter groups also qualified as MDR, 
although susceptible to carbapenems. 
 
Regarding E. coli, we found no significant difference in biocide susceptibility 
between the CREC and CSEC groups and a very similar distribution of disinfectant 
resistance genes than others (Guo et al., 2015; Zou et al., 2014) with chromosomally 
encoded emr, ydgA, ydgF, mdfA, sugE(C) being the most common ones (Table 35.). 
Importantly, another study has also failed to detect significant differences between MDR 
and susceptible groups (Guo et al., 2015) although in that project susceptibility to 
carbapenems were not analyzed. It should be noted that similarly to others (Zou et al., 
2014) we also detected a higher rate of presence of the plasmid coded qacΔE1 and 
sugE(P) genes (Kücken et al., 2000) among the more resistant isolates (Table 35.). 
Although carriers of the former gene exhibited a significantly higher MIC values to 
chlorhexidine than their negative counterparts, apparently the presence of the gene in the 
CREC group was still not widespread enough to cause significant difference in 
resistance compared to CSEC strains. Nevertheless, even though the absolute figures of 
MIC values are not high among local E. coli, the presence of plasmid-coded disinfectant 
resistance genes, and their future spread needs further monitoring. 
 
A considerably different picture emerged regarding K. pneumoniae strains. On 
one hand, the absolute MIC values of chlorhexidine and benzalkonium for this species 
were significantly higher than for E. coli (Tables 32. and 34.). Unlike in E. coli, a highly 
significant difference existed between CRKP and CSKP isolates regarding chlorhexidine 
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and benzalkonium susceptibility. Most of our isolates contained the cation efflux gene 
cepA, and we could not correlate its presence with resistance to disinfectants. This gene 
was described to be present in all strains of a collection of pre-antibiotic era K. 
pneumoniae strains but in those with lower MIC values the gene was disrupted by a 9-18 
bp insert (Wand et al., 2015). Confirming the same reason in our collection was beyond 
the scope of the study.  
 
Similarly to E. coli, plasmid-coded qacΔE1 and sugE(P) (and in small numbers, 
i.e. 4 strains, qacE) were more commonly present in CRKP then in CSKP isolates, and 
in case of  qacΔE1 it even reached the level of statistical significance. We believe that 
this observation is of particular importance. In enteric bacteria qacΔE1 is commonly 
located at the 3‘ conserved part of class 1 integrons, a structure frequently present in 
various resistance plasmids (Deng et al., 2015). They are also observed in plasmids 
carrying different carbapenemase genes (Zhao and Hu, 2015). In the current study we 
could not find any association between disinfectant resistance and any particular 
carbapenemase produced and the detailed molecular structure of the NDM and OXA 
plasmids were not established. Nevertheless, one can easily predict that the spread of 
carbapenem or other antibiotic resistance plasmids selected for by the existing antibiotic 
pressure, but also harboring these biocide resistance genes could seriously impact the 
general level of disinfectant resistance in our hospitals. Its effect will just be further 
augmented by the impact of broad substrate range efflux pumps selected for by 
antibiotics but affecting disinfectants simultaneously (Tumah, 2009).  
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One should keep in mind that there are no ―clinical breakpoint‖ values 
established for disinfectants to distinguish between susceptible and resistant isolates. 
While it has been shown that these agents are very effective against Gram-negative 
MDR organism (Reichel et al., 2014) it is still debated whether decreased susceptibility 
to these agents has any impact on health care (Harbarth et al., 2014). We believe that 
while these agents are applied in concentration way exceeding their MIC values, 
concentrations do decrease in distance and particularly in time after their application. 
Unless used with strict regularity, their subsiding concentration will allow organisms to 
grow, particularly those with higher MICs. Therefore a continuous monitoring of the 
level of resistance to these agents, particularly among high impact pathogens, such as 
CRKP and CREC, is fundamental to maintain safety of health care.  
 
Fosfomycin, a bactericidal antibiotic, was discovered in 1969 in Spain, and 
found to be active against a wide range of pathogens, including multi- or even 
extensively drug resistant Enterobacteriaceae (Endimiani et al., 2010).  It is assumed 
that the unique mechanism of action of this drug, i.e., the inactivation of pyruvyl 
transferase required in the early stage of cell wall peptidoglycan synthesis, prevents 
cross resistance with other classes of antibiotics (Popovic et al., 2010). Fosfomycin is 
considered to be one of the few ―last resort‖ antibiotics in case of infections caused by 
carbapenem resistant Enterobacteriaceae, but its use in enterobacterial infections other 
than the ones in the urinary tract caused by Escherichia coli  is not standardized, and the 
recommended intravenous formulation, fosfomycin disodium, is not universally 
available (Popovic et al., 2010). Furthermore, clinical breakpoints for fosfomycin iv. for 
non-urinary tract infections are only set by EUCAST 
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(www.eucast.org/clinical_breakpoints/). Hence, we used the EUCAST breakpoints when 
evaluating the MIC values into susceptible, intermediate and resistant categories. Our 
investigation showed that although somewhat lower percent of CRKP collection was 
susceptible to fosfomycin, this was not significantly different from the value of the 
CSKP isolates, demonstrating that fosfomycin is a possible therapeutic option against 
CRKP in countries of the Arabian Peninsula. In recent studies, susceptibility to 
fosfomycin of carbapenemase producing K. pneumoniae has been reported to be 93% 
(Endimiani et al., 2010) and 86% (Alexander et al., 2012) in the USA,  94.8% in Greece 
(Falagas et al., 2010) and 78.5% in Madrid, Spain (Pena et al., 2014). However, with the 
exception of the latter study, the higher clinical breakpoint values set by the CLSI for 
urinary tract E. coli isolates only (CLSI, 2014) were used, although, Endimiani et al. 
reported that if the MIC≤32 mg/L clinical breakpoint was used, 75% of their KPC-
producing K. pneumoniae would have been classified as susceptible, only.  
 
Our CRKP collection exhibited 78.4% susceptibility to fosfomycin, which is in 
line with observation in the US and Spain. It is noteworthy, that the CRKP fosfomycin 
resistance rate is similar in regions where the use of fosfomycin is generally lower, i.e., 
the US and countries of the Arabian Peninsula, compared to Spain or Greece, where 
intravenous fosfomycin is available and the selective pressure is supposedly higher. A 
possible explanation may arise from our search for transferable fosfomycin resistance 
genes, which also brought unexpected results. We could not identify plasmid mediated 
fosA or fosC genes. However, the fosA PCR was positive in approx. 3/4 of our 
collections of CSKP and of CRKP, both of which were non-clonal, but pools of diverse 
strains as shown by their PFGE profiles (Figure 22. and 23.). This finding is further 
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supported by the fact that we could identify a fosA-like gene in silico in a large 
proportion of K. pneumoniae whole genomes deposited in the GenBank. We speculate 
that the expression of this gene, and subsequently the level of fosfomycin resistance may 
vary in different K. pneumoniae strains. It is also possible that the chromosomally 
located fosA gene may act as a source of such genes, and when they are mobilized into 
plasmids, this may elevate the fosfomycin MIC into a clinically resistant range (Lee et 
al., 2012; Li et al., 2015; Qin et al., 2014). However, addressing these hypotheses is 
beyond the scope of this dissertation, and it is part of further ongoing studies. 
 
It has been observed in vitro that fosfomycin resistance may develop rapidly in a 
bacterial population, hence it is recommended to use it in combination with other drugs 
(Lee, 2014). The drugs that have been shown to be synergistic with fosfomycin are 
carbapenems, colistin, netilmicin and tigecycline in vitro (Samonis et al., 2012). 
Therefore, in order to avoid resistance emerging during therapy, intravenous fosfomycin 
therapy of CRKP is usually combined with aminoglycosides, colistin or tigecyline (Lee, 
2014; Pontikis et al., 2014; Tängdén and Giske, 2015). We focused on the latter two 
drugs, since our collection of CRKP mostly consisted of NDM and OXA-48-like 
carbapenemase producing K. pneumoniae (Table 31.), and aminoglycosides were 
described to be useful in the treatment of KPC-producer CRKP strains, only (Endimiani 
et al., 2010; Lee, 2014; Pontikis et al., 2014).   
 
We also evaluated the MIC of the above bacterial isolates for colistin and 
tigecycline based on the EUCAST criteria, as the CLSI has no standard for these 
antibiotics (CLSI, 2014; EUCAST, 2013). Although the rate of susceptibility to 
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tigecycline and colistin in the CRKP collection was 78.4% and 88.6%, values similar to 
those seen for fosfomycin, we found no significant association between the resistance to 
these three antibiotics, predicting the effectiveness of fosfomycin in case of CRKP 
isolate resistant to tigecycline or colistin. This may be promising, but in a prospective 
study using fosfomycin combination treatment in extensively drug resistant 
carbapenemase-producing Klebsiella pneumoniae infections of critically ill patients, the 
best clinical and microbiological outcome was found in bloodstream infections (Pontikis 
et al., 2014), and unfortunately, the blood isolates of our CRKP collection exhibited the 
highest fosfomycin MIC values (Table 38.). Furthermore, in this subgroup of our CRKP 
isolates the fosfomycin resistance was significantly associated with colistin resistance, 
leaving virtually no effective antibiotic treatment option.  On the other hand, our finding 
showed that more than 90% of our CRKP urine isolates were susceptible to fosfomycin, 
with MIC50 and MIC90 being 8 mg/L and 32 mg/L, respectively, values comparable to 
the CSKP collection‘s MIC50 and MIC90. These promising results regarding urinary 
tract infections caused by CRKP, however, should also be treated with caution, since in 
one of the few studies evaluating the clinical use of fosfomycin in UTI caused by CRKP, 
the microbiological cure rate was only half of the in vitro susceptibility to this drug: 46% 
vs 92% (Neuner et al., 2012).  
 
Considering our findings and previous observations, fosfomycin could be a 
useful addition to the treatment of extremely drug resistant CRKP in the Arabian 
Peninsula, especially in non-bloodstream infections. Nevertheless, further data regarding 
combination therapy and patient related factors should be evaluated before a 
recommendation on fosfomycin use in CRKP infections could be formulated.  
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Chapter 6: Conclusion & Recommendations 
 
 In this study, we have identified several internationally recognized E. coli and K. 
pneumoniae pandemic clones causing infections and outbreaks in hospitals of the 
Arabian Peninsula. Provide their first thorough characterization. Their presence 
and local spread calls for the establishment of state-of-art, molecular typing 
based surveillance, currently existing in the region only as limited scale research 
projects. 
 
 Characterization of the clones and sporadic isolates clearly shows that 
epidemiological fitness is a complex phenomenon and the contribution of 
resistance to antibiotics, to disinfectants, and virulence of strains can vary 
between clones. An important new observation was that international clones of 
E. coli expressed a core type previously rarely encountered. On that basis, we 
propose a hypothesis of its role in promoting the emergence of these clones.  
 
 In K. pneumoniae the higher rate of increased disinfectant resistance is alarming 
among carbapenem resistant isolates, particularly as it was associated with 
mobile, plasmid encoded genes. We suggest to start monitoring disinfectant 
resistant levels for multi-drug resistant pathogens, at least in regular point-
prevalence studies, to be able to warn infection control experts if the situation 
deteriorates further.  
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 The local fosfomycin susceptibility rate of carbapenem resistant K. pneumoniae 
was found comparable to those in countries with limited use of the drug. We 
strongly recommend to make the parenteral version of this drug available in the 
UAE. This should also require testing of susceptibility to fosfomycin in all 
hospital laboratories. However, great caution should be exercised using the drug 
and it should not be anticipated as to be a single solution to the fast emerging 
carbapenem resistant  problem in the Gulf region. 
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